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ABSTRACT 
 
 
Complex medication regimens have major implications on patient therapy. When we consider that 
these regimen therapies can also be further convoluted by co-morbidity, it is then seen as an essential 
opportunity to research possible solutions to alleviate such complications. Globally identified 
conditions such as the Human Immuno-deficiency Virus (HIV) and Tuberculosis (TB) are known to 
have such complications within their respective regimens. In many cases, the regimental therapies 
themselves are overbearing with high pill burdens having to be taken in segregated manners 
throughout the day. Within a standard TB regimen, isoniazid and rifampicin are seen to have a 
deleterious drug-drug interaction in which the bioavailability is compromised through formation of an 
insoluble complex. Despite this interaction, the 2 active drugs must be taken concurrently for 
successful TB therapy. No true solution exists as fixed dose combinations of isoniazid and rifampicin 
(Rifinah®) are still in production despite the detrimental interaction that impedes successful 
bioavailability. The once daily multi-unit drug delivery system (ODMUS) has the benefits of 
superseding the described problems and aiding in therapeutic outcomes. 
Preliminary studies utilized preliminary testing to ascertain the science surrounding the 2 components 
of the ODMUS, the memblet and the multiparticulate components. pH-sensitive polymers (Eudragit® 
L100-55 and E 100) were of critical importance to the success of the system and were individually 
manipulated for each component to produce a novel memblet and multiparticulate system through a 
unique salting out approach. 
Primary studies focused on drug release testing and drug entrapment for the multiparticulate 
component. Testing of the memblet system addressed dissolution and thermal analysis. Utilizing this 
data, a series of process variables were used to achieve an optimized formulation through a Box-
Behnken statistical design. 
Optimized formulations used response testing to establish the optimal characteristics of both 
components. Multiparticulates achieved controlled release for 12 hours with an enhanced 71% drug 
entrapment efficiency. Memblet release profiles were confirmed over 2 hours with a maximal Tg of 
56°C. Molecular modeling corroborated release understanding for both components. Surface area and 
porosity analysis, surface morphology, fourier transform infrared spectroscopy as well as thermal, 
rheological and mechanical analysis were additional tests undertaken on the optimized formulations. 
In vivo analysis was the final testing to verify validity of the ODMUS components and utilized a pig 
model for the investigation. UPLC blood analysis revealed increase blood levels of INH (CmaxINH= 
0.0138ng/mL) and RIF (CmaxRIF= 0.052ng/mL) in relation to conventional dosage forms validating 
segregated site-specific release and increased bioavailability. 
Ideally, a segregated means of drug delivery throughout the gastrointestinal tract was achieved such 
that an enhanced bioavailability, a more controlled release and a simplified medication regimen was 
produced. This study aimed to achieve said goals through novel technique analysis, innovation and 
globally approved science to critically assess the success of the ODMUS as a potential means to 
reduce the complexities of medication regimen therapy.   
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CHAPTER 1                                                                                            
AN OVERVIEW OF DRUG REGIMEN THERAPY AND CONCURRENT 
ORAL DELIVERY SYSTEMS                                                                                               
 
 
1.1 Introduction 
 
The complexities of medication regimens are pertinent and influential to therapy with both 
health care professionals and patients. Co-morbidity along with multiple drug regimens in 
conditions such as tuberculosis (TB), Human Immunodeficiency Virus (HIV), Malaria, as well 
as regimens of antibiotic and antiepileptic medication, provides an inexorable task for 
patients to adhere to on a daily basis to successfully complete the prescribed regimen. A 
major cause of treatment failure is due to poor patient compliance as a result of elaborate 
regimens (Townsend et al., 2003), but this is not the sole problem associated within regimen 
therapy. Deleterious drug-drug interactions exist even within prescribed regimens, and often 
lead to sub-therapeutic drug levels. The consequences of such prescribing can potentially 
lead to drug resistance and treatment failure. Such deleterious interactions are noted 
between isoniazid and rifampicin used in the management of TB, in which the bioavailability 
of both drugs is impaired due to the insoluble complex formed between the 2 actives, a 
reaction which is accelerated through the acidic pH of gastric fluid (Shishoo et al., 2001). 
Both drugs are an essential component of TB therapy and cannot be substituted, and 
therefore each drug should be taken for a time apart from each other. These 
pharmacological actives are taken as a fixed dose combination, such as Rifafour e-275® 
(Aventis) and Rifinah® (Aventis), with little regard as to the detrimental interaction that does 
occur. Certain regimens contain excessive intolerable side effects that inhibit a patient’s 
continuation with their regimens. Antiepileptic regimens induce a large number of side effects 
such as excess weight gain from valproate and cognitive impairment from topiramate 
(Bourgeois, 2002). 
 
Non-pharmacological methods have been implemented over the course of many years to 
bolster patient compliance and aid in regimental therapy. Table 1.1 proposes non 
pharmacological means of treatment.  
 
Methods, as shown in Table 1.1, have existed for many years for managing drug regimen 
therapy, a novel drug delivery system could possibly be a more practical approach. Well 
defined oral drug delivery systems, whilst being a singular solution to the issue of regimen 
therapy, could also be used in a synergistic program along with the methods described 
above.  
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Table 1.1 Methods for managing regimen therapy, benefits and issues 
Proposed methods Positive outcomes Negative outcomes 
Adaptive control Produces a highly 
individualised regimen by 
producing pharmacokinetic 
and pharmacodynamic 
models 
Creating precise 
pharmacokinetic and 
pharmacodynamic models, 
choosing the correct one 
and statistical issues such 
as the use of assay error 
patterns 
Bayesian method Produces individualised 
regimens from parametric 
population modelling in 
which standard deviations 
and mean values are 
implemented for the 
population parameter values 
Requires numerous data 
points which are not always 
provided through routine 
clinical data 
Therapeutic drug 
monitoring 
Involves a monitoring of 
serum levels of drug and 
classification of 
concentrations into sub-
therapeutic, therapeutic and 
toxic levels and adjusting 
regimens accordingly 
Focuses on toxic 
concentrations indefinitely 
and excludes patients 
clinical behaviour as a factor 
for adjusting drug regimens 
Motivational interviews An individualised 
counselling method 
adapting techniques such 
as reflection and issue 
reframing 
Require a highly specialised 
and trained councillor for 
successful impact on drug 
regimens 
Nurse based interventions Due to high contact rate 
with patients, nurses are 
ideally placed to implement 
usual adherence based 
interventions 
Relies solely on the  
consistent availability of 
nurses to maintain 
Adapted from Jelliffe et al., 1994 
 
Multiparticulate drug delivery systems may address the challenges found within regimen 
therapy. An advantage of adopting a multiparticulate system involves the ability to specifically 
control drug release and consequently eliminate dose dumping and reduce side effects 
(Haslam et al., 1998). Recently, many approaches have been adopted for achieving 
controlled site-specific drug delivery using multiparticulate systems.  
 
Due to the size range of multiparticulates (nm-mm), the system has previously been 
incorporated into the treatment of respiratory conditions, such as asthma, as an inhaled 
formulation as described by Corrigan and co-workers (2006). 
 
In the aforementioned study, chitosan was formulated into chitosan-salbutamol-sulphate 
multiparticulates for local delivery to the lungs. However, the system focused on delivery of a 
single drug rather than multiple drugs in a regimen. 
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Success of many patented devices, show the impact of multiparticulates, as expressed in a 
product developed by Paul and co-workers (2004). A multiparticulate bisoprolol formulation 
for once-daily oral administration was developed, in which each particle comprised a core of 
bisoprolol surrounded by a polymeric coating. The polymeric coating was effective in 
achieving an initial lag of bisoprolol release in vivo of at least 4-6 hours following 
administration and thereafter maintaining therapeutic concentrations of bisoprolol for the 
remainder of the 24 hour period. Exploitation of the oral route of administration and 
prolonged drug delivery are both evident in contrast to the investigation provided by Corrigan 
and co-workers (2006). However, limitations are evident as the production sequence is 
lengthy and intricate knowledge is required in producing the multiparticulates and coating of 
them with fillers, plasticizers and copolymers in separate steps, which further convolutes the 
disadvantage of the system. Numerous production steps are not optimal for scale up 
manufacturing and this method does not guarantee highly reproducible particles in a single 
processing step.  
 
Formulation approaches may dictate the positive and negative attributes of a multiparticulate 
drug delivery system. In a system developed by Liu and co-workers (2007), O-
carboxymethylchitosan (OCMC) multiparticulates containing pazufloxacin mesilate were 
developed. The multiparticulates were prepared via an emulsion crosslinking method, which 
released drug over both the gastric and intestinal regions making the system pH 
independent. The O-hydroxyl group of each OCMC monomer substituted by a 
carboxymethylic group through ether bond formation, conferred its swelling properties and 
pH independent controlled drug release. Though this system employs a novel polymer and 
release system, the formulation approach however, was through a duplicated emulsion 
crosslinking method. Crosslinked multiparticulates were prepared by dissolving OCMC in 
distilled water, and varying quantities of pazufloxacin mesilate were added to the above to 
complete swelling of OCMC. The polymer solution containing pazufloxacin mesilate was 
added drop wise into liquid paraffin containing a surfactant resulting in the formation of a 
W/O emulsion. Various quantities of 25% glutaraldehyde solution were added depending 
upon the crosslinking density required using a hypodermic syringe.  
 
It is apparent that such a method includes an undesirable and extensive formulation process. 
Furthermore, pazufloxacin mesilate remains the only drug to be delivered and the usage of 
multiparticulates for the treatment of drug regimens was not addressed. A recent study 
conducted by du Toit and co-workers (2007), focused on exploring modes of multiparticulate 
formulations. In the study, 3 approaches of multiparticulate production were investigated. 
These included the air-suspension method, a solvent evaporation emulsification method and 
a novel phase separation or salting-out approach. The air suspension method was a lengthy 
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formulation process with the only known flexible polymer to be included, a methacrylic acid 
copolymer derivative. The solvent evaporation-emulsification method depended largely on 
variables such as the type of solvent employed, temperature and mechanical agitation. 
Through comparative analysis of production of multiparticulates, using all 3 methods, it was 
concluded that phase separation was simple for any operational scale. 
 
A second novel system that can be of benefit to regimen therapy is that of an oral 
membranous drug delivery system. Hydrogel formation is not a new technique and has been 
developed extensively throughout the years (Hideaki et al., 2008; Akihiro et al., 2009; Chen 
et al., 2009). Hydrogels are porous polymeric networks that retain and entrap large volumes 
of water within the matrices (Rajagopal and Schneider, 2004; Nair and Laurencin, 2006; Lee 
and Yuk, 2007). Selected drug molecules (mostly hydrophilic in nature) can be directly 
encapsulated within the network by triggering self-assembly in the presence of the drug 
(Branco and Schneider, 2009). Crosslinked polymeric hydrogels exhibit both structural and 
functional advantages in pharmaceutical research. The authenticity of the hydrogel and the 
subsequently desiccated membrane, with regards to drug delivery, is highly dependent on 
the reproducibility of drug release, novelty of design and well defined physico-chemical and 
physico-mechanical properties (Lin and Metters, 2006). Controlled and sustained release 
from polymeric matrices, ensure the delivery of drugs in a predictable manner so as to match 
physiological needs. However, hydrogels exhibit weak mechanical strength and in certain 
cases, rapid erosion and drug release from the internal matrix (Ruel-Gariepy and Leroux, 
2004).    
 
Membranous systems have been utilized for implants due to their ability to retard drug 
release in a highly site-specific manner. Implants through these systems have been noted to 
bypass regular side effects associated with other suturable devices such as inflammation 
and infection (Cabañas et al., 2009). A membrane is an inter-phase between 2 adjacent 
phases acting as a selective barrier and modulating the exchange of substances between 
the 2 compartments. One of the crucial advantages of membranes includes the transport 
selectivity of the membrane itself. Up-scaling and downscaling of membrane formulation 
processes are relatively easy when compared to other methodologies (Dongming et al, 
2009).  
 
A major disadvantage of a membrane produced system includes even weaker mechanical 
properties and manipulation of the formulation process needs to be considered if targeted 
and controlled drug release is to be achieved. Membranous systems derived from hydrogels 
also exhibit these weaker mechanical properties often producing a brittle formulation. The 
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use of membranous systems very rarely strays from the implant protocol, due to its high 
success rate in this field.   
 
Chitosan has been the preferred polymer in membranous technology due to its non toxic, 
biocompatible and biodegradable properties (Wong et al., 1992; Francis and Matthew, 2000). 
This highly abundant polysaccharide does however pose some limitations particularly with 
regards to low acidic solubility and an inherent brittleness and stiffness (de Oliveira et al., 
2009). When considering gastric oral drug delivery, these are unwanted characteristics for a 
polymer to possess and if optimal gastric delivery is required, the delivery system must avoid 
the same limitations of chitosan. Additionally, novelty is hard to achieve with a polymer that 
has been so extensively manipulated.   
 
Consequently, the drug delivery system proposed in this dissertation intends to develop a 
Once Daily Multi-Unit System (ODMUS) for the site-specific delivery of a multiple drug 
regimen, developing firstly a multiparticulate system from a modified salting-out approach 
adapted from du Toit and co-workers (2007). Additionally, a novel membranous oral delivery 
system shall be developed such that concurrent delivery of at least 2 pharmacological 
actives can be achieved simultaneously with the multiparticulates, while subsequently 
providing segregated drug delivery within the gastrointestinal tract and eliminating the 
deleterious drug-drug interactions that occur amongst certain actives within a regimen.  The 
novelty of the ODMUS is purported by its advantages of decreasing the amount of tablets a 
patient needs to consume in regimen therapy, the avoidance of deleterious drug interactions 
within regimens, reduction in dosing frequency and reducing intolerable side effects by 
providing a segregated and sustained drug release.   
  
1.2 Rationale and Motivation for Study 
 
The proposed ODMUS offers positive outcomes in relation to patient compliance, the 
negation of deleterious drug-drug interactions and a decrease in frequency of dosing when 
compared to standard regimen therapy. Currently, oral drug delivery systems do not allow for 
the delivery of a multiple drug regimen as a single formulation using multiparticulates. The 
ODMUS will be able to decrease the amount of tablets required by the patient on a daily 
schedule and reduce daily dosing frequency. Conditions such as TB, HIV, Malaria and 
infections requiring numerous antibiotics, will be most suited for incorporation into the 
ODMUS, as regimen quantity is decreased.  
 
In epilepsy treatment, a common trend includes an increase in the regimen quantity as the 
disease progresses. Subsequent increases in the amount of tablets within a regimen can 
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ultimately lead to an out of control situation (dose dumping), revolving around an increase in 
intolerable side effects and decreased compliance (Haslam et al., 1998; Bourgeois, 2002). 
These situations will be easily negated by the ODMUS through its multiparticulate delivery of 
drug regimens in a single dosage form, at separate locations in the gastrointestinal tract 
(GIT) in a controlled manner. The controlled delivery of drug at site-specific regions in the 
GIT allows for a greater bioavailability and therefore should remove any need to increase the 
dose which was previously rendered insufficient. 
 
The novel formulation approach of the ODMUS is a further advantage. The method to be 
employed involves a salting-out or phase separation approach as adapted from du Toit and 
co-workers (2007). The phase separation method offers numerous advantages over 
preparations described previously. The method employs an environmentally inert latex rather 
than an organic solution of the polymer. This polymeric solution is traditionally used as a 
coating agent to protect formulations from the acidic environment of the stomach. 
Consequently, as the polymeric matrix of the multiparticulates are comprised of this polymer, 
the coating process required by other delivery systems is bypassed and is replaced by a 
single process step without the use of potentially toxic solvent vapours. Furthermore, the 
salting out approach does not use organic solvents for dissolution of the polymer and allows 
for highly reproducible particles. The entire process of drug loaded multiparticulate 
production can then be described as a simple method of assembly.  
 
The delivery of drug to various regions in the GIT highlights another positive application of 
the ODMUS. A novel tablet like membranous system has been developed to be co-
administered with the drug loaded multiparticulates and promoting the release of the 
contained drug upon coming into contact with the gastric fluids. As such the membranous 
system shall contain a drug intended for drug delivery into the stomach and the 
multiparticulate system shall contain a drug intended for the small intestine. The overall effect 
of drug delivery in such a manner is that harmful deleterious drug interactions between drugs 
within the same regimen can be negated with both drugs being given as a single dose of 2 
delivery systems. Furthermore, dose dumping can be reduced as the system provides 
controlled site-specific release of both drugs in the GIT. Crosslinking agents chosen were 
based on research concluded and discovery throughout the lab design. The crosslinking 
agents played a vital role in determining the release patterns of both drugs. The following 
Table 1.2 shows potential therapies to benefit from the ODMUS. 
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Table 1.2 Potential drug regimens to be incorporated into the Once Daily Multi-Unit System 
Drug A Drug B Therapy Problem 
Rifampicin Isoniazid Tuberculosis Deleterious drug 
interactions in 
which, in an acidic 
pH, isoniazid 
converts Rifampicin 
into an insoluble 
complex 
Carbamazepine Lamotrigene Epilepsy Deleterious drug 
interaction resulting 
in decreased 
seizure control. Poor 
compliance. 
Increase in tablet 
amount leading to 
intolerable side 
effects 
Ketoconazole Didanosine HIV and Co-morbid 
fungal infections 
Didanosine reduces 
the acidic 
environment of the 
stomach and inhibits 
the absorption of 
ketoconazole 
Adapted from the South African Medicines Formulary, 2005  
 
1.3 Aim and Objectives of this Study 
 
The aim of this study was to develop an ODMUS able to overcome multiple daily dosing for 
chronic conditions that require adherence to long term therapy. Secondly, the system also 
aimed to prevent deleterious drug interactions between 2 or more drugs utilizing 2 novel drug 
delivery systems and furthermore decrease dosing frequency. The following objectives were 
outlined to achieve the aims of the study. 
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1) To select appropriate polymers and crosslinking reagents to formulate 2 delivery systems 
i.e. a multiparticulate system and a membrane like system, both with pH dependant 
solubility profiles. 
2) To develop drug loaded multiparticulates based on a novel salting out/phase separation 
technique. 
3) To develop a novel membrane tablet like system for concurrent oral delivery with 
multiparticulates. 
4) To perform in vitro release studies in order to determine the drug release behaviour for 
both systems. 
5) To develop a stability indication study for the novel membranous tablet like system to 
assess integrity. 
6) To perform in vivo animal studies to assess the release behaviour and establish 
pharmacokinetic parameters of the system.    
 
1.4 Novelty of this Study 
 
The novelty of this study includes the formulation of a combination of 2 oral drug delivery 
systems, which allow for the concurrent administration of 2 pharmacological actives to 
achieve segregated drug delivery of the actives along the gastrointestinal tract. A single 
process step is utilized in the formulation of both systems as well as the novel use of 
Eudragit® polymers as pH-sensitive matrices which impart controlled release patterns for the 
respective drugs from each system at the individual pH of the stomach (pH1.2) and small 
intestine (pH6.8). Deleterious drug interactions that can potentially occur between the 
actives, can be negated due to segregated delivery of each compound along the 
gastrointestinal tract and an enhanced bioavailability can be achieved.     
 
1.5 Overview of the Dissertation 
 
Chapter One introduces the problem of medication regimens and emphasizes the rationale 
for the study. A background inspection on medication regimens is provided while indicating 
the aims and objectives of this research project.  
 
Chapter Two contains an in depth review of drug regimen therapy strategies, the associated 
conditions and the limitations of said strategies. Deleterious drug interactions within regimens 
are highlighted followed by an in depth look into technologies utilized to manage complex 
regimen therapy. Furthermore, an explanation of the 2 technologies (membrane and 
multiparticulate) is provided which would comprise the Once Daily Multi-Unit System 
(ODMUS). 
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Chapter Three establishes the specific polymeric Eudragit® material, crosslinkers and other 
constituents for each formulation and the subsequent method development implemented in 
producing a novel rifampicin loaded memblet for gastric drug release and a novel isoniazid 
loaded multiparticulate system for intestinal drug delivery. Preliminary analysis focused on 
producing the upper and lower limits for formulation variables of each system which were to 
be inserted into a Box-Behnken factorial design. Upper and lower limits were emulated 
through dissolution testing, drug entrapment efficiency and differential scanning calorimetry.  
 
Chapter Four describes the formulation of a design of experiments determined from the 
Box-Behnken factorial design. Fifteen formulations from both the multiparticulate and 
memblet system were subjected to response testing in order to achieve data to derive a 
candidate formulation.  
 
Chapter Five provides an in depth characterization of an optimized memblet system 
intended for gastric delivery of rifampicin. Rheological, thermal, mechanical, morphological 
and structural characterizations were thoroughly investigated. Thermal and drug release 
profiles were established as correlating with the predicated data generated through statistical 
designs. 
 
Chapter Six reviews the molecular and internal structure of an optimized multiparticulate 
system with corroborating surface area and morphological analysis. Drug entrapment and 
drug release profiles generated were validated as corroborating with predicted data derived 
in statistical designs for the system intended for isoniazid release in the small intestine. 
 
Chapter Seven includes an in depth development of an in vivo analysis protocol for the 
combined ODMUS system relative to a conventional dosage form. Selection of an animal 
model is verified and development of surgical implantation procedure for the pig model is 
described. The protocol of blood sampling, storage and blood drug analysis via ultra 
performance lipid chromatography is described. The superiority of the ODMUS over a 
conventional dosage form is provided through the simultaneous analysis of plasma from both 
systems.  
 
Chapter Eight presents the conclusions and recommendations of future work. 
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CHAPTER 2                                                                          
STRATEGIES IMPLEMENTED IN DRUG REGIMEN THERAPY AND 
THE ASSOCIATED LIMITATIONS 
 
 
2.1 Introduction 
  
Health care cannot be simply defined as diagnosis and treatment and in clinical practice, due 
to many complications, treatment failure often occurs. When considering chronic therapy, we 
cannot assume that treatment can follow a simple therapeutic guideline. Chronic conditions 
may consist of extensive medication regimens in which the patient takes multiple drugs, 
frequently throughout the day and for prolonged periods (Richter et al., 2003). These 
compounded factors lead to poor patient compliance, treatment failure and drug resistance. 
To relieve such problems, fixed dose regimens are considered vital for severe chronic 
conditions. Additionally, above stated regimens may have detrimental interactions among the 
actives of the dosing regimen requiring direct monitoring and segregation of dosing on a daily 
basis. 
 
Human Immunodeficiency Virus (HIV) is a worldwide pandemic characterised by extensive 
morbidity and mortality and is growing in severity in many countries. The development of the 
highly active antiretroviral therapy (HAART) regimens has significantly reduced associated 
morbidity and mortality (Mugavero and Hicks, 2004) and such a protocol shows the direct 
impact fixed dose regimens have on HIV therapy. Complications arise when opportunistic 
infections occur and further pharmacological actives are added to the already substantial 
quantity (Van Dyke, 1995; Manosuthi et al., 2007). Asthma is another chronic condition 
requiring fixed dose regimens for therapy and these regimens have been designed to 
optimize the physical well being of patients. As asthma is largely a self management 
condition, fixed dose regimens that simplify therapy, are of importance (Hyland and 
Elisabeth, 2004).  
 
Tuberculosis (TB) has made major impact on a global scale for its highly contagious quality 
and its high level of mortality, especially amongst the economically challenged countries and 
regions (du Toit et al., 2006). TB treatment consists of several regimens which include both 
induction and continuation phases. In an effort to make regimental therapy compliance 
standard and to combat multi-drug resistant TB, the directly observed therapy (DOTS) 
protocol has been established (Gleeson and Decker, 2006).  
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Endocrine disorders see fixed dose regimens as crucial parts of therapy.  Diabetes, growth 
hormone deficiencies, and hormonal replacement therapies include the use of fixed dose 
regimental therapy to combat symptoms associated with the disorders and on a regular 
basis, attempts have been made toward novel and innovative ways to deliver such regimens 
(Belland and Wyne, 2006; Out et al., 2006). 
 
In all examples, the commonality lies in the extensive regimens that cannot be substituted. A 
rational approach for optimization of treatment would be to develop novel oral delivery 
systems for such regimens. Drug delivery systems for regimental management have been 
approached and studied for many years. Development of such systems, are crucial towards 
successful management of chronic conditions that leave patients feeling debilitated with not 
only their condition but their extensive drug consumption. Efficacious drug delivery systems 
will not only address non-adherence issues, but also cost issues and emergence of 
resistance towards these chronic conditions. 
 
2.2 HIV/AIDS and Concomitant Strategies Utilizing Drug Regimental Therapy 
   
2.2.1 HIV/AIDS and fixed dose combinations 
When looking specifically at HIV/AIDS therapy, regimental therapy is a necessity when 
considering the host of drug-drug interactions that are likely to occur. The HIV virus has a 
highly accelerated means of viral replication or viral turnover regardless of immune response. 
Also noted is the fact that during the transcription process of the virus, mutations occur. The 
combination of mutation and accelerated viral replication results in a seriously debilitating 
condition (Gupta and Pillay, 2007).   
 
Consequently, HIV/AIDS is treated via regimental therapy in order to address the issues of 
vast replication rates and mutation of the virus, while carefully selecting the drugs in the 
regimen that minimize the possibility of drug-drug interactions. When extensive anti-retroviral 
(ARV) therapy is considered, it is noted that administration of regimens is inefficient. The 
issuing of regimens without further comprehensive strategies may propagate poor 
adherence, which can culminate to detrimental drug resistance, disease progression, 
incomplete viral suppression and, in extreme cases, death (Bangsberg et al., 2003). This 
failure to adhere is commonly instigated by the complex regimens and debilitating side 
effects (Fogarty et al., 2002). Furthermore, as with TB chemotherapy, patients have to 
consume an excessive number of tablets, which is a common cause for non-compliance. 
Non-adherence by HIV-infected patients has been associated with incomplete viral 
suppression, the development of drug resistance, disease progression, and mortality (Nicca 
et al., 2007).  
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With such factors in mind, regimen treatment needs to be designed in such a manner that 
minimizes the physical number of tablets a patient is required to take and/or reduce the 
dosage frequency while maintaining therapeutic levels. Currently, most viral strains lack 
resistance to more than one type of ARV and it is generally accepted that regimen therapy is 
an efficient way to treat highly advanced viruses. Ideal regimens for maximal efficacy should 
contain 3 different drugs from 2 separate classes, with the objective of suppression of the 
viral load to allow for an improvement in the immune system and to abstain from any 
resistance.  
 
To aid health care professionals in the dispensing of HIV anti-retrovirals (ARV’s), the highly 
active anti-retroviral therapy (HAART) program was designed. This categorized ARV’s into 4 
main subtypes: non-nucleoside reverse transcriptase inhibitors (NNRTI’s), nucleoside 
reverse transcriptase inhibitors (NRTI’s), protease inhibitors (PI’s) and fusion inhibitors 
(Boguszewski et al., 2005). NRTI’s in being nucleoside analogues function as false 
substrates for reverse transcriptase. In doing so, termination of the DNA chain occurs. 
NNRTI’s inhibit reverse transcriptase directly and as such potently suppress HIV replication. 
PI’s are potent suppressors of HIV replication and are mostly used in combination therapy. 
They inhibit the protease enzyme which prevents cleavage of viral polyproteins and results in 
poorly formed and non infectious HIV particles (Tibotec HIV information and living with HIV 
medications, 2010).The following fixed regimens are recommended for therapy:  
 
1) NNRTI-based regimen: Efavirenz + Lamivudine or Emtricitabine + Zidovudine or 
Tenofovir  
2) PI-based regimen: Kaletra® (lopinavir/ritonavir) + Lamivudine or Emtricitabine + 
Zidovudine  
 
Alternative Regimens include one of the following NNRTI-based regimens:  
1) Efavirnez + Lamivudine or Emtricitabine + Abacavir or Didanosine or Stavudine  
2) Nevirapine + Lamivudine or Emtricitabine + Zidovudine or Stavudine or Didanosine or 
Abacavir or Tenofovir   
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One of the following PI-based regimens may also be instituted:  
1) Atazanavir + 2 NRTIs  
2) Fosamprenavir + 2 NRTIs  
3) Fosamprenavir + Ritonavir + 2 NRTIs  
4) Indinavir + Ritonavir + 2 NRTIs  
5) Indinavir + Ritonavir (Kaletra®) + Lamivudine or Emtricitabine + 1 NRTI other than 
Zidovudine  
6) Nelfinavir + 2 NRTIs  
7) Saquinavir sgc or Saquinavir hgc + Ritonavir + 2 NRTIs  
Adapted from Temesgen et al., 2006  
 
With such complicated regimens, the need for a delivery system to manage the issue was 
urgent. An attempted solution was the fixed dose combination (FDC). The FDC means of 
drug delivery offers a relief from complex regimens and aimed to rectify compliance. With an 
FDC, 2 or 3 ARV’s can be incorporated into a single pill or tablet.  The implications of such a 
delivery system can be clearly outlined in terms of lowered costs and simplified dosing. The 
outcome of such implications is the limiting of monotherapy, which is a problem in resource 
poor countries. However, a problem faced with FDC design is that not all regimens can be 
formulated into a single pill and not all FDC’s have been approved (US Department of Health 
and Human Services Food and Drug Administration, 2006).  
 
One of the most frequently prescribed regimens used in Africa includes the regimen of 
nevirapine, lamivudine and stavudine. A study by Laurent and co-workers (2004) chose to 
assess the efficacy and safety of creating an FDC with the above mentioned ARV’s. A valid 
point to take note of in economically impaired countries is the lack of resources and an 
established infrastructure to meet the demands of the HAART program. The cost for the 
average HIV infected individual in such regions is quite high especially when taking into 
account that the person has to purchase individual drugs. The cost for an FDC is much lower 
than independently priced drugs and additionally improves compliance through simply taking 
fewer tablets. 60 patients were each given 1 tablet of the fixed dose combination twice a day. 
The researchers concluded that such a system was in fact reliable and efficacious with an 
adherence rate of 99%. With such a positive outcome from this study, it was concluded that 
further exploration into FDC’s is warranted.  
 
The benefits of better adherence and reverting from monotherapy highlights only more 
efficient drug therapy especially in resource poor environments where compliance and erratic 
supply of individual drugs are problematic. Despite the positive appearance of FDC’s, there 
are not enough studies underway for safety, efficacy and tolerability. More emphasis needs 
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to be placed on such studies so that more interest and development can be placed on 
FDC’s.  Current examples of FDC’s include Combivir® and Trizivir® (GlaxoSmithKline, 
Research Triangle Park, NC, 27709). Combivir® is an FDC comprising of Lamivudine and 
Zidovudine. Both actives are synthetic nucleoside analogues and fall under the category of 
nucleotide reverse transcriptase inhibitors. The use of such an FDC must be in a beneficial 
manner with other ARV’s. Studies show that use of Combivir® and a non-nucleoside reverse 
transcriptase inhibitor or a protease inhibitor decreases the likelihood of viral resistance 
(AIDS treatment data network, 2006). Trizivir® comprises Abacavir, Lamivudine and 
Zidovudine with dosage being a single tablet twice daily (TreatHIV.com, 2010).  
 
One of the main benefactors of FDC’s are developing countries in Africa. Malawi is one such 
country, suffering from more than 85000 deaths per year and numerous patients are 
receiving insufficient and inadequate ARV therapy (The Malawi Paediatric Antiretroviral 
Treatment Group, 2007). Poor economic growth and lack of capital are trademarks for many 
poverty stricken African countries and it is these countries which are affected most drastically 
by HIV/AIDS. Focus, until quite recently, remained on adults in Malawi, but in an article by 
the The Malawi Paediatric Anti-retroviral Treatment Group, emphasis for treatment was 
placed on children. The first line treatment for HIV in Malawi is Triomune®, an FDC including 
stavudine, lamivudine and nevirapine (Cipla Ltd, Mumbai Central, Mumbai, India). Adult 
therapy includes 1 tablet twice daily of Triomune-30® for patients weighing less than 60kg. 
For patients above 60kg, 1 tablet of Triomune-40® is prescribed daily (United Pharmacies, 
2010). Children require a separate dosing schedule guidelines were stipulated for FDC 
therapy as shown in Table 2.1. The consensus of the treatment group included a positive 
outlook on the development of more FDC’s especially in developing countries. Positive 
outcomes were seen in the groups used for the study, with viral loads decreasing. 
 
Table 2.1 Paediatric treatment guidelines for HIV/AIDS 
Weight of the child (kg) Dose in the morninga Dose in the eveninga 
<8 
8-11 
12-17 
18-21 
22-27 
28-31 
32-37 
>38 
¼ tablet 
¼ tablet 
½ tablet 
½ tablet 
¾ tablet 
¾ tablet 
1 tablet 
1 tablet 
None 
¼ tablet 
¼ tablet 
½ tablet 
½ tablet 
¾ tablet 
¾ tablet 
1 tablet 
aDose of Triomune® tablet having the composition: 40mg stavudine,150mg lamivudine and 
200mg nevirapine (adapted from The Malawi Paediatric Antiretroviral Treatment Group, 
2007) 
 
FDC’s are an intricate part of ARV therapy, especially in developing countries. The benefits 
from using such a delivery system cannot be ignored. FDC’s offer one of the cheapest 
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means of ARV treatment without losing any efficacy. Whilst such a treatment is beneficial so 
far as cost is concerned, the availability of combination products is limited to major cities and 
developed countries (Meldrum J, 2003). Pressure must be placed on governments to 
establish a means of procurement and distribution of basic FDC’s to resource poor 
communities. Patenting and intellectual property rights directly affect the distribution of FDC’s 
according to Warren Kaplan (2010) in his critique describing the need for FDC’s (Kaplan, 
2010). The recommendations from this critique include, making intellectual property 
information more freely available, the integration of intellectual property/ legal issues 
regarding FDC’s of both HIV and TB and to incentivize private sector development of FDC’s. 
Whilst FDC’s address compliance issues, detrimental drug interactions that occur amongst 
ARV’s and actives used in opportunistic infections are not controlled. 
 
2.2.2 Opportunistic infections with HIV/AIDS 
Opportunistic infections are critical complications for an HIV/AIDS patient. Treatment often 
means compounding already extreme regimens and potential interactions. According to 
Table 2.2, oesophageal or pulmonary candidiasis, had a 19% frequency as an opportunistic 
infection amongst children (taken from a pool of 771 patients) and is described as the most 
frequent mucocutaneous disease in HIV/AIDS paediatric patient (Van Dyke, 1995).  
 
Table 2.2 Frequency of opportunistic infections amongst paediatric patients 
Opportunistic infection % Frequency amongst paediatric 
patients (pool of 771 patients) 
Pneumocystis carinii pneumonia 31 
Lymphoid interstitial pneumonitis 20 
Candidiasis, oesophageal or pulmonary 19 
Failure to thrive 16 
HIV encephalopathy 15 
Multiple/recurrent bacterial infections 13 
Cytomegalovirus 9 
Nontuberculous mycobacteria 5 
Herpes simplex virus 4 
Cryptosporidiosis 3 
Tuberculosis, disseminated 1 
CNS toxoplasmosis 1 
Lymphoma 1 
Adapted from Van Dyke, 1995 
 
Oral candidiasis, is a common infection amongst HIV/AIDS patients and can occur in 3 forms 
individually or may even present concurrently. Pseudomembranous Candidiasis or thrush is 
presented as a loosely held creamy and yellowish plaque which is inflamed and resembling 
milk curds. These elevated lesions are prominent on any mucosal surface. Ulceration may be 
a complication and the lesions have been known to spread to most areas of the mouth. 
Erythematous Candidiasis similarly occurs on any mucous membrane but often occurs in the 
region where the tongue touches the palate and the lesions present as red patches. Angular 
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Chelitis presents with cracks and fissures at the commissures and lesions are present 
bilaterally (Greenspan, 1994; Hoepelman and Dupont, 1996). Treatment for oral candidiasis 
comprises topical formulations (usually requiring a minimal half an hour contact time) using 
nystatin, amphotericin B and the azole derivatives resulting in clearing of the lesions. 
However deep seated infections such as oesophageal candidiasis requires systemic 
treatment in the form of the azole compound ketoconazole or the triazole compounds 
itraconazole and fluconazole (Greenspan, 1994; Hoepelman and Dupont, 1996; Farah et al., 
2000). 
 
Table 2.3 Typical therapy for oral candidiasis  
Active Form Dosage 
NystatinT Cream 100 000 units/g to be 
applied 2-4 times daily 
NystatinT Ointment 100 000 units/g to be 
applied 2-4 times daily 
ClotrimazoleT Cream 1% 10mg/ g (1%) to be applied 
2-3 times daily for 2-4 
weeks 
KetoconazoleT Cream  2% 20mg/g (2%)to be applied 
twice daily until a few days 
after symptoms have 
disappeared 
KetoconazoleS Tablet 200mg 200mg to be taken once 
daily with food 
FluconazoleS Capsules 50mg, 100mg and 
200mg 
50-100mg daily for 7-14 
days 
ItraconazoleS Capsules 100mg or oral 
solution 10mg/mL 
200mg daily for 1-2 weeks 
Amphotericin B IV infusion 0.6mg/kg/day for 2 weeks 
T represents a topical formulation and S a systemic formulation (adapted from The South 
African Medicines Formulary, 2005 and Greenspan, 1994)  
 
Treatment of candidiasis follows set guidelines but complications do arise with co-morbidities 
such as HIV/AIDS. The issues surrounding treatment of the 2 conditions simultaneously has 
been under scrutiny for many years, (Sangeorzan et al., 1994; Silverman et al., 1996; 
Migliorat et al., 2004), but focus for the purpose of this dissertation shall be on the direct 
interaction that occurs between ketoconazole and didaosine. 
 
2.2.3 Interactions between ketoconazole and didanosine 
Ketoconazole is an antifungal agent belonging to the imidazole group that has been 
successfully used since the 1980’s (Maertens, 2004). It is chemically referred to as a (α)cis-
1-acetyl-4-[p-[[2-(2,4dichlorophenyl)-2-imidazol-1-ylmethyl) 1,3-dioxolan-4-yl]methoxy]phenyl] 
piperazine and is insoluble in water. The mechanism of action for ketoconazole has various 
proposals including being a cytochrome P450 inhibitor, interference with ergosterol 
synthesis, interrupting drug metabolism through blocking the activation of the nuclear 
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receptors and mobilization of Ca2+ in renal tubular cells (Jan and Tseng, 2000; Moody et al., 
2004; Ko-Long et al., 2009; Huang et al., 2007).  
 
Therapeutically, it is used for mycotic infections, antifungal therapy and is used often for 
opportunistic infections in immune-compromised patients (Córdoba-Díaz, 2001; Karasulu et 
al., 2004). Ketoconazole has very distinct advantages as an antifungal in that it can be given 
as a single dose and be used for systemic and topical infections (Patton et al., 2001).    
 
Didanosine is an anti-retroviral nucleoside reverse transcriptase inhibitor. This synthetic 
nucleoside analogue is referred to chemically as 2’,3’-dideoxyinosine and structurally, 
didanosine follows a similar structure to adenosine but for the presence of hydrogen at the 3’ 
position on the ribose ring in place of the hydroxyl group. Additionally, a substituted primary 
amine on the nucleoside moiety is present. Dideoxyadenosine 5’-triphosphate is the active 
metabolite formed intracellularly by cellular enzymes. HIV-1 reverse transcriptase is inhibited 
from its natural substrate deoxyadenosine 5’triphosphate by dideoxyadenosine 5’-
triphosphate and furthermore, the active metabolite of didanosine assimilates itself into the 
viral DNA consequently leading to termination of DNA chain elongation (Videx package 
insert, 2010; World Health Organisation Didanosine guidelines, 2005; Acosta and Fletcher, 
1995). 
 
One of the challenges in didanosine therapy is its instability in an acidic environment 
resulting in its degradation to hypoxanthine with bioavailability as low as 20%. In many cases 
and studies bioavailability often fluctuates but at a low level (Sinko et al., 1994; Acosta and 
Fletcher, 1995). Increasing the dose can even lead to a decrease in bioavailability in a study 
conducted by Knupp and co-workers (1991). The presence of food also promotes an 
increase in gastric acidity and gastric retention further propagating the detrimental effect on 
didanosine (Crevoisier et al., 2003; Schubert and Peura, 2008). The addition of buffers to the 
formulation or the concomitant usage of antacid allows bioavailability to reach up to +/- 40% 
but this low bioavailability can still be attributed to the acidic environment of the stomach and 
first pass metabolism even with the presence of a buffer (Blum et al., 1988; Bramer et al., 
1993; Moreno et al., 1993; Acosta and Fletcher, 1995; Taburet Singlas, 1996; Aungst, 1999; 
Videx package insert, 2010). 
 
The interaction between didanosine and ketoconazole is referred to as an absorption 
interaction (Gupta et al., 1999).  Ketoconazole requires an acidic environment for favourable 
absorption and the concurrent administration with food enhances an acidic environment. 
Didanosine is converted into the non-active hypoxanthine compound reducing the absorption 
and availability of didanosine. The co-administration of the 2 actives can be seen to lead to 
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the reduction in didanosine absorption and possibly treatment failure. Medication should 
therefore be separated by at least 2 hours with ketoconazole taken at meals and didanosine 
2 hours after (Acosta and Fletcher, 1995; Dykeman et al., 1996; Gupta et al, 1999). 
 
Table 2.4 Discrepancies between didanosine and ketoconazole 
Actives Required pH Time Taken Bioavailability at an 
acidic pH 
Didanosine Basic After meals Low/Impaired 
Ketoconazole Acidic During meals Good 
Adapted from Acosta and Fletcher, 1995; Dykeman et al., 1996; Gupta et al., 1999  
 
2.3 Tuberculosis Regimen Treatment Schemes 
 
2.3.1 Tuberculosis and fixed dose combination liposomal therapy  
TB has been a worldwide crisis for many years. The severity of TB can be attributed directly 
to it being contracted like the common cold (an airborne contaminant), with only a small 
portion required to be inhaled for infection to commence. According to the World Health 
Organization (WHO):  
 
• Someone in the world is newly infected with TB bacilli every second.  
• Overall, one-third of the world's population is currently infected with the TB bacillus.  
• 5-10% of people who are infected with TB bacilli (but who are not infected with HIV) 
become sick or infectious at some time during their life. People with HIV and TB infection 
are much more likely to develop TB (World Health Organisation Tuberculosis fact sheet, 
2010). 
 
The WHO has been vigilant on the current escalation of TB and derived the following 
statistics, as reported in Figure 1 which highlights prevalence and mortality of tuberculosis. 
TB therapy cannot be defined as a simple drug treatment plan. Therapy consists of 
regimental therapy in conjunction with Directly Observed Therapy (DOT). TB therapy is a 
standardized treatment protocol. A 2 months induction period is the first approach and 
includes isoniazid, rifampicin, pyrazinamide and ethambutol. This is then followed by a 4 
month continuation phase of isoniazid and rifampicin (Gleeson and Decker, 2006). TB if left 
untreated or if inadequately treated can lead to further dissemination of TB in the individual, 
spread towards others and multiple drug resistance. The implementation of the DOT protocol 
was aimed at ensuring compliance and efficacious treatment. The program was initiated 
more than 40 years ago and remains today one of the most successful and well studied 
adherence programs to date. Thus the WHO has been ever vigilant on the current escalation 
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of TB and derived the following statistics, as reported in Figure 2.1 and Figure 2.2: 
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Figure 2.1 Estimated worldwide prevalence of tuberculosis (adapted from the World Health 
Organisation Tuberculosis facts sheet, 2010) 
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Figure 2.2 Estimated worldwide mortality from tuberculosis (adapted from the World Health 
Organisation Tuberculosis facts sheet, 2010) 
 
DOT’s for TB is usually carried out with once-daily administration of 4 anti-TB drugs 
(isoniazid, rifampicin, pyrazinamide, and ethambutol), usually 5 days per week for 2 months, 
followed by once-daily treatment with isoniazid and rifampicin, 3–5 days per week, for a total 
of 6–9 months of therapy (Migliori et al., 1999; Friedland et al., 2004).  
 
Whilst DOTS is an effective means of treatment, a more reliable means of drug delivery is 
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required for adequate therapy to ensue. TB therapy must also be observed with a distinct 
complication. This prevalent, common complication is that of resistance to treatment. 
Multidrug-resistant tuberculosis (MDR-TB) and the more recent Extensively-resistant TB 
(XDR-TB) is rife in heavily populated areas with poor infrastructure and ill equipped health 
care services. Drug resistance can be attributed to direct causal aspects such as non 
adherence or failure to complete courses and the tendency of some strains of 
mycobacterium to undergo mutation and co-morbidity with conditions such as HIV/AIDS (Rad 
et al., 2003; Shah et al., 2007).  
 
The severity of such resistance can be seen in areas incapable of upholding a reliable DOTS 
program. The DOTS program requires a dynamic and committed effort from both private and 
public sectors of health care and consequently, developing countries are affected by both 
MDR and XDR TB with an increasing affinity (Pepper et al., 2007). MDR TB can be defined 
as TB resistant to initial TB therapy (isoniazid and rifampicin) whilst XDR TB can be defined 
as being resistant to isoniazid and rifampicin and to any of the fluoroquinolones and to at 
least one of the following injectable drugs: capreomycin, kanamycin, and amikacin. This 
problem can be seen to extend to developed countries as resistant strains can easily spread 
from region to region through a host of travel mediums such as commercialized flights and 
trade routes through both sea and air transport agents and even travel holidays (Aziz et al., 
2001; Dowdall et al., 2006; Martinez  et al., 2007).      
 
Drug delivery systems that have the potential to negate the challenges associated with TB 
therapy include liposomal drug delivery, developed more than 25 years ago. Brenda Ryman 
in the 1970’s, proposed the idea of targeted drug delivery using liposomes and described the 
use of the technology in anticancer and antimicrobial therapy (Gregoriadis, 1995). 
Applications of liposomes are seen in a range of daily uses from cosmetic applications to 
drug delivery (Lasic and Papahadjopoulos, 1998). Liposomal design and theory has been 
well defined in the past as micro- to nanoscale, spherical vesicles formed through the 
hydration of phospholipids (Bangham, 1968). Anticancer and antibiotic therapies are most 
often associated with liposomal therapy and reveal much success (Bao et al., 2006). The 
formation of liposomal vesicles is due to hydration of phospholipids. The advantages of 
liposomes include the ability to encapsulate a large volume of drug and the functionalization 
of the liposome composition (Lasic, 1993). Liposomes can be categorized as conventional, 
long circulating, cationic or targeted liposomes. In order for liposomes to have a desired 
function, they must bypass the mononuclear phagocyte system to decrease the rate of 
uptake by phagocytes. To counter this, long circulating or stealth liposomes have been 
developed by attaching polyethylene glycol (PEG) via coupling PEG to 
phosphatidylethanolamine in the liposome bi-layer. Uptake into the reticular endothelial 
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system and opsonization are prevented as the PEG provides a layer of steric hindrance 
(Crommelin  et al., 2002). PEG has seen many applications where block copolymers are 
formed with the process of PEGylation in which PEG is added to a particular polymer. The 
addition of PEG is a process that has been incorporated into numerous drug delivery 
systems, the copolymers of which have many beneficial functions. Functionally, PEGylation 
can offer an improvement in solubility of proteins, a protection from immune response and a 
decrease in antigenicity (Pierce the protein people, 2008). 
 
Monomeric repeating units of ethylene glycol comprise a single molecule of water soluble 
PEG and has a formula of H(OCH2CH2)nOH, with ‘n’ as the average number of repeating 
ethylene oxide groups as depicted in Figure 2.3. The conventional uses of PEG include a 
thickening agent and when chemically reacted with fatty acids results in detergents having 
both thickening and foam stabilizing characteristics. Further utilization can be seen in the 
cosmetic, ceramics and textile industry revealing the versatility of PEG. Grading of PEG is 
greatly dependent upon the average molecular mass of the molecule in which higher 
molecular masses results in a decrease in water solubility and solubility in certain solvents. 
Due to these properties it is evident that PEG is extensively used in the development of drug 
delivery systems even by forming co-polymers in the process of PEGylation (Quellen, 2003, 
Khandare; Minko, 2006). When PEGylation occurs the PEG molecule is incorporated onto 
the surface of the molecule providing the entire system a physical shielding against the 
body’s immune system. This concept of a stealth system has been furthered in more than 
just liposomes and has seen expression in microparticle drug delivery as depicted in Figure 
2.4 (Dorati et al., 2007). The injectable microparticle system is effectively shielded from the 
immune system due to the presence of PEG in a similar manner to the liposome delivery 
system (Panoyan et al., 2003).       
 
 
OH
O OH
n
 
Figure 2.3 Chemical structure of polyethylene glycol) (Quellen, 2003) 
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Figure 2.4 A schematic depiction of superficial polyethylene glycol segments on a 
microparticulate imparting the stealth function (adapted from Dorati et al., 2007) 
 
When considering the management of TB using regimental therapy, liposomal drug delivery 
was implemented in a recent study by Khuller and co-workers (2004), where isoniazid and 
rifampicin were incorporated into intravenously administered stealth liposomes. Preparation 
of the liposomes included the use of probe sonication and the addition of O-
stearylamylopectin, which provided an increased affinity of the liposomes to lung tissue. It 
was found that the liposomal therapy was more effective than administering free drug. The 
liposomal delivery system provided sustained drug release and was considerably stable, less 
toxic and exhibited a greater efficacy in clearance of mycobacterial infections compared to 
the drugs administered individually. The use of stealth liposomes was concluded to be an 
effective carrier of both the antimycobacterial drugs isoniazid and rifampicin. Numerous 
studies have also shown that drug concentration is more vital in the alveolar macrophages 
than the systemic circulation as the mycobacterium accumulates in these specific cells 
(Suarez et al., 2001). Therefore, emphasis has been placed on the development of more 
site-specific drug delivery to the lung alveolar macrophages, as opposed to conventional 
systemic delivery. Liposomes may also act as drug reservoirs to provide slow and sustained 
drug release and their nanoscale size has applicability in the targeting of the alveolar 
macrophages. This approach would not only be advantageous in reducing the cost of TB 
treatment but also have the potential to shorten the duration of the treatment. Liposomal 
technology has been in existence for many years but has not been fully exploited. Particular 
interest can be shown for pulmonary delivery due to the nano-size and the diversion from 
invasive injectable administration. Sustained drug release can be achieved for chronic 
conditions such as TB, asthma and even diabetes using liposomal technology (Liu et al., 
1993; Huang and Wang, 2006). Liposomes as a mode of FDC administration should be 
explored with reference to other chronic conditions such as hypertension, asthma, and 
diabetes that require multi-drug therapy, in view of the highly controlled and sustained drug 
release and the decrease in total therapeutic doses required. 
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Figure 2.5 Schematic representing the various liposomes (adapted from Khuller et al., 2004) 
 
Further exploration of TB treatment has been shown with drug-loaded polymeric 
nanosystems. du Toit and colleagues (2008) developed nanosystems using an emulsion-
based-salting-out approach. The foremost challenge with site-specific drug delivery for 
pulmonary pathologies is the anatomical barrier in which most particles are prevented from 
reaching the terminal ends of the pulmonary system. Nanosystems can effectively bypass 
this barrier and offer a flexible yet rate controlled release of the selected drug. Nanosystems 
are an emerging technology, in particular for regimen therapy but an oral delivery system is 
still the preferred medium to date.     
   
2.3.2. Tuberculosis and osmotically regulated drug delivery systems 
Osmotically regulated multi-drug delivery systems have been introduced for the management 
of TB and have been considered to be an oral system catering to regimental concerns. As 
the name describes, the system offers an oral drug delivery system and the simultaneous 
delivery of more than one type of drug in a single delivery system. Prabakaran and co-
workers (2004) demonstrated the use of an osmotic drug delivery system for the concurrent 
administration of rifampicin and isoniazid for the treatment of TB in which asymmetric 
membranes were utilized. Asymmetric membrane capsules are osmotic delivery systems 
used for precisely controlled drug delivery (Figure 2.6). 
 
Asymmetric membrane coatings for tablets were developed to further increase coating 
permeability. The coating consists of a porous substrate with a thin outer layer or skin. Drugs 
that have poor solubility or a higher dose can be delivered osmotically and at a more 
controlled and higher release rate compared to conventional osmotic systems. This approach 
of osmotic delivery is due directly to the high water flux provided by the asymmetric 
membrane coatings. The basic framework of an asymmetric membrane capsule is that of a 
single-core osmotic delivery system comprising a drug-loaded core surrounded by the 
asymmetric membrane. The advantages of the delivery system include the selection of 
membrane permeability by altercation of the membrane structure which in turn may modify 
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the drug release profiles. In addition, the porosity of the outer layer or skin can be 
manipulated and thereafter minimize the lag time prior to the commencement of drug 
release. This feature allows drug to be released from a large number of delivery ports. The 
technology can be applied to both multiparticulate and capsular delivery systems (Herbig et 
al., 1995; Thombre et al., 1999; Lin and Ho, 2003). The study performed by Prabakaran and 
colleagues (2004) utilized a variety of materials for designing the asymmetric membrane. 
The capsule shell that modulates the drug release from the delivery system usually 
comprises a water soluble polymer such as cellulose acetate. Normal capsular systems are 
composed of gelatin but with the substitution of cellulose acetate, sustained release of the 
chosen drug from the system may be achievable. Cellulose acetate is defined as an 
adaptable polymer. Due to its extreme versatility, cellulose acetate can be easily bonded with 
heat, pressure and plasticizers. The wide range of applications, found in numerous 
methodologies, is directly related to the solubility of cellulose acetate in a host of solvents. 
Furthermore it is biocompatible and therefore is often used for the design of drug delivery 
systems (Audoin, 2003).    
 
 
Cross-section of membrane
Porous region
Dense, thin region
 
Figure 2.6 Schematic of an asymmetric membrane capsule (adapted from Prabakaran et al., 
2004) 
 
2.3.3 The interaction between isoniazid and rifampicin 
In 1994, the World Health Organization (WHO) and the International Union against 
Tuberculosis and Lung Disease (IUATLD) cautioned the use of FDC’s which included 
simultaneous use of rifampicin and isoniazid. The use would only be permitted should the 
bioavailability of rifampicin prove adequate (World Health Organization Communicable 
Diseases Cluster, 1999). A recent study by Shishoo and co-workers (2001) demonstrated the 
low bioavailability of rifampicin when co-administered with isoniazid in an FDC. It has been 
postulated that the presence of isoniazid enhances the degradation of rifampicin in the 
stomach (Seifart et al., 1991).  
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A recent study by Mariappan and co-workers (2000) discovered a new peak (due to the 
formation of isonicotinyl hydrazone) that coincided with the degradation of rifampicin in the 
presence of isoniazid. It is proposed that once 3-formylrifamycin is formed within the acidic 
conditions of the stomach, there is a direct interaction with isoniazid to form isonicotinyl 
hydrazone, through a fast second-order reaction.  
 
The isonicotinyl hydrazone is unstable in an acidic environment and consequently 
regenerates isoniazid and the insoluble 3-formylrifamycin by a pseudo first-order reaction. As 
the second-order forward reaction is faster than the preceding (rifampicin to 3-
formylrifamycin) and the following (hydrazone to 3-formylrifamycin and isoniazid) first order 
reactions, the overall reaction is favoured towards the formation of isonicotinyl hydrazone as 
rifampicin is degraded to 3- formylrifamycin (Singh et al., 2001). Figure 2.7 shows the 
chemical pathway leading to the degradation of rifampicin. 
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Figure 2.7 The pathway of the decomposition of rifampicin due to the presence of isoniazid 
(adapted from Singh et al., 2001)    
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2.4 Regimen Strategies for the Asthma Management 
 
2.4.1 Asthma and fixed dose combination drug delivery systems 
Currently asthma is another regimentally treated condition affecting individuals on a daily 
basis with more than 300 million people affected worldwide. If inappropriately managed, 
asthma can become a debilitating condition to any patient in many circumstances. As a 
general definition, asthma is a chronic respiratory condition marked by inflammation of the 
lung tissue, though there is no generally accepted accurate definition of asthma. Airway 
obstruction, hyper-responsiveness and remodelling are also noted to occur (Diamant et al., 
2007). The actual occurrence of asthma may in fact be much higher due to the fact that 
asthma does not have a precise definition and in many case misdiagnosis is a frequent 
occurrence (GINA science and executive committee Global Strategy for Asthma 
Management and Prevention, 2009). The debilitating nature of asthma can affect a patient’s 
daily routine through a host of stimulating factors. Simple activities such as walking, running 
climbing stairs or participating in sports are factors than can elicit an asthmatic attack. 
Allergens can elicit both early and late asthmatic responses and act through an IgE-mast 
cell-triggered immune response, resulting in the typical inflammatory action associated with 
an acute attack (Boulet et al., 2007).  
 
Certain patients exhibit asthmatic attacks due to drugs such as aspirin. Bronchoconstriction 
occurs as leukotrienes are released by eosiniphils due to aspirin degradation in aspirin 
sensitive patients (Nasser et al., 1996). More emphasis needs to be placed on studies 
relating to clinical proof of concept so that exact causative factors of asthma can be 
understood. Too much uncertainty surrounds the aetiology of asthma and in particular what 
may elicit an asthmatic attack. Functional and relative testing should be explored further such 
that current regimens with asthma therapy can be evaluated for efficacy and the quality of 
treatment (Diamant et al., 2008). Most cases of patient therapy reveal an unmet treatment 
plan due to: 1) patient non-compliance, 2) poor understanding of treatment plans 3) poor 
patient-practitioner communication and 4) unmet treatment needs. Whilst treatment regimens 
for asthma are designed to optimize therapy, they fail to take into consideration a patient’s 
daily functions and lifestyle. It is therefore quite understandable that the most frequent 
complaint from most patients is maintaining vigilance with drug administration (Hyland and 
Hi, 2004). Asthmatic therapy can be expressed as short-term relief and long-term 
management. Acute onsets or attacks are treated with selective short-term drugs and long-
term drugs are crucial for the sufficient control over asthma. The combination of drugs into a 
single FDC may pose a few challenges with the treatment of asthma. The combination of 2 
or more drugs should not result in a deleterious interaction between the 2 drugs. Specifically, 
3 types of interactions that are likely to occur include interactions between the drugs, the 
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drugs and the carriers and the drug and the device (Sanders, 2003). However, despite these 
potential drawbacks on manufacturing and cost, the patient’s benefits outweigh the failure 
rate. Various inhalation devices have been developed for the purpose of acknowledging 
patients needs with regards to complex asthma regimens.  
 
Advair Diskus® is an inhaler drug delivery system utilizing a FDC. The system comprises 2 
drugs, fluticasone proprionate (a corticosteroid) and salmeterol (a long-acting β-agonist) 
(Nelson, 2001). The combination of the 2 drugs offers benefits in that there are now 2 distinct 
and separate mechanisms of actions occurring in a single drug delivery system. A study by 
Baraniuk and co-workers (1997) showed that therapeutic doses of glucocorticoids can 
increase the number of β-receptors functionally depicting the 2 drugs simultaneously (Figure 
2.8). Furthermore β-agonists such as salmeterol initiate ligand independent activation of 
glucocorticoid receptors (Eickelberg et al., 1999). This approach therefore offers superior 
function and efficacy, an economical treatment option as opposed to purchasing the 
individual drugs separately and improved patient compliance (Nelson, 2001).  
 
Corticosteroids
Anti-inflammatory effect
Corticosteroid increases 
density of beta-agonist 
receptors
Beta-agonist enhances steroid 
receptor translocation
Long acting beta-agonists
Bronchodilation
 
Figure 2.8 Illustration depicting the complimentary effect of corticosteroids and long-acting β-
agonists in a single fixed dose combination (adapted from Baraniuk et al., 1997) 
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Table 2.5 Typical drugs employed in asthma treatment regimens 
Type of drug Short/long-term 
therapy 
Mechanism of action 
 
β-Agonists 
 
Short 
 
Bronchodilators responsible for smooth muscle 
relaxation 
Corticosteroids Short Anti-inflammatory used in conjunction with 
short acting β-agonists for acute attacks 
Anticholinergics Short Reduction in vagal tone of airways via 
antagonistic effect on muscurinic receptors 
Methylxanthines Long Mild-moderate bronchodilator used in 
combination with inhaled corticosteroids 
Immunomodulators Long Monoclonal antibody preventing IgE mediated 
inflammation 
Leukotriene 
modifiers 
Long Leukotriene receptor antagonist and a 5-
lipoxygenase inhibitor 
Cromolyn sodium 
and Nedocromil 
Long Interferes with chloride channels function and 
stabilizes mast cells 
Corticosteroids Long Anti-inflammatory 
β-agonists Long Bronchodilators with a duration of action up to 
12 hours 
Adapted from the National Heart Lung and Blood Institute, 2010 
 
Furthermore, the drug eformoterol has been formulated with budesonide in a single drug 
delivery system known commercially as Symbicort®. This delivery system is also a metered 
dose inhaler and similarly to Advair® comprises both a corticosteroid and a long-acting β-
agonist. The delivery system offers the same advantages of combination therapy such as 
reducing the drug quantity, enhancing efficacy and an instantaneous bronchodilating effect 
with the use of eformoterol (Palmqvist et al., 1999). Use of an inhaled corticosteroid in 
conjunction with a long-acting β-agonist in a FDC inhaler is noted as beneficial to patients 
with regards to efficacy, convenience and the decrease in systemic side-effects (Currie et al., 
2005). 
 
As detailed in this chapter, 3 relevant and prominent conditions and the associative regimen 
therapies have been detailed as well as the pertinent drug delivery systems. The ODMUS 
shall cater for these and any other therapies requiring regimen therapy but shall not utilize 
the delivery systems discussed in Chapter 2.  
 
In retrospect, all aforementioned systems have drawbacks and a different approach to 
formulating a novel delivery system was sought after taking into account:  
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• Novelty  
•  A simplified formulation method 
• Cost effectiveness 
• Scale up  
• Oral delivery  
•  And site-specific controlled delivery of 2 different pharmacological actives 
  
2.5 The Role of a Dualistic Oral Drug Delivery System Encompassing both 
Multiparticulate and Membranous Technology for Drug Regimen Therapy 
 
Multiparticulate carrier systems have vast positive implications for advanced drug delivery. In 
particular multiparticulates or hydrogel beads have been shown increasing interest due to 
their small size, which allows the particulates to easily pass through the upper 
gastrointestinal tract (GIT) (Meyer et al., 1985). This has an advantage over larger drug 
delivery systems such as tablets or capsules due to their size, which allows an even or more 
uniform dispersion of drug throughout the GIT, more reliable and accurate drug absorption 
with less intra and inter-patient variability (Zhang et al., 2002) and the overall delivery of drug 
is independent of the nutritional state of the patient (Kramer and Blume, 1994; Schmidt and 
Bodmeier, 2001). This is specifically beneficial for the simultaneous treatment of candidiasis 
and HIV in which didanosine is taken after meals and ketoconazole during meals as stated in 
Table 2.4 in Chapter 2.2.3. Furthermore it has long been established that multiparticulates 
have the potential to be retained in the colon for longer durations thus making them suitable 
in instances where one of the drugs within a FDC is required for local or site-specific 
treatment within the colon (Wilson and Wood, 1958). Therefore, multiparticulates are an ideal 
delivery system to be used in the ODMUS. 
 
One of the most reliable factors of multiparticulates includes the ability to deliver reliable 
quantities of drug. This can be explained in that the loss of a single particulate does not 
translate to failure of the entire delivery system. Most multiparticulate systems undergo a 
spray congealing process which allows for further entrapment of drug, so as to be used for 
regimental drug therapy in order to obtain a pulsatile effect or release rate. The core of the 
particulate comprising of a suitable water soluble/swellable polymer is encapsulated by an 
insoluble polymer. Upon contact with gastric/colonic fluid, the swellable layer expands and 
ruptures the outer layer allowing for the pulsatile drug release that is required (Dashevsky 
and Mohamad, 2006). A study by Lamprecht and co-workers (2000) showed the use of 
multiparticulates in delivering FDC’s. Sulfasalazine and betamethasone were entrapped 
within the multiparticulates and microencapsulation was performed by a solvent 
evaporation/extraction technique. Selection of the technique is determined by the solubility of 
the drug and polymer in various solvent systems (Alex and Bodmeier, 1990; Nihant et al., 
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1994) and allowing for encapsulation of either water soluble or insoluble drugs (Bodmeier et 
al., 1994). For the purposes of the ODMUS however, a simplified method was developed 
avoiding the intricate process of microencapsulation. In addition, polymers used for the 
design of drug regimen therapies have to be carefully selected, as the type of polymer 
dictates the site-specific release capabilities of the system.  
 
Previously described in Chapter 1, hydrogels are intricate porous polymeric networks that 
retain and entrap large volumes of water (Rajagopal and Schneider, 2004; Nair and 
Laurencin, 2006; Lee and Yuk, 2007). Functionally, a hydrogel has the ability to swell in an 
aqueous environment and entrap large volumes of water while maintaining its 3-dimensional 
network (Qiu et al., 2003). Membranous systems formulated from the described hydrogels 
offer an attractive solution for regimen therapy, in particular biodegradability and 
biocompatibility (Gong et al., 2009) and can be used in conjunction with multiparticulates. 
The versatility of membranous systems can be seen through its extensive use with artificial 
organs, tissue regeneration, diagnostic devices and drug delivery (Stamatialis  et al., 2008).  
In terms of drug delivery, membranes have utilized various delivery systems to achieve 
controlled drug release illustrated in Figure 2.9. Most often, membranes find expression in 
osmotic membrane systems, which is composed of a semi-permeable membrane allowing 
water to diffuse in and the concentrated drug to leave its reservoir in a modulated manner 
(Kuethe et al., 1992). Fick’s Law of diffusion governs the release mechanism for diffusion 
controlled membrane systems in which membranes can be porous, non-porous and 
biodegradable. A popular formulation method for membranous systems is that of phase 
inversion. A homogenous solution of solvent, polymer and various constituents (including 
drug), undergoes phase separation due to the solvent evaporating into the atmosphere or by 
a solvent-nonsolvent exchange in a quench bath resulting in membrane formation (McHugh 
2005; Ma and McHugh, 2007).   
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Figure 2.9 Sub-classes of membranous systems (adapted from McHugh, 2005) 
 
Other systems utilizing membranous technology include pills, implants and patches clearly 
identifying the versatility of membranes (Stamatialis et al., 2008). The core release 
mechanisms for synthesized polymeric membranes include dissolution, diffusion and 
erosion. The complexity of these release mechanisms is that they can be exhibited 
concurrently within the same membrane obscuring a desired controlled release (Temtem et 
al., 2009). Additionally, methodology, chemical and physical properties and drug content 
effects release patterns incidentally demanding arduous development of membrane systems 
(Siepmann and Siepmann, 2008). In summary, membranes offer an attractive candidate as 
an oral delivery system with the primary advantages being biocompatibility and 
biodegradability. Efficacy is however compromised due to potentially erratic and influenced 
drug release patterns.         
 
The delivery of drug to various regions within the GIT highlights a positive application of such 
a delivery system. A combination of the multiparticulate system and a novel tablet-like 
membranous system is shown in Figure 2.10 and this was the framework upon which the 
ODMUS was designed. Drug release in this manner was pH-dependant, based on the 
polymeric material selected for each component within the multiparticulate and membranous 
system. The multiparticulate system contained a polymeric material rendering the beads 
impervious to the acid like conditions of the stomach. Consequently no leeching of drug 
occurred in the stomach region.  
 
The tablet like membranous system or ‘memblet’, released its active at an acidic pH due to 
its polymeric constituents. The system may offer outcomes in relation to patient compliance, 
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deleterious drug-drug interactions and controlled release of the respective actives. Currently 
oral drug delivery systems do not allow for the delivery of a multiple drug regimens within a 
combination of systems including multiparticulates and a membranous system in unison and 
therefore the ODMUS will be able to decrease the quantity of tablets required for the patient 
to consume on a daily basis. Illnesses such as TB, HIV/AIDS, asthma and infections 
requiring multiple drugs may be most suited for incorporation into the ODMUS.  
 
 
STOMACH (pH1-3.5)
DUODENUM (pH5.5-
6.5)
JEJANUM (pH 6.3-7.3)
The mebranous like tablet or
‘memblet’ consists of a
polymer that erodes at a pH of
between1-3.5 releasing its drug
into the stomach in a rate
controlled manner.
The bead like
multiparticulate system
contains a polymer that
gives the beads and acid
resistant characteristic such
that the beads remain intact
whilst in the stomach. Drug
is site specifically released
at a higher pH of 6.8 in the
small intestine over a period
of 10-12 hours.
A novel, membranous,
tablet like polymeric
system intended for site
specific delivery of drug
into the stomach.
A novel set of bead like
multiparticulates
intended for site
specific delivery of
drug into to small
intestine.
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drug is specifically 
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intestine
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Figure 2.10 Schematic representation of the functional Once Daily Multi-Unit System 
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2.6 Concluding Remarks 
 
This Chapter sought to address the modern therapies requiring regimental treatment and a 
brief synopsis was provided for HIV/AIDS, tuberculosis and asthma. The challenges 
including drug-drug interactions were highlighted and reviewed with particular emphasis on 
ketoconazole-didanosine in HIV/AIDS treatment and rifampicin-isoniazid in tuberculosis 
management. Novel approaches towards regimental therapies were viewed in relation to 
asthma, HIV/AIDS and tuberculosis. Novel delivery systems were discussed to highlight a 
need for development and research with respect to regimen therapy. The necessity for a 
novel delivery system to be developed was enforced. Finally, the selection of membranous 
and multiparticulate technology was introduced and discussed to be incorporated into a once 
daily multiple unit delivery system for the management of regimen therapies to negate drug-
drug interactions, maintain controlled release and improve patient compliance through 
reducing pill quantities.    
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CHAPTER 3                                                                        
PRELIMINARY STUDIES FOR THE DEVELOPMENT AND DESIGN OF 
THE ONCE DAILY MULTI-UNIT SYSTEM 
 
 
3.1 Introduction 
 
In this Chapter, method development and preliminary testing of the ODMUS was the 
primordial focus. A rudimentary understanding of the mechanistic release patterns and 
behaviour of each component of the ODMUS was prerequisite for optimization studies. When 
considering method development, method simplicity and scale up for bulk manufacturing 
were critical points. The methods were not exclusively similar for each respective delivery 
system, but retained the attributes stated above. 
 
Multiparticulate desired properties included a robust quality, relatively aesthetic appearance, 
as accurately as possible a spherical shape and uniformity in shape and size. The 
multiparticulates were to avoid being produced as brittle and ideally not be influenced, with 
regards to bead integrity, by various factors whilst under storage conditions. A generally 
acceptable appearance would circumvent aesthetic coating of the beads and therefore a 
bypassed procedure simplifying bulk manufacturing and formulation procedures. In terms of 
the means of delivery, the multiparticulates had to achieve site-specific drug delivery in the 
small intestine and simultaneously retard any release of drug within the stomach to avoid 
deleterious drug-drug interactions with the chosen drug loaded on the memblet system. 
 
Memblet development followed a parallel study of controlled drug release and 
characterization studies, which required the development of individualized methods. 
Characterization of said memblets influenced methodology in relation to drying time, shape, 
stability and drug loading techniques, bearing in mind that scale up, method simplicity and 
reproducibility were similarly linked to characterization parameters.        
 
Polymeric material was scrutinized to select a polymer of which the inherent properties would 
be imparted to the spheres and the memblet system, such that a functional coating process 
would be negated. An in depth study of Eudragit® polymers was undertaken for both 
systems, taking into account the individual requirements of each respective system in that 
spheres and memblets were to release drug at a higher pH of 6.8 and at a pH of 1.3 
respectively.      
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3.2 Selection of Polymeric Material for the Individual Oral Delivery Systems 
 
3.2.1 Rationale for the selection of polymers for the once daily multi-unit system 
Polymer selection was vital to the success of the ODMUS as the polymeric material indicated 
for each system would influence drug release patterns, release location along the GIT and 
susceptibility of the system towards pH. Novelty was another key factor in polymer selection 
to allow for an innovative means of using the polymeric compound.  
 
Polymethyl methacrylates (PMMA’s), a subclass of the acrylates, have seen extensive use 
as bone cements in orthopaedic surgery (Mestiri et al., 1993) and shatter proof replacements 
for glass. The more conventional use includes surface coating agents for tablets, capsules 
and other dosage forms (El-Malah and Nazzal, 2008; Fini et al., 2008; Ma et al., 2008). With 
regards to pharmaceutical drug delivery systems, Eudragit® products, PMMA’s, are 
traditionally utilized as coating agents. Much exploitation of these polymers has occurred 
over the years as polymethacrylates are excreted unchanged (pharmacologically inert), 
require small amounts for coating and are biologically compatible polymers (Degussa 
Eudragit®, AG Pharma Polymers, Darmatadt, Germany, 2007). Chemical stability and good 
compactability makes these products very relevant and effective choices for novel drug 
delivery research (Ceballos et al., 2005). Figure 3.1 depicts the molecular structure of 
Eudragit® and Table 3.1 categorizes the classes of Eudragit® based on the R functional 
group which ascertains the selective applications and highlights the diverse properties of 
these polymers. The extensive variety of Eudragit® polymers has been directly linked to the 
site-specific release of each polymer and a graphical depiction of individual pH dependant 
release at various points of the GIT, is provided in Figure 3.2.   
 
The use of the Eudragit® PMMA products, whilst extensive, is very limited to spray drying 
from its aqueous dispersion (Rattes and Oliveira, 2007; Al-Zoubi  et al., 2008; Oosegi et al., 
2008) to form a surface coating and based on the grade chosen, elucidate an effect within 
the GIT or to provide taste masking in formulations which have undesirable tastes. Very few 
studies have been conducted to use any Eudragit® PMMA products as the primary polymers 
for formulating the dosage form and loading drug into the said delivery system, (Pignatello et 
al., 2002; Fujimori et al., 2005; Elgindy and Samy, 2009), and as such, very few attempts 
have been made to use any Eudragit® products in a novel way. Cui and co-workers (2007) 
demonstrated a different use of Eudragit® E 100 by using the taste masking polymer as a 
drug carrier and an emulsifying agent in the formulation of a novel redispersible dry 
emulsion. The study successfully produced a novel dry emulsion through incorporation of 
Eudragit® E 100. 
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It was deduced for the purposes of this study that Eudragit® polymers would constitute the 
core of both components of the ODMUS. Due to the extensive range of Eudragit® polymers, 
range is a further look into the various grades in addition to their function was warranted.   
 
C
C O O H-Alkyl
CH2
CH3
R
CH3
 
Figure 3.1 The molecular structure of Eudragit® (adapted from the Degussa Eudragit® 
manual, AG Pharma Polymers, Darmatadt, Germany, 2007)  
 
Table 3.1 Grades of Eudragit® and their properties  
Eudragit® 
Grade 
Type of 
copolymer 
Functional group 
(From Figure 3.1 R=) 
Solubility Applications 
L 100 Methacrylic COOH Gastroresistant 
and 
enterosoluble 
Resistance to 
gastric fluid, 
release in the 
colon 
L 100-55 Methacrylic COOH Gastroresistant 
and 
enterosoluble 
Resistance to 
gastric fluid, 
release in the 
colon 
L 30D-55 Methacrylic COOH Gastroresistant 
and 
enterosoluble 
Resistance to 
gastric fluid, 
release in the 
colon 
E 100 Aminoalkyl 
Methacrylate 
COOH2CH2N(CH3)2 Gastrosoluble Taste and 
odour 
masking, 
protection 
against 
moisture 
E PO Aminoalkyl 
Methacrylate 
COOH2CH2N(CH3)2 Gastrosoluble Taste and 
odour 
masking, 
protection 
against 
moisture 
NE 30D/NE 
40D 
Methacrylate COOCH3 Insoluble, 
permeable, pH-
independent 
Sustained drug 
release 
RL PO/RS 
PO 
Ammonioalkyl 
Methacrylate 
COOCH2CH2N+(CH3)3Cl- Insoluble, 
permeable or 
dispersible, pH-
independent 
Sustained drug 
release 
RL 30D/RS 
30D 
Ammonioalkyl 
Methacrylate 
COOCH2CH2N+(CH3)3Cl- Insoluble, 
permeable or 
dispersible, pH-
independent 
Sustained drug 
release 
Adapted from the Degussa Eudragit® manual, AG Pharma Polymers, Darmatadt, Germany,  
2007 
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Stomach
Eudragit® E 100
Eudragit® EPO
Jejunum
Eudragit® L 100
Ileum
Eudragit® S 100
Eudragit®  FS 30 D
Duodenum
Eudragit® L 30 D-55
Eudragit®  L 100-55
Ascending Colon
Eudragit® S 100
Eudragit®  FS 30 D
 
Figure 3.2 Site-specific release of grades of Eudragit® throughout the gastrointestinal tract 
(adapted from the Degussa Eudragit® manual, AG Pharma Polymers, Darmatadt, Germany, 
2007) 
 
3.2.2 Rational selection of polymers and materials for the multiparticulate portion of 
the once daily multi-unit system 
Figure 2.10, illustrated in Chapter 2.5, graphically summarized the functional application of 
the ODMUS. The multiparticulate delivery system is intended for intestinal drug release 
whilst simultaneously negating the erosion-like effects of the acidic environment of the 
stomach. From Table 3.1, 3 polymers showed functional capability including Eudragit® L 100, 
Eudragit® L 100-55 and, Eudragit® 30D-55. Eudragit® L 100-55, an anionic copolymer of 
methacrylic acid and ethyl acrylate with a carboxylic acid functional group (Figure 3.3), was 
selected due to its gastroresistant and enterosoluble characteristics coupled with its solubility 
at a pH of 6.8 allowing for site-specific delivery of drug to the small intestine. This polymer 
has been traditionally used as an enteric coating agent initially formulated as a latex before 
being applied as a coating (Abbaspour et al., 2008; Oosegi et al., 2008). Additionally, 
Eudragit® L 100-55 contains surfactants sodium lauryl sulphate and polysorbate 80, which 
aid in prevention of aggregation or clumping of polymeric material. As the compound 
contains the above stated surfactants, the burden of physically adding the surfactants is 
bypassed in the formulation method.    
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Figure 3.3 Molecular structure of Eudragit® L 100-55 (adapted from the Degussa Eudragit® 
manual, AG Pharma Polymers, Darmatadt, Germany,  2007) 
 
Prolonged controlled release was a key factor during preliminary studies of the ODMUS. A 
gastroprotectant sphere was inadequate if the sphere exhibited a burst release once 
reaching the proximal portion of the small intestine. Ethyl cellulose has been widely used to 
achieve sustained drug delivery due to its hydrophobic properties (Chambin et al., 2004; 
Desaia et al., 2006). Coating, tablet binding, incorporation into microspheres and 
microcapsules are some of the ways in which ethyl cellulose is used (Babar and Muhammad, 
2002). Therefore, ethyl cellulose was a prime candidate based on these qualities as well as 
its non toxic and relatively stable properties (Crowley et al., 2004).   
 
Pankaj and co-workers (2005) utilized ethyl cellulose as a coating agent for multiparticulates 
to achieve controlled release of chlorpheniramine maleate. For the purposes of the OMDUS, 
the avoidance of a spraying process was mandatory and an alternate means of incorporating 
ethyl cellulose into the ODMUS was used to achieve the same effect. 
 
Crosslinking agent selection was highly dependent on achieving sustained and controlled 
release and consequently a range of cationic crosslinking agents were chosen from Table 
3.2 to achieve the desired effects. Additionally, crosslinking time and concentration were 
factors to consider during method formulation. Potential crosslinking agents were identified 
based on the anionic copolymer Eudragit® L 100-55 molecule.   
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Table 3.2 Potential crosslinkers for the multiparticulate segment of the Once Daily Multi-Unit 
System 
Monovalent ions Divalent ions Trivalent ions 
Na+ Zn2+ Al3+ 
K+ Mg2+ - 
- Ba2+ - 
- Ca2+ - 
 
3.2.3 Rational selection of polymers and materials for a polyethylene glycol 
crosslinked novel tablet like polymeric oral membranous system  
Eudragit® E 100 is a methacrylic copolymer (-Butylmethacrylat-(2-Dimethylamioethyl) 
methacrylat-Methylethacrylate) with the monomer ratio of 1:2:1 respectively. This is a water-
soluble polymer consisting of hydrophilic groups, fitting hydrophobic groups and a low 
viscosity as shown in Figure 3.4. Said cationic polymers exhibit solubility from a pH of 1.2-5 
making the polymer suitably soluble in gastric acid (pH 1.2) (Kohri et al., 1989), a preferred 
selection in relation to chitosan when trying to elucidate gastric release of drug. Table 3.1 in 
Chapter 3.2.1 identifies Eudragit® E 100 as a gastro-soluble polymer conventionally used for 
taste masking. Very few studies have been undertaken to utilise Eudragit® E 100 beyond its 
conventional use as a coating and taste masking agent (Moustafine et al., 2005; Quinteros et 
al., 2008).   
  
Goddeeris et al. (2008) utilized Eudragit®’s gastro-protectant capability by using Eudragit® E 
100 and a surfactant to develop a novel ternary solid dispersion to deliver the poorly soluble 
UC-781 (an anti-HIV drug) to enhance its dissolution.  
 
Eudragit® E 100 also shows the potential for use in sustained drug delivery, due to it being 
minimally impacted by changes in environmental pH (Kabanova et al., 2006). Specifically, 
the Eudragit® E 100 polymer requires half an hour to completely dissolve in an acidic 
environment making the polymer ideal for gastric drug delivery as gastric transit time can 
vary between 3 and 4 hours. The disadvantage of incorporating this polymer for drug delivery 
is that total release will occur within 30 minutes and this is not a guaranteed controlled 
release mechanism.  
 
The cationic properties of Eudragit®, due to its tertiary amine group have been useful in the 
stabilization of other polymers both natural and synthetic. This property has influenced its 
use as an excipient in pharmaceutical products and in drug-in-adhesive transdermal systems 
where it also serves the purpose of prevention of crystallization of the active drug (Ausar et 
al., 2003).   
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Polyethylene glycol (PEG) has been used as early as the mid 90’s as a means of covalent 
attachment to various compounds (Zalipsky, 1995). Use of PEG has even been expressed in 
terms of demulcents or soothing agents, used as laxatives and as food additives (Karlsson et 
al., 2005).  
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Figure 3.4 Eudragit® E 100 molecular structure where R= CH3C4H9 (adapted from 
Moustafine et al., 2005)
 
 
 
With regards to manipulating PEG into an oral dosage form, this amphiphilic polymer exhibits 
ideal characteristics such as low toxicity and good solubility in water (Zalipsky, 1995; Sun 
and Chu, 2006) and has even been used to improve biocompatibility and in other 
formulations (Chung et al., 2003). Incorporation of PEG into the memblet system was based 
on the extensive work PEG has been used for (Hossainy and Hubbell, 1994; West and 
Hubbell, 1995; Park et al., 2004; Sun and Chu, 2006).  As an anionic crosslinker, it was 
postulated that PEG would retard drug release from the polymeric memblet while 
incorporating the benefits stated above. Additionally PEG has plasticizing effects which can 
drastically affect thermal properties (Feldstein et al., 2000; Cao et al., 2009). 
 
3.2.4 Method development of novel multiparticulates and a novel memblet drug 
delivery system  
Eudragit® polymeric materials have a primary function as coating agents and are developed 
with advantages such as an improved chemical stability, better compliance and enhanced 
therapeutic efficacy (the Degussa Eudragit® manual, AG Pharma Polymers, Darmatadt, 
Germany, 2007). The application benefits of the polymethacrylates make them ideal 
polymeric materials to be incorporated into the ODMUS. Application benefits of Eudragit® 
coatings include: 
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• pH-dependent drug release 
• protection of actives against the acidic gastric environment 
• protection of gastric mucosa from aggressive actives 
• improvement on drug effectiveness 
• acceptable storage stability 
• controlled release of active 
 
As explained in Figure 3.2 of Chapter 3.2.1, Eudragit® polymers have been extensively used 
as coating agents in pH dependant or site-specific drug delivery, but the coating process is 
an additional formulation step. The ODMUS shall aim to bypass all coating procedures and 
utilize the Eudragit® polymers by incorporating the polymer into the matrix of the 
multiparticulate and ultimately simplifying formulation procedures.  
 
Figure 3.5 depicts cross-sectioned multiparticulates in which Figure 3.5a represents a novel 
ODMUS multiparticulate incorporating Eudragit® L 100-55 within the internal matrix and the 
outer layer in a single process step, whilst Figure 3.5b represents a multiparticulate 
comprised of another polymeric material comprising the core of the sphere and coated with 
Eudragit®. 
 
Additionally, Eudragit® E 100 was formulated into a novel tablet like system diverting from its 
role as a traditional coating agent. Formation of a Eudragit® E 100 based hydrogel with 
subsequent membrane formation led to the preliminary memblet formation. Degussa 
products follow set guidelines for re-dispersion and the procedures for Eudragit® L 100-55 
and Eudragit® E 100 are displayed in Table 3.3.  
 
Table 3.3 Redispersion procedures for Eudragit® L 100-55 and Eudragit® E 100 
Eudragit® Grade Constituents 
Eudragit® L 100-55 NaOH 10%, Water-60%, Solid Content- 30% 
Eudragit® E 100 Acetone/Isopropyl alcohol- 85%, Water 5% 
Solid content-10% 
Adapted from the Degussa Eudragit® manual, AG Pharma Polymers, Darmatadt, Germany, 
2007 
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Figure 3.5  Comparison between a novel Once Daily Multi-Unit System multiparticulate and 
a traditionally coated multiparticulate via cross-sectional examination 
 
3.2.5 Ionotropic gelation and polyelectrolyte complexation  
Ionotropic gelation, due to method authenticity and efficacious drug delivery in the past, 
provides success as a delivery system (Sadeghi et al., 2008; Sriamornsak et al., 2008; Ma 
and Liu, 2010). Specifically, ionotropic gelation is described as the ability of poly-electrolytes 
to ionically crosslink (non-covalently) with counter ions to form a hydrogel complex in a 
spontaneous manner (Patil et al., 2010). Poly-electrolytes are defined as polymers with 
ionizable groups. In the case of the Eudragit® polymers utilized in this study, each polymeric 
structure has natural anionic/cationic moieties and can subsequently form intermolecular 
meshworks amongst their respective counter ions/polymers. Poly-electrolyte complexes with 
closely related ion to cation ratios are insoluble in water (Holappa, 2005). As the ionic bond is 
based on electrostatic attractions, the ionic strength of the crosslinking solution plays an 
integral role in the formation of the poly-electrolyte complex. When crosslinking occurs in an 
aqueous environment, the crosslinkers present potentiate ionic remodeling of bonds shifting 
equilibrium to thermodynamic stability such that the degree of complexation is controlled by 
the ratio of polymer to crosslinker (Zintchenko et al., 2003). The ratio is critical to solubility 
resulting in either a readily soluble or an insoluble complex essential for controlled drug 
release.    
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In the case of Eudragit® L 100-55, functional moieties are anionic and dropping the latex into 
a cationic solution results in ionic attraction. Cationic poly-electrolytes diffuse into the latex 
droplet and form a 3-dimensional lattice of ionically crosslinked groups. Attraction between 
cationic metals and the anionic polymer are based on the concentration of metal ions at the 
polymeric surface functional groups. Specifically, complexation occurs between polyvalent 
metal ions and the halogenide salt (Holappa, 2005). Attraction follows 2 distinct pathways 
namely, territorially and directly to functional groups. Territorially refers to ions that are 
thermodynamically bound but move via electrostatic attraction within the poly-electrolyte 
domain (Radeva , 2001).  Direct binding of ions to the functional group are referred to as 
sight bound and can be described as ion pairs, multidentate complexes and chelate 
complexes (Radeva, 2001). However, the multiparticulate system utilizes a combination of 
polyvalent cations to achieve double crosslinking and retard release and this Chapter aimed 
to limit the combinations that could be used with the goal of optimizing to a rudimentary pair 
of metal ions.   
 
Eudragit® E 100 readily produces a polyelectrolyte membrane when expelled into a 
crosslinking solution under constant agitation. As such, 2 types of polyelectrolyte membranes 
can be produced, namely ones that contains a polyelectrolyte and a low molecular weight ion 
with an opposite charge or membranes that contain 2 polyelectrolyte polymers that have 
opposite charges with the latter referred to as the more stable of the 2 methodologies (Zhu, 
2006). The memblet system adopted the more stable double poly-electrolyte complex 
system.  A recent study by de Vasconcelos et al. (2006) illustrated the concept of 
polyelectrolyte complexation, between a polymethacrylic acid (anionic functional groups) and 
chitosan (cationic functional groups) through a drop wise expulsion of the methacrylate latex 
into a 2%w/v chitosan solution in a similar formulation procedure to the ODMUS memblet. 
Figure 3.6 highlights the ionic attraction between the 2 polymeric constituents.         
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Figure 3.6 Formation of a polyelectrolyte complex through electrostatic attraction between 2 
polymeric macromers (adapted from de Vasconcelos et al., 2006)  
 
3.3 Materials and Methods 
 
3.3.1 Materials 
Eudragit® L100-55 was donated by Degussa AG, Pharma polymers, RÖhm GmbH 
(Germany).  Triethyl Citrate (TEC), isoniazid (INH) and ethylcellulose (EC) were of analytical 
grade and purchased from Sigma Aldrich (Pty) Ltd. (St Louis, MO, USA). All electrolytes 
identified in Table 3.2 of Chapter 3.2.2 for crosslinking were of analytical grade and 
purchased from Merck Chemicals (Halfway House, Gauteng, South Africa). Sodium 
Hydroxide pellets were purchased from Rochelle Chemicals (Johannesburg, South Africa). 
Silicone was obtained from Merck Chemicals (Halfway House, Gauteng, South Africa). All 
chemicals and raw materials were used as received without further processing. Water was 
purified by a MilliQ Millipore water purification system (Milli-Q, Millipore, Billerica, MA, USA). 
 
Eudragit® E 100 was kindly supplied by Evonik Degussa Africa (Pty) Ltd. (Midrand, Gauteng, 
South Africa) and polyethylene glycol 4000 (PEG 4000) was purchased from Merck 
chemicals (Halfway House, Gauteng, South Africa). Acetone, triethyl citrate (TEC), isopropyl 
alcohol, sodium lauryl sulphate (SLS) and tween 80 were all of analytical grade.  Water was 
purified by a MilliQ Millipore water purification system (Milli-Q, Millipore, Billerica, MA, USA). 
Rifampicin (RIF) was of analytical grade and donated by Sigma Aldrich.Inc (South Africa). 
 
3.3.2 Multiparticulate method development: preparation of a 50mL Eudragit® L 100-55 
latex   
An aqueous solution of 30%w/v Eudragit® L 100-55 was prepared. The PMMA polymer was 
added gradually to the aqueous phase (deionized) under constant agitation using a magnetic 
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stirrer over a period of 5 minutes to avoid agglomeration and sedimentation. To prevent 
foaming, 0.4mL of silicone was added to the latex and the solution was left to stir for 45 
minutes referred to as 45t1 in Figure 3.7 During 45t1, 2 solutions of 4%w/v NaOH and 20%w/v 
Ethylcellulose (EC) were dissolved. EC was added gradually to 50mL of Ethanol till complete 
dissolution was achieved. At 45t1’s conclusion, 5mL of the NaOH solution was drawn up with 
a 20mL syringe and added to the latex within 5 minutes in a drop wise manner for 
neutralization of the carboxyl functional groups of the PMMA.  
 
The latex was left to stir for a further 45 minutes, referred to as 45t2, to ensure proper 
dispersion and neutralization of the latex. Following 45t2, 3g of INH and 5mL of TEC was 
introduced to the latex and left for a final 45 minutes under constant agitation, 45t3.  
 
Ethyl Cellulose was incorporated into the latex in preliminary designs in an attempt to 
improve drug release in the small intestine from between 10-12 hours. A 5%w/v solution of EC 
solution was drawn up using a 20mL syringe and gradually added to the latex during 45t3 
prior to homogenization (Polytron Kinematica, Switzerland) for a full 15 minutes. As 
homogenization generated substantial heat, the latex was then left on the stirrer to cool for 
10 minutes prior to crosslinking. Potential crosslinking agents detailed in Table 3.2 of 
Chapter 3.2.2 were then selected for crosslinking. 
 
50mL Latex constituents 
at 45t1 minute stirring 
period
•30% w/v Eudragit® L 100-
55
•0.4mL Silicone 
Antifoament
50mL Latex constituents 
at 45t2 minute stirring 
period
•30% w/v Eudragit® L 100-
55
•0.4mL Silicone 
Antifoament
•4% w/v Sodium Hydroxide
50mL Latex constituents 
at 45t3 minute stirring 
period
•30% w/v Eudragit® L 100-
55
•0.4mL Silicone 
Antifoament
•4% w/v Sodium Hydroxide
•3g Isoniazid
•5mL Triethyl Citrate
•5mL Ethyl Cellulose
Magnet and 
Magnetic Stirrer 
ensuring constant 
agitation for a 45 
min period
 
Figure 3.7 Eudragit® L 100-55 latex (50mL) preparation 
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3.3.3 Multiparticulate method development: polymethyl methacrylate multiparticulate 
formation through an ionotropic gelation double crosslinking procedure 
Batches of multiparticulates were formulated and crosslinked initially in
 
electrolyte 
combinations as shown in Table 3.4.The crosslinking solution was kept on a magnetic stirrer 
for the duration of crosslinking to keep the formed polyspheres in constant motion to prevent 
unwanted agglomeration. In batches 3-5, first and second electrolyte solutions were 
saturated with 3g of INH in an attempt to improve on drug entrapment efficiency. A measured 
10mL of the 50mL PMMA latex was drawn up with a syringe and the latex was expelled in a 
drop wise manner into the first electrolyte solution for crosslinking. The above process is 
graphically depicted in Figure 3.8.
 
After complete expulsion of the latex, the multiparticulates 
were left to cure for 20 minutes in a dark cupboard. The polyspheres were washed twice in 
500mL double deionized water
 
and placed in a second crosslinking solution and left to cure 
in a dark cupboard for a further 20 minutes. The double cured and drug saturated 
multiparticulates were then washed with 500mL deionized water and left to air dry under an 
extractor for 12 hours at room temperature. Batches of spheres were then weighed and 
placed in glass containers until testing.  
 
Table 3.4 Parameters used for the formulation of preliminary multiparticulates 
Batch 
Number 
Combinations of 
Crosslinking 
Agents 
Duration of 
curing in 
both 
solutions 
(minutes) 
Contained 
Ethyl Cellulose 
Saturated 
with INH 
1 MgSO4a (15%w/v) + 
ZnSO4b(25%w/v) 
20 No No 
2 CaCl2 a(25%w/v) + 
AlCl3b(25%w/v) 
40 No No 
3 MgCl2a(30%w/v) + 
AlCl3b(25%w/v) 
20 Yes Yes 
4 BaCl2 a(15%w/v) + 
AlCl3b(25%w/v) 
20 Yes Yes 
5 BaCl2 a(25%w/v) + 
AlCl3b(25%w/v) 
20 Yes Yes 
6 K2S2O8 a(25%w/v) + 
AlCl3(25%w/v) b 
20 No No 
7 NaCl a(25%w/v) + 
AlCl3b(25%w/v) 
20 No No 
a and b represent the first and second crosslinking solutions respectively 
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Figure 3.8 The formation of multiparticulates through the crosslinking of the Eudragit® L 100-
55 latex within a variable cationic solution 
 
3.3.4 Memblet method development: formulation of a Eudragit® E 100 latex 
Method development required the manipulation of a standard Eudragit® E 100 re-dispersion 
procedure in a similar manner to the multiparticulate method as indicated in Table 3.3 of 
Chapter 3.3.1. Amounts of 34%v/v of acetone, 46.9%v/v of isopropyl alcohol and 1.8%v/v of de-
ionized water were measured and added to a 200mL beaker. A measured 13.6%w/v of the 
Eudragit® E 100 polymer was gradually added to the aforementioned latex with constant 
agitation employing a magnetic stirrer at room temperature (21°C) for 1 hour.   
 
This preliminary latex was left under agitation until complete dissolution of the Eudragit® E 
100 beads. TEC and the remaining constituents (Tween 80 and SLS) were gradually added 
to the latex and left to stir for approximately an hour. Simultaneously, 30%w/v and 60%w/v 
PEG 4000 solutions were produced. A measured 5mL of the Eudragit® E 100 latex was 
drawn up and expelled through a syringe into each solution. Crosslinking resulted in 
hydrogels A (60%w/v PEG 4000) and B (30%w/v PEG 4000), which were subsequently left to 
cure in their respective solutions for twenty minutes. Following the curing, samples were 
washed 3 times in 500mL de-ionized water before storage in a desiccant jar (using silica 
crystals) for 10 days of drying time. The dried membranes were then ground using a 
standard coffee grinder and the powder obtained was mixed with 150mg of RIF and 
subsequently compressed into a tablet like structure or memblet (memblets A and B).  
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The Eudragit® E 100 latex is expelled 
via syringe into a PEG 4000 solution 
resulting in the formation of a hydrogel
Hydrogel samples 
were placed within a 
sealed desiccant jar 
with silica crystals to 
remove excess water 
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and passed through a 
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compressed using a 
Beckman hydraulic 
press to form the tablet 
like memblet. 
Eudragit® E 100 expelled 
via syringe into a PEG 4000 
solution, forming  cross-
linked hydrogel
Sieved polymeric powder 
compressed using a Beckman 
hydraulic press to form the 
tablet like membrane
        
Figure 3.9 Formulation procedures implemented in the formulation of the memblet system 
 
3.4 Testing Procedures for the Once Daily Multi-Unit System 
 
3.4.1 Construction of a calibration curves for spectrophotometric quantification of 
drug entrapment efficiency and in vitro analysis 
A calibration curve for INH was plotted using a known series of dilutions of INH (using an 
initial 0.1mg/mL) dissolved in the same medium to be used for entrapment efficiency testing 
and in vitro analysis (phosphate buffer solution pH 6.8). A linear curve was plotted to 
determine the R2 value using Sigma Plot Version 10.0 Systat Software, Inc, GmBH, 
Germany.    
 
3.4.2 Drug entrapment efficiency evaluation of double crosslinked drug saturated 
polymethacrylate multiparticulates and an overview of superficial morphological 
structure 
Solutions of 200mL phosphate buffer solution (PBS), pH 6.8, were prepared and used for 
drug entrapment efficiencies. Polyspheres of weight 100mg, from respective batches, were 
weighed out in triplicate (N= 3) and placed within 200mL of PBS and left to achieve complete 
dissolution overnight with aided agitation from a stirrer at room temperature. UV analysis 
49 
 
through a spectrophotometer (Cecil CE 3021, Cambridge, CB24 6AZ, England) was 
conducted and drug entrapment was evaluated through the following equation: 
 
                            1
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D
D
%DEE
t
a
×=
                                                    
     (Equation 3.1) 
 
Where, DEE % represents drug entrapment efficiency, Da represents the actual amount of 
drug within the multiparticulates and Dt represents the theoretical amount of drug within the 
multiparticulates. 
 
Surface morphology, in the case of oral delivery systems, is required to be of an aesthetic 
quality for compliance purposes. Additionally, the surface characteristics of batches would 
give an educated guess as to the release patterns based on solid structure, the presence of 
highly porous areas, colour and genuine spherical shape.     
 
3.4.3 Preliminary in vitro drug release of double crosslinked drug saturated 
polymethacrylate multiparticulates  
Drug release studies were conducted following the USP 33 apparatus II (ERWEKA DT 700 
GmbH Germany), in which 100mg of spheres were weighed out in triplicate from each batch 
and placed within the vessel under a stainless steel ring mesh assembly, to prevent the 
paddle inflicting physical/mechanical damage to the spheres and alter release profiles as well 
as to prevent erratic fluctuation due to unstable hydrodynamics (Pillay and Fassihi, 2000).  
 
Each vessel was filled with 900mL PBS and heated to a temperature of 37°C prior to the 
addition of the multiparticulates and the stainless steel ring mesh assembly. The rotating 
paddle method was selected at a rotational speed of 50rpm and the machine was calibrated 
for a 12 hour run with samples taken at hourly intervals. Sampling involved the drawing of 
5mL of now drug incorporated solution from the dissolution vessel with subsequent refilling of 
removed buffer to maintain sink conditions. Samples were then subject to UV spectroscopy 
using a spectrophotometer (Cecil CE 3021, Cambridge, CB24 6AZ, England).    
  
3.4.4 Preliminary in vitro drug release of polyethylene glycol crosslinked 
polymethacrylate based memblet system 
Drug release studies were conducted following the USP 33 apparatus II (ERWEKA DT 700 
GmbH Germany), in which a single memblet in triplicate was placed within the vessel under 
a stainless steel ring mesh assembly, to prevent the paddle inflicting physical/mechanical 
damage to the spheres and alter release profiles as well as to prevent erratic fluctuation due 
to unstable hydrodynamics (Pillay and Fassihi, 2000). Each vessel was filled with 900mL 
simulated gastric fluid (SGF) and heated to a temperature of 37°C prior to the addition of the 
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memblet and the stainless steel ring mesh assembly. The rotating paddle method was 
selected at a rotational speed of 50rpm and the machine was calibrated for a 2 hour run with 
samples taken at half hourly intervals. Sampling involved the drawing of 5mL of now drug 
incorporated solution from the dissolution vessel with subsequent refilling of removed buffer 
to maintain sink conditions. Samples were then subject to UV spectroscopy using a 
spectrophotometer (Cecil CE 3021, Cambridge, CB24 6AZ, England). 
 
3.4.5 Thermal analytical method development and subsequent thermal profiling of 
polyethylene glycol crosslinked polymethacrylate based memblet systems 
Thermal analysis was conducted on a DSC1 STARe system (Mettler Toledo DSC1 STARe 
System, Switzerland). Testing of memblets required method development of both differential 
scanning calorimetry (DSC) and alternating differential scanning calorimetry (ADSC) prior to 
analysis. All samples were prepared in 40µl aluminum crucibles. DSC was conducted using a 
temperature range of 0-200 °C and ramped at 10°C per minute. ADSC was carried out with 
an underlying heating rate of 1°C per minute and a modulated temperature of 0.1°C per 0.8 
minutes.  All samples were run in duplicate to remove thermal history.  
 
3.5 Results and Discussion: Analysis of Preliminary Testing 
 
3.5.1 Calibration curves for isoniazid and rifampicin to evaluate drug entrapment 
efficiency and in vitro drug release profiling 
Calibration curves for INH and RIF were plotted to determine DEE and in vitro results and 
can be seen in the following Figure:  
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Figure 3.10 Calibration curves for a) isoniazid and b) rifampicin with corresponding 
regression co-efficient and y values 
 
3.5.2 Drug entrapment efficiency of double crosslinked drug saturated 
polymethacrylate multiparticulates and superficial morphological structure scrutiny 
Early assessment of samples revealed uniformly low entrapment efficiencies with the 
exception of batch 3 and batch 5, identified in Table 3.5. Poor drug loading within 
multiparticulates was attributed to compounding factors. Primarily, the presence of 2 cationic 
molecules competing for positioning along the PMMA polymeric backbone prevented INH 
from having a higher loading tendency. Furthermore, the double curing procedure within 2 
separate solutions at 20 minute intervals provided an abundant crosslinker saturation 
resulting in a reduced distribution of INH within the multiparticulates. In the case of batch 2, a 
40 minute curing time in each solution vastly depleted drug loading, identifying a maximum 
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20 minute curing period. The aqueous medium of the above mentioned crosslinkers provided 
a diffusion gradient for already entrapped drug to leech into, a common problem encountered 
during crosslinking (Pongjanyakul and Rongthong, 2010). As INH is readily soluble in water, 
drug passively diffused through the concentration gradient from the internal matrix into the 
crosslinking solution.  
 
A contrary DEE was in evidence for batch 3 and 5 of preliminary results. Almost double the 
entrapment was achieved for 50% and 61% respectively, validating the proposal of 
saturating INH within crosslinking solutions. It was postulated that a drug saturated aqueous 
environment created a reverse concentration gradient and effectively minimized the leeching 
process. What is important to note is that a higher entrapment occurs whilst in the presence 
of an additional polymeric component (ethyl cellulose). The addition EC to modulate release 
profiles would always be contradictory to DEE values, but on the contrary, the incorporation 
of this additional component demonstrated a 61% DEE. These preliminary studies 
corroborated 2 method parameters to improve DEE including a maximum 20 minute duration 
of curing and the saturation of crosslinking solutions with INH. Of particular interest were the 
influence of Mg2+ and Ba2+ ions with higher concentrations (between 25%w/v and 30%w/v) and 
the inclusion of EC. A synergistic effect between the 2 parameters, rather than the expected 
antagonistic inadequate DEE results, displayed an improved DEE and controlled release 
indicated with the release studies in Chapter 3.5.3 Figure 3.12. 
 
Table 3.5 Preliminary formulation parameters with subsequent drug entrapment efficiencies  
Batch 
Number 
Combinations of 
Crosslinking 
Agents 
Duration of 
curing in both 
solutions 
(minutes) 
Contained 
EC 
Saturated 
with INH 
DEE (%) 
1 MgSO4a (15%w/v) + 
ZnSO4b(25%w/v) 
20 No No 32 
2 CaCl2 a(25%w/v) + 
AlCl3 b(25%w/v) 
40 No No 10 
3 MgCl2a(30%w/v) + 
AlCl3 b(25%w/v) 
20 Yes Yes 50 
4 BaCl2 a(15%w/v) + 
AlCl3 b(25%w/v) 
20 Yes Yes 42 
5 BaCl2 a(25%w/v) + 
AlCl3 b(25%w/v) 
20 Yes Yes 61 
6 K2S2O8 a(25%w/v) + 
AlCl3(25%w/v) b 
20 No No 33 
7 NaCl a(25%w/v) + 
AlCl3 b(25%w/v) 
20 No No 35 
a and b represent the first and second crosslinking solutions respectively 
 
 
53 
 
Through general observation, and without the initial use of powerful tools such as scanning 
electron microscopy for this part of the study, an array of data and theoretical concepts were 
derived. Batches 6 and 7 were aesthetically, the worst formed spheres. Both displayed 
compromised physical integrity and were brittle to the touch which could be postulated to 
reveal a poor drug release profile. Physical stability of these formulations was undesirable. 
The yellow discoloration of batch 7 was attributed to a residual deposit of INH agglomerating 
superficially, a potential indicator of poor entrapment which was verified through entrapment 
results of 33% shown in Table 3.5. K2S2O8 was determined to be an unsuccessful crosslinker 
due to its formation of irregularly shaped particulates and brittle nature. The highly porous 
nature viewed in Figure 3.11 for batch 6, eluded to a mostly hollow internal structure as the 
crosslinking process between Na+ and Al3+ was not sufficient to form a solid spheroid 
multiparticulate.  
 
The physical content of these spheres were at a minimum to the extent that some spheres 
were completely hollow for both batches 6 and 7. Coupled with the brittle quality, it was 
considered realistic to assume these spheres would provide as poor a release pattern as the 
DEE (33% and 35% for batches 6 and 7 respectively as indicated in Table 3.5).  
 
The aesthetic success of batch 5 in relation to DEE (61%) and release profiles cannot be 
overlooked. Spheres displayed unique characteristics such as a smooth spherical shape, a 
sturdy texture and a glossy white exterior. This glossy even exterior was obtained without the 
additional process step of active coating which is seen as a beneficial and sought after 
characteristic of this batch of spheres. The presence of the Eudragit® L 100-55 is not limited 
to the exterior however (illustrated in Figure 3.5 of Chapter 3.2.4) and it is this specific 
characteristic that makes this system unique.     
 
Saturation of crosslinking solutions with INH drastically increased DEE % to 50%, 42% and 
61% in batches 3, 4 and 5 respectively through the reversal of the INH concentration 
gradient, despite the inclusion of EC and 2 crosslinking solutions. Similarly to batch 5, 
batches 3 and 4 yielded spheres of solid texture, colour and multiparticulate integrity. 
 
In an attempt to improve release profiles, multiparticulate curing time was extended for a 40 
minute duration in batch 2. The spheres produced were aesthetic relative to the qualities 
desired, but were stained a yellow colour. The extended curing period promoted drug surface 
agglomeration rather than matrix incorporation and a drastically reduced DEE (10%), which 
was further propagated by the absence of INH in the crosslinking solutions. Preliminary 
studies concluded that 20 minutes was an optimal crosslinking time to achieve maximal ionic 
interaction and drug loading.  
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To reduce formulation variables during optimization, the secondary crosslinker was identified 
during preliminary studies as AlCl3. Batch 1 relative to other formulations, did not achieve the 
physical and aesthetic success of the other batches which used AlCl3.  
 
Table 3.6 Initial observational data of cured spheres 
Batch Number Physical 
Texture 
Visual 
Porosity 
Spherical 
Shape 
Coloration 
1 
MgSO4a(15%w/v) 
+ZnSO4b(25%w/v) 
Weakly formed 
with an uneven 
texture 
None Irregularly 
shaped 
White 
2 
CaCl2a(25%w/v) 
+AlCl3b(25%w/v) 
Sturdy with a 
smooth texture 
None Roughly 
spherical 
Yellowish 
tinge 
3 
MgCl2a(30%w/v) 
+ AlCl3 b(25%w/v) 
Sturdy and large 
with a smooth 
texture 
None Roughly 
spherical 
Glossy white 
colour 
4 
BaCl2 a(15%w/v) 
+ AlCl3 b(25%w/v) 
Sturdy and large 
with a smooth 
texture 
None Roughly 
spherical 
Glossy white 
colour 
5 
BaCl2 a(25%w/v) 
+ AlCl3 b(25%w/v) 
Sturdy and large 
with a smooth 
texture 
None Roughly 
spherical 
Glossy white 
colour 
6 
K2S2O8 a(25%w/v) 
+ AlCl3(25%w/v) b 
Weakly formed 
with an uneven 
texture 
Large pores 
evident 
Tailed hollow 
spheres 
White 
7 
NaCl a(25%w/v) + 
AlCl3 b(25%w/v) 
Weakly formed 
with an uneven 
texture 
Large pores 
evident 
Irregularly drop 
shaped 
Yellowish 
tinge 
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Figure 3.11 Photographic depiction of inter-sample variance due to formulation parameters 
for formulations 1-7 
 
3.5.3 In vitro drug release patterns of multiparticulates with varying crosslinking 
agents 
As per the objectives stated in Chapter 1.3, the release profiles for the multiparticulates were 
explored through dissolution testing. Contrasting release profiles were attributed to the 
variant formulation parameters and constituents of the latex. The general pattern emerging 
was an initial burst release seen in Figure 3.12 for batches 1, 6 and 7. More than 80% of 
INH was released within an hour of testing. This was expected in the case of batches 6 and 7 
with poorly formed spheres. Similarly, a burst effect was seen for the release profile of batch 
1, even though relatively aesthetic spheres were formed. Batch 4, though saturated with INH, 
displayed a higher burst release compounded with erratic release thereafter due to the 
minimized concentration of the secondary crosslinker (Ba2+ 15%w/v).    
 
Relative to the above mentioned batches, batch 2 displayed a more controlled means of 
release. A similar burst release occurred at 2 hours, but this was moderated to 48%, 
substantially less than previous batches. Thereafter, a release until 12 hours was achieved 
but the profile generated was erratic and deviating from zero-order release.   
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A more controlled and desirable release pattern was shown with batches 3 and 5 Figure 
3.12c and Figure 3.12e). The typical burst release with an hour of testing was drastically 
reduced, with an effective continual release pattern thereafter up to a period of 12 hours. In 
these profiles, the initial burst effect was limited to 30%w/v and 25%w/v for batches 3 and 5 
respectively with subsequent data points indicating a relatively controlled release pattern. 
Such results were attributed to the incorporation of EC and the higher crosslinking 
concentration.  
 
Further manipulation of formulation parameters were required to achieve as close to zero-
order release as possible whilst maintaining a high DEE with a concurrent aesthetic looking 
multiparticulate. From preliminary release profiles data, it was evident that double cross-
linking with the inclusion of the EC as an acid protectant polymer and the saturation of the 
crosslinking solutions with INH were imperative to achieve controlled release of INH for 
extended hours and to significantly improve DEE. 
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Figure 3.12 Preliminary in vitro release profiles for a) MgSO4 15%w/v + ZnSO4 25%w/v  b) 
CaCl2 25%w/v + AlCl3 25%w/v c) MgCl2 30%w/v + AlCl3 25%w/v d) BaCl2 15%w/v + AlCl3 25%w/v  
e) BaCl2 25%w/v + AlCl3 25%w/v  f) K2S2O5 25%w/v + AlCl3 25%w/v  and g) NaCl 25%w/v + AlCl3 
25%w/v; where N= 3 and SD < 1.4 in all cases   
 
3.5.4 Preliminary in vitro drug release results of polyethylene glycol crosslinked 
polymethacrylate based memblet system 
In contrast to multiparticulate studies, memblet samples had to release within 2 hours but 
analogous relative zero-order drug release was required. For the purposes of this study, 
complete dissolution within 2 hours was warranted to ensure a total release of RIF prior to 
gastric emptying which was successfully achieved as illustrated in Figure 3.13.  
 
Of importance to note, is the difference in release patterns. A lower crosslinker concentration 
(30%w/v) benefited release comparatively to a burst effect with more than 60% released 
within 30 minutes and complete release at 1.6 hours as in memblet A (60%w/v). The potential 
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of a lower crosslinker concentration is seen with both the release pattern and the extended 
duration of release (2 hours).          
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Figure 3.13 In vitro release patterns of a) memblet A and b) memblet B  with varying 
crosslinker concentrations of 30%w/v and 60%w/v respectively; where N= 3 and S.D <1 in all 
cases 
 
 
 
 
Figure 3.14 Rifampicin loaded, polyethylene glycol 4000 crosslinked novel memblet system  
 
3.5.5 Thermal analytical method implementation and analysis of thermal profiles of 
polyethylene glycol crosslinked polymethacrylate based memblet systems 
 
3.5.5.1 Critical theoretical concepts 
Calorimetry is defined as the measurement of heat and such analysis plays a critical role in 
characterization studies for drug delivery systems. This particular thermal analysis tool has 
been used to evaluate the unknown thermal properties of the memblet to provide a full 
thermal characterization.    
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To measure heat an instrument must exchange heat and this exchanged heat causes a 
temperature change in the body/mass (in this case, the memblet system) and this ultimately 
induces the heat change or measurement of heat. Another explanation is that through the 
exchange of heat, a heat flow is created and this heat flow causes local temperature 
changes in the mass/body which can be used to measure the heat flow. 
  
Differential Scanning Calorimetry (DSC) has the ability to measure heat/heat flow within the 
memblet’s matrix and the rate of heat flow (power). Furthermore, this analytical technique 
was adopted to ascertain thermal transitions or even chemical reactions that may occur due 
to the influence of heat on the memblet system. DSC can be defined as the measurement of 
the change of the difference in the heat flow rate to the sample and to a reference sample 
while they are subjected to a controlled temperature program (Celej et al., 2006). 
 
DSC utilized 40µL aluminium crucibles (a blank reference and a sample) to analyze slivers of 
the memblet. The sample and reference crucibles were subjected to an identical heat 
induction, but due to weight differences, a greater energy input for the sample crucible was 
required to ensure an equal temperature increase between sample and reference crucibles 
to validate data. For the purposes of thermal analysis, the excess heat required to keep the 
rates even constitute thermal data.   
  
The amount of heat required to elucidate a certain temperature increase is called the heat 
capacity, or Cp. Cp is better defined as the amount of energy required to raise the 
temperature of 1g of memblet sample by 1K under a constant pressure (Mettler Toledo 
Usercom 7, 1998; Xua et al., 2000). Usually, Cp is not measured during first order transitions 
(such as melting and cold crystallization) as the values are infinitely large. The heat capacity 
is calculated by dividing this heat supplied by the resulting temperature increase or change in 
temperature. Heat capacity can best be described in saying that it is the heat flow (HF) 
divided by the heating rate (HR) as shown in Equation 3.2:  
 
HR
HFCp =                                                    (Equation 3.2) 
 
By subjecting the memblet system to the aforementioned theory, we can evaluate the Cp for 
the memblet, but further thermal information can be evaluated when heating pass this point. 
 
Upon further heating of the polymeric memblet beyond the Cp value, an increase in the heat 
flow would be observed and an alteration to the thermogram would be noted. This also 
means that the Cp value of the memblet has increased concurrently. This phenomenon 
60 
 
occurs as the polymer has reached the glass transition temperature or Tg. This Tg is a 
temperature at which change of physical state occurs and is a phenomenon that occurs 
within many polymers (Edwards, 1994; Fujimori et al., 2005). Below the Tg, polymers are 
hard and brittle just like glass, but above it they are rubbery and elastic and may exhibit flow 
properties. Polymers tend to have a higher heat capacity above their Tg than below it. The 
change in heat capacity does not occur instantaneously but over a range of temperature, 
such that the Tg is taken at the midpoint of the peak.     
  
A glass transition always requires the presence of a certain amount of disorder in the 
molecular structure of the sample. It is very sensitive to changes in molecular interactions. 
Measurement of the glass transition can thus be used to determine and characterize 
structural differences between memblet samples or changes within the memblet polymeric 
backbone. In many cases, the Tg is dependent on the degree of saturation of crosslinking 
which is an important factor to evaluate within the memblet studies (Maes et al., 1995).  
 
With regards to the actual thermogram, the glass transition is not displayed as a peak or 
trough in the curve as this is neither an endothermic or exothermic reaction as heat is neither 
taken nor given off by the polymer molecules during the glass transition.  As there is a 
change in the heat capacity but no latent heat given off or absorbed, this phenomenon is a 
second order transition. The transitions of crystallization and melting are first order 
transitions.  
 
Above the Tg, the polymers molecules are highly mobile and align themselves in a highly 
ordered manner in the form of crystals. The formation of these crystals is an exothermic 
process and as such gives off heat. Consequently, the machine has heat added to it and it 
does need to use its own heating system to increase heat flow and is depicted in 
thermograms as a peak.  
 
The temperature at the highest point in the peak is the Tc or the polymers crystallization 
temperature. The area within the peak indicates the latent energy of the crystals whilst the 
peak itself indicates that the polymer can or has undergone crystallization. This exothermic 
type of thermal transition is one type of transition that can occur due to heat. 
 
Melting Temperature or Tm is another type of thermal transition that can occur when heating 
continues past the Tc. The aligned polymer chains (in the form of crystals) begin to lose their 
uniform distribution and melting begins.  For melting to occur, polymers must absorb heat 
and doing so forces the DSC machine to put in additional heat to maintain equal rates and as 
such the heat flow curve increases to form a trough. This transitional process is an 
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endothermic one. The latent heat of melting can be determined by calculating the area under 
this peak.  The temperature at the apex of the peak is the Tm (Mettler Toledo Usercom 11, 
1998; The University of Southern Mississippi, Differential Scanning Calorimetry, 2005; Silicon 
Far East, 2005). 
 
Alternating Differential Scanning Calorimetry (ADSC) provides the same qualitative and 
quantitative information about physical and chemical changes as conventional DSC, and it 
also provides unique thermochemical data that is unavailable with conventional DSC. The 
effects of baseline slope and curvature are reduced, increasing the sensitivity of the system. 
Overlapping events such as molecular relaxation and glass transitions can be separated. 
Heat capacity can be measured directly with ADSC in a minimum number of experiments.  
 
Both ADSC and DSC measure the difference in heat flow to a sample and to an inert 
reference. The sample and reference cells are identical. However, ADSC uses a different 
heating profile. DSC measures heat flow as a function of a constant rate of change in 
temperature and in comparison ADSC superimposes a sinusoidal temperature modulation on 
this rate. The sinusoidal change in temperature permits the measurement of heat-capacity 
effects simultaneously with the kinetic effect. Typical experimental procedure for an initial 
ADSC experiment include a heating rate from isothermal to 5°C/min and a modulation 
amplitude from 0.01 to 10°C. The modulation period can vary from 10 to 100 seconds or 
expressed as a frequency from 10 to 100MHz. 
 
The advantages of ADSC include improved resolution and sensitivity, in addition to being 
able to separate overlapping phenomena. Comparatively, when we use standard DSC and a 
high heating rate, we get large peaks but relatively low resolution. In the case of lower 
heating rates, we get small peaks which are well separated. ADSC utilizes the periodic 
temperature program which provides both large peaks and good separation (high resolution). 
The temperature program of ADSC comprises a periodic succession of short, linear heating 
and cooling phases. The heating or cooling rates lie between 2 and 5K/min. For a heating 
measurement the final temperature of the cooling phase is higher than that of the start 
temperature of the previous heating phase by a small amount thus leading to the low, 
average rate. ADSC uses the heat flux DSC instrument design and configuration to measure 
the differential heat flow between the memblet sample and an inert reference material as a 
function of time whilst at the same time superimposing a sinusoidal temperature flux. The 
temperature programme derived is such that the average sample temperature varies 
continuously in a typical sinusoidal manner. The modulation of the sinusoidal temperature 
includes alterations to the amplitude (AT) and the frequency ώ is expressed in Equation 3.3: 
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                                                           )tωsin(AtqTT T00 ++=                                            (Equation 3.3) 
 
Where, T= the average sample temperature, To= the initial temperature, qot= the underlying 
linear heating rate, AT= the amplitude of modulation and ω= 2pi/p (where p= the modulation 
period).  
 
Total heat flow at any point in a DSC or ADSC experiment can be given by Equation 3.4: 
 
)t,T(fβCdt
dQ
p +=                                                     (Equation 3.4) 
 
Where Q= heat (in Joules), t= time(s), Cp= sample heat capacity and f(T,t)= heat flow from 
kinetic processes which are absolute temperature and time dependent.  
 
Conventional DSC only measures the total heat flow. ADSC by effectively applying 2 
simultaneous temperature profiles to the sample can estimate the individual contributions to 
Equation 3.3. The heat capacity component of the total heat flow, Cpβ, is generally referred 
to as the reversing heat flow. From an ADSC curve, information on the Cp complex, Cp in 
phase, Cp out phase, reversible heat flow, non reversible heat flow and total heat flow can be 
obtained. 
 
Heat capacity for a standard DSC curve was previously defined as dividing HF by HR in 
Equation 3.2. Thus the complex heat capacity of the ADSC curve can be defined with 
Equation 3.5: 
 
                                               AHR
AHF
complexCp =                                                      (Equation 3.5) 
 
 
Where, AHF= the amplitude of the heat flow modulation and AHR= the amplitude of the 
heating rate modulation.  
  
The average value of heat flow, also called total heat flow, is very similar to the signal 
obtained by conventional DSC at the same heating rate.  
 
A complex heat capacity can be further defined as:  
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''p
_
pp CCcomplexC =                                             (Equation 3.6) 
 
Where, Cp’= the in phase heat capacity and Cp’’= the out phase heat capacity. 
 
As a result of the periodical temperature variation the heating rate, we get a periodic heat 
flow signal which is shifted by the phase angle (φ) with respect to the heating rate. Therefore, 
the phase angle is between the heating rate and the heat flow. The Cp in phase and Cp out 
phase heat capacities are represented by the Equation 3.7 and Equation 3.8 respectively: 
 
φcosCC p'p =                                                                         (Equation 3.7) 
 
φsinCC p''p =                                                                          (Equation 3.8) 
 
Where, φ= the phase angle.   
 
The phase angle occurs between the modulated heat flow and the heating rate. This phase 
shift occurs during the ADSC measurement due to the relaxation process. In the glass 
transition region, the phase angle is relatively small and the Cp' is practically equal to the Cp 
complex.  Any linear and time-invariant system follows the premise that if the system is 
subjected to a sinusoidal stimulus the output will also be sinusoidal with the same frequency, 
though with a different amplitude and a shifted phase.  
 
Based on these theories, 3 types of heat flow can be derived from an ADSC study namely 
reversible heat flow, non reversible heat flow and total heat flow. 
 
Total heat flow curves correspond to the heat flow that would be obtained with conventional 
DSC at the same heating rate. This curve shows thermal effects due to aging in the glass 
transition region. The glass transition value is based on the heating rate. 
 
Reversible heat flow curves normally show the glass transitions and the endothermic melting 
peak. This does not show thermal information due to aging as compared to the total heat 
flow curve in the glass transition region. Glass transitions found in the reversible heat flow 
and total heat flow curves are not the same. A frequency dependant dynamic glass transition 
is measured. Normally effects such as cold crystallization are not observed but in some 
instances a small oscillation may be seen. Modulation of the heating rate gives us the 
reversing heat flow. This is not analogous with the term thermodynamically reversible.  
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The non reversing heat flow is defined as the total heat flow minus the reversible heat flow. 
Kinetic effects contribute mainly to the non reversing heat flow. Examples of kinetic effects 
are cold re-crystallization and enthalpic recovery (Flikkema et al., 1998; Carpentier et al., 
2002; Yuji et al, 2007; Yanga et al., 2009). 
  
3.5.5.2 Pre-formulation differential scanning calorimetry thermal profiling on memblet 
systems 
The pre-formulation studies were conducted on memblets A only, as this was method 
development and not comparative analysis. Samples were conducted in this manner to 
determine test parameters rather than ascertain credible results for comparison and analysis.  
After an initial training session from METTLER Toledo training staff, a suitable level of 
competency was achieved to begin basic DSC analysis on membrane samples. DSC 
analysis for membrane samples included testing individual polymeric constituents     
(Polyethylene Glycol 4000 and Eudragit® E 100). Successful DSC analysis depended on 
knowing information on test samples prior to analysis to allow accurate analysis of results. 
Table 3.7 displays prerequisite information for rudimentary DSC analysis. 
 
Table 3.7 Thermal information on constituent polymers 
Test samples Tg Mpt Tc 
PEG 4000 - 53-58°C - 
E 100 40°C - - 
Tg= the glass transition temperature, Mpt= melting point of sample, Tc= crystallization 
temperature, PEG 4000= polyethylene glycol 4000 and E 100= Eudragit® E 100 
(Polyethylene glycol general properties, 2000; Inc. Morflex, 2004) 
 
With this information obtained, DSC temperature ranges can be narrowed during the testing 
phase. Testing consisted of a wide temperature range at a set ramping rate to determine the 
optimal testing of each individual polymer and to verify literature surveys for thermal 
information.  
  
Table 3.8 Method development criteria 
Test samples Temperature 
range 
Ramping rate Crucibles used Weight 
PEG 4000 -30°C-150°C 10°C 40µL 18mg 
E 100 -30°C-150°C 10°C 40µL 18mg 
 
In comparison to literature surveys, a large discrepancy was found between E 100 tested 
samples and the information gathered. Glass transition temperatures were observed to have 
a larger value with the E 100 beads tested on the DSC1 STARe system as depicted in Figure 
3.15. All samples were weighed to precisely 18mg and inserted into 40µL crucibles and the 
lids were punctured 3 times to account for pressure differentials. Thereafter, crucibles were 
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hermetically sealed using the sealant clamp. Samples were run in duplicate for accuracy and 
to remove thermal history from a sample and in all runs a glass transition endset of between 
55°C-58°C was evaluated for raw E 100 bead samples. PEG 4000 samples fell less out of 
range than the E 100 and out of the range of the melting points stated in literature (53-58°C) 
with, an endset temperature of 61.91°C as shown in Figure 3.16. 
 
From the individual polymeric testing it was deduced that a temperature range of between 
0°C-200°C, ramped at 10°C would be initially used until a precise temperature range could 
be determined for DSC membrane runs. A standard weight of 18mg would be used for all 
memblet samples for DSC measurements. All samples were prepared in 40µl aluminium 
crucibles. ADSC was carried out with an underlying heating rate of 1°C per minute and a 
modulated temperature of 0.1°C per 0.8 minutes. All samples were run in duplicate. 
 
Integral 51.8 mJ
Endset 56.51°C
 
Figure 3.15 Differential Scanning Calorimetry thermogram of Eudragit® E 100 identifying the 
larger endset glass transition temperature in comparison to literature findings 
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Integral 5827 mJ
Endset 61.91 °C
 
Figure 3.16 Differential scanning calorimetry thermogram of polyethylene glycol 4000 
corresponding to literature findings 
 
Figure 3.17 shows a definite thermal profile of the memblet system comprising of both 
Eudragit® E 100 and PEG 4000. The thermogram has a well defined trough which can 
display the melting point of the PEG 4000. The melting point shows a very similar value to 
the test conducted on the individual polymeric material having a melting point of 52.12°C. 
This value still however falls in the range of the tested Eudragit® E 100 beads and as such a 
distinction must be made as to whether the thermal event depicted is the glass transition 
temperature of the Eudragit® E 100 beads or the melting point of the PEG 4000. There were 
2 factors that influenced the decision made. Firstly, the trough itself is not a gradual slope 
seen with a glass transition but is a sharp spike typically expressed with a melting point. The 
second factor indicating that the event is a melting point is the integral (or Cp) value of 
712.67mJ. As previously explained in Chapter 3.5.5.1, melting is a first order endothermic 
energy transition requiring a considerable amount of energy in the form of heat to transpire. 
Relative to the integral value of the Eudragit® E 100 Tg, 51.86mJ, the memblet system 
requires a large amount of energy for an event to take place.  
 
Though the event is classified as a melting point, it is known from preliminary studies that the 
Eudragit® E 100 polymeric component comprises of a Tg though the event is not seen on the 
thermogram. As the glass transition and melting point of Eudragit® E 100 and PEG 4000 
respectively are close values, it is assumed that there was an overlapping of thermal events 
taking place. A solution offered was to decrease the ramping temperature from 10°C to 5°C 
at the detriment to resolution to separate the thermal events.  
67 
 
A more thorough and practical solution was opting for Alternating Differential Scanning 
Calorimetry (ADSC) to allow for individual analysis of events. The memblet sample showed 
an erratic behaviour towards the 300°C temperature range which is indicative of either 
release of gas or thermal decomposition. The second run of the same crucible, shown in 
Figure 3.18, displayed an atypical curve which establishes that the event is in fact thermal 
decomposition. From this data, it is non-conducive to accurate results to keep this 
temperature range as the sample must follow the duplication procedure in analysis to remove 
any thermal history. The upper end range should therefore be within 260°C.  
 
Integral 712.67 mJ
Endset 52.12°C
 
Figure 3.17 Preliminary Differential Scanning Calorimetry thermogram of a novel memblet 
system 
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Figure 3.18 Thermal decomposition of the memblet system once passing 300°C establishing 
upper testing limits 
 
Integral 693.19 mJ
Endset 54.23°C
 
Figure 3.19 A second Differential Scanning Calorimetry run validating the upper limits of the 
temperature range for subsequent analysis 
 
A remodelled test was conducted on the DSC1 STARe system with upper limit being at 150°C 
in which the second run, depicted in Figure 3.19, yielded no thermal decomposition. An 
upper limit of 200°C was verified for all DSC memblet samples. 
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3.6 Concluding Remarks 
 
Preliminary studies provided a framework for formulation variables to be selected. Fixed 
formulation parameters were also decided, as variation in their incorporation into method 
development would drastically alter results.  
 
The multiparticulate component of the ODMUS required an increase in DEE and a closer to 
zero-order release pattern for a period of between 10 and 12 hours at a pH of 6.8. Fixed 
method parameters included a 20 minute curing period for both crosslinker solutions in which 
the second crosslinker would be AlCl3 for all formulations.  
 
The inclusion of ethyl cellulose into the formulation was also a fixed formulation parameter as 
its influence positively influenced release profiles though the physical amount to be included 
was yet to be determined by optimization analysis detailed in Chapter 4 of this dissertation. 
Saturation of crosslinker solutions provided an acceptable DEE and subsequently an amount 
of 3g INH was to be saturated with the crosslinker solutions as the final fixed formulation 
parameter. 
 
Memblet samples in preliminary studies showed an effective duration of release (under 2 
hours) for the respective crosslinker concentrations (30%w/v and 60%w/v). Thermal analysis 
methods were successfully developed for both DSC and ADSC for subsequent testing 
elaborated in Chapter 4 of this dissertation.   
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CHAPTER 4                                                                           
FORMULATION AND OPTIMIZATION OF ISONIAZID-LOADED 
MULTIPARTICULATES AND A RIFAMPICIN-LOADED ORAL 
MEMBRANOUS SYSTEM 
 
 
4.1 Introduction 
 
Preliminary studies outlined in Chapter 3, were of critical importance for the optimization of 
the ODMUS. Through these studies upper and lower limits (formulation independent 
variables) for both multiparticulate and memblet systems were ascertained, as will be 
detailed in this Chapter. An individualised experimental design was employed through 
manipulation of the variables to determine measured responses as per component of the 
ODMUS. The multiparticulate system included independent variables that were both 
qualitative and quantitative in comparison to the memblet system’s quantitative independent 
variables only. Based on these statistical results, an optimized formulation was formulated for 
both the multiparticulate and the memblet systems. These optimized versions of the ODMUS 
were then put through drug delivery testing and characterization prior to in vivo studies.   
 
When implementing the design of experiments, a response surface methodology approach 
was selected to evaluate the best combination of formulation components to achieve an 
optimal ODMUS formulation. Functionally, this methodology was selected to optimize both 
components of the ODMUS utilizing statistical experimental designs, specifically a Box-
Behnken design. Response surface methodology achieves its objective of optimization 
through:  
 
• Formulating a design of experiments derived from the upper and lower limits of the 
formulation variables (independent variables) 
• Conducting the physical tests on the design of experiments 
• The manipulation of regression analysis techniques to evaluate the coefficients of a 
mathematical model 
• Prediction of responses (dependent variables) and validation of the mathematical 
model resulting in optimization of that particular formulation (Raya et al., 2009; 
Raya et al., 2010). 
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4.2 Optimization Utilizing a Box-Behnken Factorial Design 
 
4.2.1 Selection of suitable independent variables to elucidate positive responses for 
the once daily multi-unit System 
Selection of factors and factor levels for the design of experiments was based on preliminary 
studies discussed in Chapter 3. Factors were selected for each component of the ODMUS 
such that individualised mathematical models were generated.  
 
Of specific importance for the multiparticulates was the incorporation of ethylcellulose (EC) 
and the choice and concentration of the second crosslinker. Effectively, the independent 
variables constituted qualitative and quantitative variables relative to type of crosslinker and 
concentration of EC and crosslinker respectively. The main effect, or factor averaged above 
all other levels of factors relating to the largest magnitude of change in responses (Bolton, 
1997), would be allocated to an individual factor or a combination of factors after responses 
were obtained through mathematical modelling. 
 
With regards to the multiparticulate component, Figure 3.12e of Chapter 3.5.3 authenticated 
that relatively good release with a concurrently improved DEE of 61% was achieved with 
batch 3. A test amount of 5%w/v (1g of EC) was used and subsequently, upper and lower 
limits of this numerical value were selected as shown in Table 4.1.  
 
The type of secondary crosslinker was limited to 3 of the most proficient cationic electrolytes 
namely BaCl2, CaCl2 and MgCl2 for the purposes of simplifying mathematical modelling. 
ZnCl2 was excluded due to the poor release patterns relative to the other 3 metal ions. 
Successful release patterns shown for batch 3 could not be attributed to any single variable 
at that point. Concentrations of secondary crosslinkers were therefore subject to scrutiny in 
mathematical modelling with upper and lower limits of 20%w/v and 40%w/v, respectively.  
 
For the purposes of this study, responses in Table 4.1, mean dissolution time (MDT) and 
drug entrapment efficiency (DEE) were to be maximized in all situations to achieve an 
optimal formulation. 
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Table 4.1 Listing of formulation variables with appropriate responses and objectives 
Independent variables Upper 
limits 
Lower 
limits 
- 
Type of crosslinker BaCl2, CaCl2 
or MgCl2 
BaCl2, CaCl2 
or MgCl2 
- 
Concentration of secondary 
crosslinker (%w/v) 
40 20 - 
Ethylcellulose content (g) 2.000 0.750 - 
Response Upper limit Lower Limit Objective 
Drug Release (MDT) 65 45 Maximize 
DEE (%) 65 45 Maximize 
 
In a similar context, the memblet system would require a controlled release pattern, but 
conversely, a shorter duration of release. Rifampicin (RIF) would require a total release in the 
stomach within 2 hours prior to gastric emptying to avoid any associative release in the small 
intestine. It was already postulated that the main effect of independent variables on the 
dependent responses would be a synergistic influence through a combination of factors as 
polyethylene glycol (PEG) 4000 and triethyl citrate (TEC) had a similar plasticizing effect and 
would alter release patterns.  
 
Furthermore, a high glass transition temperature (Tg) was imperative to ensure structural, 
functional and aesthetic integrity for the period prior to dosing. Specifically, the Tg of the 
memblet was required to be above 37°C so as not to undergo premature degradation in vivo.  
 
Independent variables numerical values were chosen based on the influence each had on 
the Tg, bearing in mind that both TEC and PEG 4000 had a compounding effect of lowering 
Tg as both are plasticizers. Table 4.2 depicts the upper and lower limits for the independent 
variables obtained through preliminary studies including desired responses based on said 
preliminary studies.  
 
   
Table 4.2 Listing of formulation variables with responses and objectives for the memblet 
Independent variables Upper limits Lower limits - 
Concentration of Polyethylene 
Glycol 4000 (%w/v) 
70.0%w/v 30.0%w/v - 
Concentration of Triethyl 
Citrate  (%v/v) 
10.0%v/v 1.0%v/v - 
Concentration of Sodium 
Lauryl Sulphate (g) 
2.0g 0.5g - 
Response Upper limit Lower limit Objective 
Drug Release (MDT) 200 100 Maximize 
Glass Transition Temperature 
(°C) 
65 35 Maximize 
 
73 
 
4.2.2 Generation of a design of experiments through a box-behnken design and 
subsequent testing  
With the establishing of the independent variables, a design of experiments was formulated 
in the form of runs or trials. These experimental runs aimed to produce a minimum amount of 
runs that would ascertain maximum efficacy of information for prediction of responses. A 
Box-Behnken design was selected for this generation of runs requiring only 3 levels ie. 
upper, lower and central numerical values such that the use of an independent quadratic 
design resulted in 15 formulations as 3 independent factors were chosen for each 
formulation of the ODMUS (MINITAB®,V14, Minitab, USA). Table 4.3 and Table 4.4 
demonstrates the experimental runs of double crosslinked, isoniazid-loaded 
polymethacrylate multiparticulates and PEG 4000 crosslinked Eudragit® E 100 memblet 
systems respectively, generated by a Box-Behnken design. Measured responses employed 
in the Box-Behnken design for the experimental runs, are similarly displayed in Table 4.5 for 
both multiparticulates and memblets. During the design of experiments stage, experimental 
responses are recorded for the runs of experiments carried out in a systematic way to 
develop a mathematical model. 
 
Table 4.3 Factors and levels of independent variables generated by the 33 Box- Behnken 
design for isoniazid-loaded, double crosslinked, polymethacrylate based multiparticulates 
 Independent factors 
Experimental Run Ethyl Cellulose (g) Crosslinking agent Crosslinking 
solution 
concentration 
(%w/v) 
1 0.750 MgCl2 40 
2 2.000 CaCl2 30 
3 0.750 CaCl2 30 
4 1.375 MgCl2 30 
5 1.375 BaCl2 40 
6 2.000 MgCl2 40 
7 0.750 BaCl2 30 
8 1.375 MgCl2 30 
9 1.375 BaCl2 20 
10 2.000 MgCl2 20 
11 1.375 CaCl2 20 
12 1.375 MgCl2 20 
13 1.375 CaCl2 40 
14 0.750 MgCl2 20 
15 2.000 BaCl2 30 
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Table 4.4 Factors and levels of independent variables generated by the 33 Box- Behnken 
design for rifampicin-loaded, polyethylene glycol 4000 crosslinked, Eudragit® E 100 memblet 
systems 
 Independent factors 
Experimental Run Triethyl citrate 
(mL) 
Polyethylene 
glycol 4000 (%w/v) 
Sodium lauryl 
sulphate (g) 
1 1 70 1.25 
2 10 50 2.00 
3 1 50 2.00 
4 5.5 50 1.25 
5 5.5 70 0.50 
6 10 70 1.25 
7 1 50 0.50 
8 5.5 50 1.25 
9 5.5 30 0.50 
10 10 30 1.25 
11 5.5 30 2.00 
12 5.5 50 1.25 
13 5.5 70 2.00 
14 1 30 1.25 
15 10 50 0.50 
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Table 4.5 Measured responses of the experimental run for the optimization of 
multiparticulates 
Multiparticulate component experimental run 
Experimental Run MDT DEE(%) 
1 68.663 49.39 
2 71.273 40.13 
3 69.793 60.40 
4 66.345 46.94 
5 66.877 45.69 
6 70.166 44.49 
7 59.854 43.76 
8 68.352 46.40 
9 60.757 48.39 
10 70.841 40.45 
11 67.355 63.66 
12 71.911 50.09 
13 59.176 48.62 
14 49.646 49.14 
15 69.115 63.76 
Memblet component experimental run 
Experimental Run MDT Tg (°C) 
1 163.773 47.72 
2 167.328 53.40 
3 165.438 53.45 
4 161.449 51.09 
5 152.095 53.94 
6 146.740 54.44 
7 150.841 54.65 
8 147.790 49.00 
9 143.705 51.58 
10 150.198 55.89 
11 142.552 55.97 
12 159.178 57.94 
13 146.422 55.30 
14 245.833 52.15 
15 159.341 49.30 
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Figure 4.1 Release profiles for the multiparticulates design of experiments where a) 
represents formulations 1-4, b) represents formulations 5-8, c) represents formulations 9- 
12and d) represents formulations 13-15; where N= 3 and SD < 1.0 in all cases   
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Figure 4.2 Release profiles for the memblet design of experiments where a) represents 
formulations 1-4, b) represents formulations 5-8, c) represents formulations 9-12 and d) 
represents formulations 13-15; where N= 3 and SD < 1.6 in all cases   
 
4.2.3 Comparative analysis of actual experimental and fitted response values 
calculated for the optimization of both components of the once daily multi-unit system   
Data collected from the design of experiments were comparatively plotted for a) memblet 
MDT b) memblet Tg c) multiparticulate DEE and d) multiparticulate MDT, against Fitted 
responses which resulted in R2 values of 0.796, 0.535, 0.869 and 0.551 respectively. An 
acceptable correlation between the experimental and fitted responses was determined 
verifying the Box-Behnken design for the responses of MDT and Tg for the memblet system 
and MDT and DEE for the multiparticulate system.                                                
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Figure 4.3 Regression plots for a) memblet mean dissolution time b) memblet glass 
transition c) multiparticulate drug entrapment efficiency and d) multiparticulate mean 
dissolution time to ascertain R2 values to verify the correlation between fitted and actual 
values for the formulation responses 
 
4.2.4 Graphical response data analysis 
The data obtained from response surface methodology can be suitably modelled to produce 
mathematic relationships between the independent variables (Factors) and the dependent 
variables (Responses). Graphically, these are depicted as 3-D models (response surface 
plots) representing the independent variables and the responses. Of critical importance is the 
interaction (if any) between the independent variables and the effect of these factors on the 
response, to give us a deeper look into the behaviour of the system. Additionally, residual 
plots such as Normal Probability Plot of the Residuals, Residuals Versus the Fitted Values,   
Histograms of the Residuals and Residuals Versus the Order of the Data are plotted for 
comparative purposes.    
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4.2.4.1 Response inspection of the once daily multi-unit system via 3-dimensional 
plotting 
Mean dissolution time (MDT) and glass transition temperature (Tg) were the responses 
measured for the memblet system. Surface plot analysis validates the relationship between 
the independent variables PEG 4000 and TEC on the response of MDT in Figure 4.4a and 
Figure 4.4b. A direct linear relationship exists for these factors as a simultaneous decrease in 
PEG 4000 (between 30 and 45%w/v) and TEC (<5%w/v) elucidates a maximal MDT (>200) or 
a positive effect on response. The relationship between these factors can be termed as 
synergistic for the response of MDT. Conversely, sodium lauryl sulphate (SLS) influences a 
relatively negative response on MDT in comparison to the synergistic effect of PEG 4000 and 
TEC. A maximal amount (>1.8g) produced a maximum MDT response of only 180 in either 
case of increasing PEG 4000 (50%w/v) or TEC (6%w/v). For the purposes of optimizing the 
response of MDT, PEG 4000 and TEC have a more positive effect through synergistically 
decreasing levels to rate control release of rifampicin, as compared to any manipulation of 
SLS. Tg was required to be maximized, in particular to be well above 37°C (homeostatic body 
temperature). Surface responses (Figure 4.4) indicated a similar pattern as for the response 
of MDT for all factor levels (i.e. 45%w/v PEG 4000, a slightly increased 5%w/v TEC and a 
maximum 1.8g SLS) to achieve a Tg of >54°C.   
 
Data analysis postulated that an effective MDT of >200 and a Maximum Tg value of >54°C 
for factor levels of PEG 4000 30-45%w/v, TEC 1-5%w/v and SLS > 1.8g.  
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 Figure 4.4 Illustration of the relationship between independent variables and the response of 
a) mean dissolution time (MDT) and b) glass transition temperature (Tg) through 3-D surface 
plots for the memblet system 
 
Responses of MDT and DEE for the multiparticulate system were dependent upon the 
factors ethylcellulose, type of crosslinker (1= Ba2+, 2= Mg2+ and 3= Ca2+) and concentration 
of crosslinker shown in Figure 4.5a. As a function of DEE, when a maximum ethylcellulose 
81 
 
concentration (2g) is selected, a crosslinker concentration of (20%w/v) elucidates a 55% DEE. 
An indirect relationship exists between the factors as a decrease in crosslinker concentration 
with simultaneous increase in EC results in a positive effect on the response of DEE. TOC or 
type of crosslinker is displayed as 1 or Ba2+ for both an increase and decrease of EC and 
TOC respectively. From the collated data, a positive response of maximizing DEE is based 
on using Ba2+, decreasing crosslinker concentration to 20%w/v and increasing EC to 2g. 
Figure 4.5b revealed an optimal MDT value (>60) for crosslinker concentrations of between 
20 and 30%w/v and EC amounts of 2g revealing the indirect relationship between the factors. 
The effect on the MDT due to the TOC varied based on the co-factor i.e. Ca2+ when EC is 2g 
and Ba2+ when crosslinker concentration is between 20 and 30%w/v.           
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Figure 4.5 Illustration of the relationship between independent variables and the response of 
a) drug entrapment efficiency (DEE) and b) mean dissolution time (MDT) through 3-D 
surface plots for the multiparticulate system 
 
4.2.4.2 Analysis of the box-behnken design through residual plots for optimization and 
subsequent response optimization of the once daily multi-unit system  
Residual plots are model diagnostic plots which function to validate transformation of data 
(Singh et al., 2004). Specifically, 1 or more plots are used to investigate fit of the proposed 
model data to data collated and these plots are indicated in Figure 4.6 and Figure 4.8.  
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Residual analysis of data for the memblet system indicated an even distribution of data for Tg 
and MDT as illustrated in Figure 4.6a and Figure 4.6b respectively. The normal probability 
plots of the residuals showed a close distribution of data points along the medial line forming 
a linear curve. For the graph of residuals versus the fitted values, the plot tests the 
assumption of constant variance. Here desirable data points were obtained with a random 
and uniform scatter, with these data points close to the zero axis and validating the 
assumption of constant variance. Additionally, the histograms confirmed the assumption of 
constant variance and that the residuals had a normal distribution with zero mean. The plot 
of residuals versus the order of the data is a plot of residuals versus the order of the 
experimental runs. Traditionally, this graph is used to test for lurking variables that may have 
influenced responses and to identify non-random errors. The plots for both MDT and Tg 
showed a negative correlation through the alternating data points (alternating through 
positive and negative values), whilst the MDT plot indicated a concurrent positive correlation 
through clustering of formulations 6-11.  
 
Through data capturing from selected experimental responses, an empirical mathematical 
model was formulated. This mathematical model functions to predict formulation responses 
based on independent variable input. Specifically, response surface modelling involves fitting 
the generated coefficients into the mathematical model equation of a particular response 
variable and mapping the response over the whole region of the experimental domain in the 
form of a surface (Singh et al., 2004). ANOVA testing was adopted as a test of significance. 
The polynomial equation calculated the varying responses based on different variables used. 
A statistically significant effect is indicated by p<0.001 for any factor.  The factor coefficients 
and their respective p values are depicted in Table 4.6 and the mathematical models 
generated for each component depicted in Equation 4.1 and Equation 4.2.  
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Figure 4.6 Residual plots of a) mean dissolution time (MDT) and b) glass transition (Tg) of 
the memblet system 
 
 
 
 
Table 4.6 ANOVA analysis indicating factors for responses mean dissolution and glass 
transition
 
and corresponding factor p values for the memblet system 
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Term MDT factor 
coefficients 
MDT factor p 
values 
Tg factor 
coefficients 
Tg factor p 
values 
[TEC] -12.785 0.218 +0.6325 0.680 
[PEG] -9.157 0.360 -0.5238 0.732 
[SLS] +1.970 0.837 +1.0813 0.488 
[TEC]*[TEC] +17.520 0.247 -0.8121 0.718 
[PEG]* [PEG] +2.977 0.833 +0.6854 0.760 
[SLS]*[SLS] -12.922 0.378 +0.8354 0.710 
[TEC]*[PEG] +19.651 0.187 +0.7450 0.730 
[TEC]*[SLS] -1.652 0.903 +1.3250 0.545 
[PEG]*[SLS] -1.130 0.933 -0.7575 0.726 
[TEC]= triethyl citrate, [PEG]= polyethylene glycol, [SLS]= sodium lauryl sulphate, MDT= 
mean dissolution time and Tg= glass transition temperature 
 
SLS]×1.130[PEG-SLS]×1.652[TEC-        
PEG]×19.651[TEC+]12.922[SLS-2.977[PEG]+        
]17.520[TEC+1.970[SLS]+9.157[PEG]-]12.785[TEC-140.156MDT
22
2
=
         (Equation 4.1) 
 
SLS]×0.7575[PEG-SLS]×1.3250[TEC+    
PEG]×0.7450[TEC+]0.8354[SLS+]0.6854[PEG+    
]0.8121[TEC-]1.0813[SLS+]0.5238[PEG-]0.6325[TEC+52.6767T
22
2
g =
        (Equation 4.2) 
 
Regression Equation 4.1 and Equation 4.2 for the responses of mean dissolution time (MDT) 
and glass transition (Tg) for the memblet system. 
 
Response optimization was finalized through MINITAB®, V14, Minitab, USA statistical 
software resulting in fixed levels for all factors to achieve optimal and desired responses. 
Response optimization sets of values (3), were achieved for the memblet system as seen in 
Figure 4.7 including a Hi, Lo and optimal set of factors. For the optimal set of factors, a 
desirability of 0.99848 was achieved indicating an optimal set of factor variables in which 
TEC= 1.6168mL, PEG= 30%w/v and SLS= 1g. Predicted responses based on these optimal 
factor variables were: 
 
 
 
MDT= 200.913 (Desirability= 1.00000) 
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Tg= 54.909°C (Desirability= 0.99545)          
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Figure 4.7 Optimization plots of the memblet system indicating optimal factors and factor 
levels and desirability 
 
Residual analysis of data for the multiparticulate system revealed a similar even distribution 
of data for DEE and MDT illustrated in Figure 4.8a and Figure 4.8b respectively. The normal 
probability plots of the residuals showed a general close distribution of data points along the 
medial line with slight deviations indicating that the experimental values were analogous to 
predicted values. For the graph of residuals versus the fitted values, desirable data points 
were obtained with a random and uniform scatter with these data points close to the zero 
axis and validating the assumption of constant variance. The plots for both DEE and MDT 
showed a negative correlation through the alternating data points (alternating through 
positive and negative values). A statistically significant effect is indicated by p<0.001 for any 
factor.  The factor coefficients and their respective p values are depicted in Table 4.7 and the 
mathematical models generated for MDT and DEE are shown in Equation 4.3 and Equation 
4.4 respectively.  
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Figure 4.8 Residual plots of a) drug entrapment efficiency (DEE) and b) mean dissolution 
time (MDT) of the multiparticulate system 
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Table 4.7 ANOVA analysis indicating factors for responses drug entrapment efficiency and 
mean dissolution time and the corresponding factor p values for the multiparticulate 
component of the Once Daily Multi-Unit System 
Term DEE factor 
coefficients 
DEE factor p 
values 
MDT
 
factor 
coefficients 
MDT factor p 
values 
[EC] +5.3952 0.045 +2.2154 0.495 
[CROSSLINKER] -4.0495 0.103 +0.5148 0.871 
[TOC] -3.5343 0.143 -0.5550 0.861 
[EC]*[EC] +2.4897 0.444 +2.4993 0.598 
[CROSSLINKER]* 
[CROSSLINKER] 
-1.9836 0.537 +3.6817 0.445 
[TOC]*[TOC] +6.3679 0.087 -0.7095 0.879 
[EC]*[CROSSLINKER] -0.0141 0.996 -1.0155 0.821 
[EC]*[TOC] +0.3195 0.916 +0.3952 0.930 
[CROSSLINKER]*[TOC] +2.4526 0.433 +3.0357 0.508 
[EC]= ethyl cellulose, [CROSSLINKER]= concentration of crosslinker, [TOC]= type of 
crosslinker, DEE= drug entrapment efficiency and MDT= mean dissolution time 
 
TOC]×SSLINKER3.0357[CRO+        
TOC]×0.3952[EC+R]CROSSLINKE×1.0155[EC-        
]0.7095[TOC-SSLINKER]3.6817[CRO+2.4993[EC]+        
]0.5550[TOC-SSLINKER]0.5148[CRO+2.2154[EC]+63.0908MDT
222
=
         (Equation 4.3) 
 
[TOC]×SSLINKER]2.4526[CRO+        
TOC]×0.3195[EC+R]CROSSLINKE×0.0141[EC-        
]6.3679[TOC+SSLINKER]1.9836[CRO-2.4897[EC]+        
]3.5343[TOC-SSLINKER]4.0495[CRO-5.3952[EC]+45.2214DEE
222
=
         (Equation 4.4) 
 
Regression Equation 4.3 and Equation 4.4 for the responses of mean dissolution time and 
drug entrapment efficiency for the multiparticulate system. 
 
Response optimization was achieved through MINITAB®, V14, Minitab, USA statistical 
software producing optimal levels for all factors to achieve optimal and desired responses of 
MDT and DEE. A total of 3 response optimization sets of values were achieved for the 
multiparticulate system as seen in Figure 4.9 including a Hi, Lo and optimal set of factors. 
For the optimal set of factors, a desirability of 1.0000 was achieved authenticating optimal 
factor levels for maximal responses. Predicted responses based on these optimal factor 
variables were: 
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DEE= 67.2216% (Desirability= 1.00000) 
 
MDT= 74.4739 (Desirability= 1.00000)    
 
Hi
Lo1.0000
D
Optimal
Cur
d = 1.0000
Maximum
MDT
d = 1.0000
Maximum
DEE
y = 74.4739
y = 67.2216
1.0
3.0
20.0
40.0
0.750
2.0
[CROSSLI TOC[EC]
[2.0] [20.0] [1.0]
 
Figure 4.9 Optimization plots of the multiparticulate system indicating optimal factors and 
factor levels and desirability 
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4.3 Concluding Remarks 
 
The purpose of Chapter 4 was to achieve an optimal set of formulation variables or 
independent factors for both the memblet and multiparticulate components of the ODMUS. A 
design of experiments proved to be an authentic methodology for the clarification of optimal 
formulation variables. Varying statistical analysis methods were chosen, employed and 
comparatively scrutinized to produce the variables and to ensure verification and validity of 
these produced factors in relation to the optimal responses.  
 
The memblet system optimized formulation variables of TEC, PEG and SLS with a 
desirability of 0.99848 in which TEC= 1.6168mL, PEG= 30%w/v and SLS= 1g. Predicted 
responses based on these optimal factor variables were an MDT= 200.913 (Desirability= 
1.00000) and Tg= 54.909°C (Desirability= 0.99545). During the optimization process, SLS 
was found to have very little impact on the formulation responses relative to the large effect 
produced on both MDT and Tg for both TEC and PEG.  
 
A desirability of 1.00000 for the multiparticulate system expressed the confidence in the 
formulation variables [EC],[CROSSLINKER] and [TOC]. As indicated through testing, EC 
was to be maximized to achieve and optimal response for both DEE and MDT and the 
concentration of the crosslinker was between 20-30%w/v for the same responses. The type of 
crosslinker varied on the response and consequently the most desired responses were 
achieved through EC= 2.0g, [CROSSLINKER]= 20%w/v and [TOC]= Ba2+. Predicted 
responses generated were an MDT= 74.4739 (Desirability= 1.00000) and DEE= 67.2216% 
(Desirability= 1.00000).            
   
Both components achieved a high desirability for all levels of factors. The following Chapters 
shall delve into the full and relevant analytical testing as per component of the ODMUS.    
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CHAPTER 5                                                                            
FORMULATION AND INVESTIGATION OF AN OPTIMIZED 
RIFAMPICIN-LOADED ORAL MEMBRANOUS SYSTEM FOR 
TARGETED DRUG DELIVERY TO THE STOMACH 
 
 
5.1 Introduction 
 
When considering non-invasive delivery systems, the oral route is generally preferable when 
considering site-specific drug release, patient compliance, ease of administration and patient 
acceptance (Sastry et al., 2000; Sangalli et al., 2001; Weidner, 2001). Past research has 
explored the oral dosage form in ardour to obtain a succinct design that amalgamates 
method simplicity and design efficacy. The tenuous balance between theses desired factors 
has always been difficult to achieve. Membranous/hydrogel delivery systems have been 
thoroughly investigated (Peppas et al., 2000; Lee and Mooney, 2001; Kim et al., 2007) and 
could potentially achieve this balance between formulation method simplicity and efficacy. In 
retrospect, many studies have achieved efficacy but are unable to yield basic method 
parameters and periodically involve complex procedures (Chun et al., 2005; Lin and Metters, 
2006; Bae et al., 2008; Huynh et al., 2008). Oral membranous systems however remain 
preferred delivery systems for therapeutic agents (Knuth et al., 1993; Lin et al., 2008; Ma and 
McHugh, 2008) with much success in their respective applications. Standard protocol implies 
that oral membranous/hydrogel systems should be biodegradable or biocompatible with 
impetus placed upon excluding toxicity (Mandal et al., 2009).   
 
The memblet delivery system achieved equilibrium in both method simplification and site-
specific, segregated drug delivery. The novelty of the system lies in the innovative 
manipulation of the taste masking agent Eudragit® E 100 by crosslinking the cationic 
methacrylate functional moiety with the anionic polyethylene glycol 4000 to produce a 
crosslinked hydrogel. This single process step provides an attractive methodology compared 
to its membranous predecessors fabrication procedures and significantly decreases 
formulation time. The dried, drug-loaded, compressed and optimized memblet was placed 
under investigation in this Chapter.   
 
Previous Chapters focused on preliminary studies and a rudimentary understanding of the 
novel system and optimizing the fabrication of the system. This Chapter aimed to fully 
characterise the memblet through rheological, thermal, textural and surface morphological 
understanding. Scrutiny was placed on the memblet’s efficacy for drug release, elucidated 
through the acidic pH of the stomach through dissolution studies. An in depth molecular 
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examination was conducted to understand the role the molecular structure induced on the 
memblet. 
 
5.2 Materials and Methods 
 
5.2.1 Materials 
Eudragit® E 100 was kindly supplied by Evonik Degussa Africa (Pty) Ltd (Evonik Degussa 
Africa (Pty) Ltd. (Midrand, Gauteng, South Africa) while polyethylene glycol 4000 (PEG 4000) 
was purchased from Merck chemicals (Merck chemicals, Halfway House, Gauteng, South 
Africa). Acetone, triethyl citrate (TEC), isopropyl alcohol, sodium lauryl sulphate (SLS) and 
tween 80 were all of analytical grade and employed as purchased.  Water was purified by a 
MilliQ Millipore water purification system (Milli-Q, Millipore, Billerica, MA, USA). Rifampicin 
was of analytical quality Sigma Aldrich.Inc (Pty) Ltd. (St Louis, MO, USA).  
 
5.2.2 Fabrication of the optimized crosslinked memblet for gastric drug release  
For fabrication of a memblet, 34%v/v of acetone, 46.9%v/v of isopropyl alcohol and 1.8%v/v of 
de-ionized water were measured and added to a 200mL beaker. Affectively, 13.6%w/v of the 
Eudragit® E 100 polymer was gradually added to the aforementioned latex with constant 
agitation employing a magnetic stirrer at room temperature (21°C) for 1 hour. This was left 
under agitation until all the Eudragit® E 100 beads were completely dissolved. TEC 
(1.6168mL) and the remaining constituents [tween 80 (4g) and SLS (1g)] were gradually 
added to the latex and left to stir for approximately an hour. Simultaneously a 30%w/v (the 
optimized formulation) and 60%w/v (a control sample) PEG 4000 solutions were prepared. A 
measured 5mL of the Eudragit® E 100 latex was drawn up and expelled through a syringe 
into both solutions. Crosslinking resulted in hydrogel A (optimized) and B (control), which 
were subsequently left to cure in their respective solutions for 20 minutes. Following the 
curing, samples were washed 3 times in 500mL de-ionized water before storage in a 
desiccant jar (using silica crystals) for 10 days of drying time. The dried membranes were 
then ground using a standard coffee grinder and the powder obtained was mixed with 150mg 
of rifampicin. Subsequently, compression of the mixed powders resulted into the tablet like 
structure termed the memblet.      
   
5.2.3.1 Rheological principles for the assessment of a novel semisolid Eudragit® E 100 
based memblet system  
The memblet system has the potential to undergo deformation and flow with the addition of 
heat, as was determined through the basic DSC preliminary analysis in Chapter 3.5.5.2 
which conveyed a glass transition temperature below 100°C (52.12°C). Rheological analysis 
was crucial in determining deformation and flow due to a shear rate and a shear force. The 
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consistency of the memblet could potentially oscillate between solid and liquid based on a 
shear force and shear rate, due its semisolid nature complicating and impeding standard 
rheological characterization techniques. The viscoelastic nature of the memblet was to be 
evaluated and defined through the more powerful dynamic oscillatory testing. 
 
Traditionally, a basic curve of viscosity () versus shear rate (Y) garners crucial information 
with regards to storage and optimizing method parameters in bulk manufacturing (Herh et al., 
1998). Basic flow curves derived from these parameters include Newtonian Flow, Dilatant 
Flow, and Pseudoplastic Flow curves which have been employed to indicate how structure 
changes occur to comply with shear forces under storage conditions, processing and during 
the pharmaceutical products use. For characterization purposes of the memblet, further 
testing through more intricate and powerful analyses have been developed. 
 
The basic Law of Viscometry described by Isaac Newton defines the ideal flow properties of 
a liquid as:  
 
                                                                                                    (Equation 5.1) 
 
Where,  is expressed as shear stress,  as viscosity and Υ as the shear rate (Schramm, 
2004). 
 
Shear force can be defined as a force applied tangentially to an area between the interface 
of the measuring plate and the sample tested (memblet).  
 
The following equation depicts shear stress or : 
 
 A
F
                                                                              (Equation 5.2) 
 
Where, F= force in Newton’s and A= area in m2 (Schramm, 2004). 
 
As a shear force is applied to a system, a flow speed is concurrently associated with the 
sample. From the superficial layer of the sample, the flow rate begins to decreases the lower 
the layer due to the displaced tangential force. Laminar flow is described which states that 
infinitesimally thin liquid layers slide on top of each other. This decrease in velocity is termed 
the shear rate or Υ. For the purposes of rheometric analysis Υ is expressed as: 
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y
v max
                                                 (Equation 5.3) 
 
Where Vmax= the velocity of flow at that particular layer of sample and y= the gap size 
between the measuring plate and the stationary lower plate (Schramm, 2004). 
  
For the purposes of rotational rheometry with a Thermohaake Rheometer, a rotating cone or 
cylinder sensor system is utilized to generate the basic parameters of shear rate, shear force 
and viscosity. The shear stress applied allows the cone to only rotate at a particular speed or 
shear rate according to the applied shear force. This is inversely proportional to the viscosity 
of the sample. The individualized mathematical equations used to interpolate data points 
through the sensor from the sample between the cone and the stationary plate are depicted 
accordingly: 
 
]s[ω.Mω
αtan
1 1-
=×                       (Equation 5.4) 
 
Where Y= shear rate, α= cone angle (C35/1° Ti cone), M= shear rate factor [1/rad], 
 , , ω = angular velocity (rad/s) and n = rotor speed (rev.min-1) 
 
dd3
c
c M.AM]Rpi2
3[T =×=
                      (Equation 5.5) 
 
Where c= shear stress on the cone, Rc= outer radius of the cone, Md= Torque to be 
measured and A= shear stress factor (Schramm, 2004). 
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C35/1° Titanium cone with the function 
of linear and dynamic rotation to 
elucidate shear stress (Ʈc) and shear 
rate (Y) as per the equations : 
Stationary plate
Sample
Motor and compressor 
introducing calibrated 
rotation and compression
= 1tan . = . [−1] =  32. 3 .  = .  
 
Figure 5.1 Thermohaake rheometer used in the analyses of rheometric parameters for the 
memblet 
 
Yield stress (measured in  or Pa) is defined as the minimal shear force/stress required to 
induce deformation or flow. It is only an estimation of the force required as this is a time 
dependent test (Herh et al., 1998), but the relevance for preliminary understanding of the 
memblet system is pertinent. Below the yield stress, deformation occurs in a linear manner 
with an increase in shear stress and the viscoelastic sample (in this case the memblet) is 
categorized as a solid. Above the critical yield value, the sample undergoes unlimited 
deformation and flows. 
        
Dynamic oscillatory experiments subject the test sample to sinusoidal stress and this is a 
non-destructive test unlike the yield stress test. The term non-destructive implies that the 
internal structure of the sample will remain unchanged for the duration of the test. The cone 
rather than turning in a unidirectional manner, oscillates at a pre-determined frequency 
dependent sinusoidal time function which imparts the same sinusoidal shear strain on the 
sample in a non destructive manner producing a time dependent strain: 
  
 
)t.ωsin(
                                      (Equation 5.6) 
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Where, = the amplitude of the stress, ω= angular velocity and t= time (Schramm, 2004). 
The amplitude of the resulting stress and the phase angle between the imposed stress and 
the strain are the data points derived. Benefits of this test can be correlated to the memblet 
as this specific test can gather information on material that cannot be sheared due to their 3-
D structure, as in the case of hydrogels. As the experiment is running, the stress applied 
leads to a deformation. Due to the elastic and viscous properties of the sample, the 
amplitude of deformation is not reached at the same time as the stress amplitude. There is 
thus a phase shift between stress and deformation referred to as a phase shift angle or δ.  
  
Pure elastic materials have a phase shift of 0° (stress and strain are in phase) and pure 
viscous samples exhibit a phase shift of 90° (a 90° out of phase stress). Viscoelastic 
materials exist between 0-90°. The following equation incorporates the above data into the 
stress equation used in dynamic oscillation studies: 
 
  
)δt.ωsin( +
                                (Equation 5.7) 
 
Where, = stress, = amplitude of stress, ω= angular velocity, t= time and δ= phase shift.  
ω= 2π.f where f= frequency of oscillation (Schramm, 2004). 
 
Dynamic oscillation studies concurrently introduces the concept of the complex modulus or 
G* which indicates the total resistance of a testing material against the applied strain and is 
derived from the amplitude of stress ( ) and the amplitude of deformation ( ) depicted in 
Equation 5.8 (Schramm, 2004). 
 
G*                                                (Equation 5.8) 
 
Once a test material is subjected to sinusoidal oscillation, the sample can potentially undergo 
elastic energy storage (storage modulus or G’), viscous energy dissipation (loss modulus or 
G’’) or more commonly, a combination of both.  The storage modulus implies the stress 
energy stored in a transitory manner for the duration of an oscillatory test with the ability of 
recovery of said energy upon completion of the study. Conversely, the loss modulus 
describes energy used to induce flow and impart deformation and consequently irreversibly 
transforming into heat. Both, energy states are dependent upon the phase shift and the 
complex modulus. Utilizing the Theorem of Pythagoras in Figure 5.2, equations for both 
storage and loss moduli have been produced in Equation 5.9 and Equation 5.10:    
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δ
G*
G’’
G’
 
Figure 5.2 Inter-relations of storage modulus (G’), loss modulus (G’’), complex modulus (G*) 
and the phase shift through the Pythagorean Theorem 
 
δcos*G'G =                                                   (Equation 5.9) 
 
δsin*G''G =                                                 (Equation 5.10) 
 
5.2.3.2 Rheological testing of crosslinked hydrogels prior to drying 
Rheological measurements were performed on a MAARS Thermohaak Rheometer 
(THERMO HAAKE, modular advanced rheometer system, LASEC South Africa). A 1o 35mm 
titanium cone was used for standard rotational studies (yield stress test) and dynamic 
oscillatory measurements (stress and frequency sweeps in which there is the constant 
application of sinusoidal shear stress). Samples tested included the Eudragit® E 100 latex 
prior to crosslinking and crosslinked hydrogels A and B prior to drying through a desiccant 
jar. The hydrogels (A and B) were used for no more than 2 tests before a fresh sample had 
to be prepared and all tests were conducted in triplicate (N= 3).  Separate testing parameters 
were chosen for each of the samples (latex and hydrogel) as depicted in Table 5.1. Upon 
reaching full dispersion, the latex was poured directly onto the rheometer plate for analysis.   
 
Sample preparation for the hydrogel involved a far more intricate method. Methods proposed 
in previous studies include the use of sand paper glued to the parallel plates with the gap 
size set 2mm to account for the thickness of the sample (Roger et al., 2008; Sozer, 2008).  
 
The method was replicated but proved unsuccessful as the hydrogel was deformed by the 
sand paper and though slippage of the memblet was prevented, the required gap size of 
0.051mm was not reached. A successful method was developed by using the cone of the 
rheometer to compress the sample thrice with ample recovery time between compressions, 
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until the sample was of a uniform surface area to reach the required gap size without 
detrimental deformation. Samples were coated with petroleum jelly to prevent excess water 
loss during the test. 
 
Table 5.1 Method parameters for yield test, stress sweep and frequency sweep tests 
Yield test E 100 Latex Hydrogel A Hydrogel B 
Temp (ºC) 20 20 20 
 start (Pa) 0 0 0 
 end(Pa) 5 100 400 
Duration (s) 200 200 200 
Stress Sweep - Hydrogel A Hydrogel B 
Temp (ºC) - 20 20 
 start (Pa) - 0 0 
 end (Pa) - 100 100 
Frequency (Hz) - 1 0.1 
Steps - 20 20 
Frequency 
Sweep 
- Hydrogel A Hydrogel B 
Temp (ºC) - 20 20 
Fixed  (Pa) - 6.5 6.5 
Start Freq (Hz) - 1 1 
End Freq (Hz) - 0.01 0.01 
 
5.2.4 Assessment of the surface morphology and inter- and intra-polymeric 
interactions of the memblet 
Surface morphology was characterized by a FEI PHENOM integrated scanning electron 
microscope system (Hillsboro OR 97124-5793 USA). Samples were mounted onto a metal 
stub prior to analysis.   
 
Fourier Transmission Infrared Spectroscopy (FTIR) was performed on the individual 
polymers being Eudragit® E100 and PEG 4000 prior to memblet analysis. Samples were 
analyzed with a Spectrum 2000 FTIR spectrometer with a MIRTGS detector (PerkinElmer 
Spectrum 100, Beaconsfield, UK). The spectrum was a ratio spectrum of 16 sample scans 
against 16 ranging from 4000-650cm-1. 
 
5.2.5 Mechanical evaluation of the memblet system 
Textural profiling was conducted with a Texture Analyzer (TA.XTplus, Stable Microsystems, 
Surrey, UK) to evaluate memblet deformation energy, flexibility and resilience. For 
deformation energy and memblet flexibility, a flat steel probe was used to puncture the 
memblet matrix. A cylindrical probe, which applied surface pressure to the memblet, 
determined matrix resilience. Table 5.2 shows the parameters chosen for each study. 
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Table 5.2 Parameters for flexibility, deformation energy and resilience testing 
Parameters Flexibility (N.mm) Deformation Energy (J) Resilience (%) 
Pre-test speed 1mm/sec 1mm/sec 1mm/sec 
Test speed 0.5mm/sec 0.5mm/sec 0.5mm/sec 
Post-test speed 1mm/sec 1mm/sec 1mm/sec 
Compression 
Force 
40N 40N - 
Trigger type Auto Auto Auto 
Trigger Force 0.05N 0.05N 0.05N 
Load cell 5kg 5kg 5kg 
 
5.2.6 Thermal analysis of crosslinked polymethacrylate based memblets  
Thermal analysis was conducted on a DSC1 STARe system (Mettler Toledo DSC1, STARe 
System, Switzerland).Testing of memblets were conducted using both Differential Scanning 
Calorimetry (DSC) and Alternating Differential Scanning Calorimetry (ADSC). All samples 
were prepared in 40µl aluminum crucibles. DSC was conducted using a temperature range 
of 0-200°C and ramped at 10°C per minute. ADSC was carried out with an underlying 
heating rate of 1°C per minute and a modulated temperature of 0.1°C per 0.8 minutes.  All 
samples were run in duplicate (N= 2).  
 
5.2.7 In vitro drug release of a polyethylene glycol 4000 crosslinked polymethacrylate 
based memblet system 
Drug release studies were conducted following the USP 33 apparatus II (ERWEKA DT 700 
GmbH Germany), in which a single memblet in triplicate (N= 3) was placed within the vessel 
under a stainless steel ring mesh assembly, to prevent the paddle inflicting 
physical/mechanical damage to the spheres and alter release profiles as well as to prevent 
erratic fluctuation due to unstable hydrodynamics (Pillay and Fassihi, 2000). Each vessel 
was filled with 900mL simulated gastric fluid (SGF) and heated to a temperature of 37°C prior 
to the addition of the memblet and the stainless steel ring mesh assembly. The rotating 
paddle method was selected at a rotational speed of 50rpm and the machine was calibrated 
for a 2 hour run with samples taken at half hourly intervals. Sampling involved the drawing of 
5mL of now drug incorporated solution from the dissolution vessel with subsequent refilling of 
removed buffer to maintain sink conditions. Samples were then subject to UV spectroscopy 
using a spectrophotometer (Cecil CE 3021, Cambridge, CB24 6AZ, England). 
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5.3 Results and Discussion 
 
5.3.1 Rheological analysis of crosslinked hydrogels prior to desiccation and memblet 
formation 
 
5.3.1.1 Determination of the critical yield point for a polymethacrylate based latex and 
novel crosslinked interpolyelectrolyte complex hydrogels  
Rheological evaluation was conducted on the Eudragit® E 100 latex prior to crosslinking to 
assess whether the latex was being produced in an accurate and reproducible manner. In 
previous studies an inconsistently formulated hydrogel matrix resulted in erratic membrane 
formation and non-reproducible results. Latex solutions of 10mL were crosslinked and cured 
in their respective crosslinking PEG solutions of 30%w/v and 60%w/v for hydrogel A 
(optimized) and B (control) respectively.  
 
Yield stresses for all samples are plotted in Figure 5.3. Typical latex samples showed very 
similar critical yield points. Yield stress tests resulted in an average critical yield point of 
0.36Pa that correlates to the viscous nature of the latex. The consistent yield point can be 
attributed to the astringent and meticulous method used for preparing the latex each time. 
Uniform dispersion was achieved through vigorous stirring protocols and through a gradual 
addition of constituents. It could be postulated that there were no major and highly altering 
physico-chemical interactions and that the distribution of the particles was isotropic. No 
mechanical alteration or damage to the latex was incurred. All samples had very similar 
deformation (Υ) points at the 57.73Y region, indicating that this is the region at which the 
latex behaved in a very fluid-like manner.  
 
For analysis of hydrogels, the critical yield point was determined to assess maximal 
crosslinking potential of the novel membranous system subsequent to the drying protocol. 
Critical yield points are dependent upon formulation parameters such as type of crosslinker, 
crosslinker concentration and temperature. Yield stress curves for hydrogels A and B varied 
in that hydrogel B achieved a greater critical yield point, 14.94Pa, than hydrogel A, 5.23Pa 
(Figure 5.3). This can be explained with an understanding of the properties of hydrogels. 
Hydrogels are defined as 3-dimensional, hydrophilic polymer networks, which when in their 
swollen state, have the capability to retain water and swell to a much larger size than their 
original state. Furthermore, hydrogels are insoluble in water due to chemical or physical 
crosslinking that has occurred. Physical ionic crosslinking has occurred between PEG’s ether 
functional group (anionic) and Eudragit® E 100’s dimethyl aminoethyl methacrylate functional 
group (cationic) resulting in an interpolyelectrolyte complex hydrogel. Hydrogel B consisted 
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of a higher degree of saturation of functional groups, with regards to crosslinking, and 
resulted in a dense accumulation of polyethylene glycol to produce a more rigid structure. In 
addition, there may have been fewer free functional groups along the polymeric backbone of 
hydrogel B (as compared to hydrogel A) due to the higher degree of crosslinking in the 
60%w/v PEG solution impeding the polymeric backbone’s mobility. This dense accumulation 
of polymeric material rendered hydrogel B less flexible rheologically. Both factors resulted in 
retarded molecular mobility. Molecular movement described by a lower critical yield point of 
5.23Pa, due to the fewer free functional groups, was improved in hydrogel A, indicating a 
more flexible and versatile formulation.  
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5.24Pa
14.94Pa
0.36Pa
a)
b)
c)
 
Figure 5.3 Yield stress curves for a) hydrogel A b) hydrogel B and c) the latex prior to 
crosslinking to indicate the critical yield point (Pa) 
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5.3.1.2 Viscoelastic evaluation through stress sweep curves of novel crosslinked 
polyelectrolyte-complex hydrogels 
The viscoelastic region for each hydrogel was determined such that a value for input into the 
frequency sweep curves to generate values of G’ (storage modulus) and G’’ (loss modulus) 
could be obtained. The stress sweep curves illustrated the viscoelastic regions for hydrogels 
as shown in Figure 5.4. The presence of a viscoelastic region in both samples confirmed that 
the hydrogel was a viscoelastic or semisolid material displaying both solid and liquid 
properties. Such data is crucial in understanding the final memblet’s stability as a drug 
delivery system. Hydrogel B demonstrated a viscoelastic region below 10.67Pa and hydrogel 
A below 2.542Pa, corroborating with the findings in yield stress that flexibility and versatility 
was improved with for the optimized formulation with a lowered crosslinker concentration 
(30%w/v). 
  
 
Figure 5.4 Viscoelastic regions of hydrogel B (- 0) and hydrogel A (- X) 
 
5.3.1.3 Determination of the storage and loss modulus of novel crosslinked 
polyelectrolyte-complex hydrogels 
The semi-solid hydrogels used in the testing were evaluated and found to encompass 
viscoelastic properties through the stress sweep curves. As such the hydrogels of samples A 
and B displayed both elastic (solid) and viscous (liquid) properties which can be determined 
simultaneously through frequency sweep tests. In testing both samples, frequency ranges of 
1-0.01Hz and a  value of 6.5Pa were chosen to assess the effect on loss and storage 
moduli for both samples at the same parameters. For a frequency sweep test, G’ is a 
measure of the deformation energy stored within a sample during the shearing process. G’ is 
therefore a measure of the elastic (solid) nature of the sample. G’’ is a measure of 
deformation energy used in the sample during the shearing process and lost to the sample 
afterwards, making G’’ a measure of the viscous (liquid) nature of the sample.  
104 
 
Figure 5.5 depicts very different rheological responses for hydrogels A and B with the same 
testing parameters. Hydrogel B has a continuous curve in which G’ is constantly above G’’. 
This is indicative of a solid, immobile and rigid structure for all of the frequency ranges and 
with no G’ / G’’ crossover. Within the testing parameters, the formulation remains rigid for all 
shear rates and shear forces. The accumulation and saturation of PEG 4000 results in a rigid 
membrane, which would require larger shear forces to achieve the desired mobility. Hydrogel 
A however can be described as having gel like properties (Lee and Anema, 2009). At the 
same testing parameters, hydrogel A displayed the converse of hydrogel B with G’’ being 
above G’ for all frequency ranges indicating highly mobile characteristics.  Such a curve was 
obtained due to a lower saturation of free bonds in hydrogel A as compared to hydrogel B. 
The formation of bonds between functional groups of both Eudragit® E 100 and PEG 4000 
were evenly distributed within the optimized hydrogel due to a lower crosslinker 
concentration of 30%w/v. This enhanced flexibility and improved rheological properties 
promote the use of a lower concentration of crosslinker in comparison to high crosslinker 
content.  
 
a)
b)a)
b)
 
Figure 5.5 Dynamic oscillation curves depicting storage (G' depicted by x) and loss (G'' 
depicted by o) moduli of: a) hydrogel A; and b) hydrogel B 
 
5.3.2 Assessment of the inter- and intra-polymeric interactions of the memblet 
This assessment was conducted to evaluate any unforeseen chemical interactions between 
molecules, surface morphologies and the extent of crosslinking that occurred between the 
samples. In Figure 5.6, FTIR analysis showed that no unforeseen chemical bonding has 
occurred resulting in new functional bonding within the 2 structures. FTIR analysis of the 
memblets were conducted and Figure 44a indicates the optimized memblet and emphasized 
an amine functional group for the Eudragit® E 100 polymer at a wavelength of 1143.45cm-1 
and a primary alcohol group of wavelength of 1059.63cm-1 was determined for the PEG 4000 
polymer.  
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These 2 functional groups allowed for the ionic crosslinking that occurred between the 2 
polymers to result in the memblet structure. When comparing the memblet’s A and B (Figure 
44b), it was evident that formulation A displayed sharper and more defined peaks when 
compared to formulation B. Peak sharpness enforced an improved even distribution of PEG 
4000 described as enhanced membrane flexibility in rheological studies. Peak sharpness is 
similarly observed when FTIR is conducted on a plain powder and then compared to its 
compressed form. In this case, the bonding between the primary alcohol and the amine 
group in formulation A is evidently more prominent and defined when compared to B which 
leads us to conclude that formulation A has greater membrane flexibility properties. This 
corroborates with statistical analysis in Chapter 4 which identifies a 30%w/v crosslinker 
concentration
 
of PEG 4000 as the optimal concentration for saturation of bonding between 
functional groups and that any higher concentrations can lead to weaker flexibility and 
compromised rheological properties. 
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Figure 5.6 Fourier Transmission Infrared Spectroscopy analysis in which a) represents the 
optimized memblet and the bonding of functional groups from polyethylene glycol 4000 and 
Eudragit® E 100 functional groups; and b) represents formulation A and B overlaid for which 
A is represented by the dotted line and B by the solid line emphasizing the peak sharpness 
of A 
 
5.3.3 Assessment of the surface morphology of the optimized crosslinked memblet  
Scanning Electron Microscopy (SEM) was utilized to evaluate the surface morphology of the 
optimized memblet formulation. This evaluation was used to substantiate the results obtained 
in FTIR analysis which indicated that the optimized formulation had superior mechanical 
properties. The SEM for the optimized memblet (Figure 5.7a) revealed a consistently even 
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surface with limited crevices, cracks or large pores. A scattering of white powder like debris 
could be seen and this was attributed to the sodium lauryl sulphate which may have been in 
excess. The uniformity of structure and surface morphology gives an indication of the solid 
structural integrity of the formulation.   
 
With regards to the control formulation, a notable difference in surface morphology was seen. 
A greater amount of surface debris was found compared to the optimized memblet (Figure 
5.7b). This could be attributed to an aggregation of polymeric material of non crosslinked 
PEG 4000 and sodium lauryl sulphate which were viewed as congested white areas. This 
could be deduced as having a detrimental effect on thermal and mechanical properties due 
to the amount of non crosslinked polymer segments. The memblet itself had a large amount 
of cracks and pores relative to the optimized formulation and this could further influence 
structural integrity. Uniformity was not seen clearly throughout the imaging. Certain areas 
had surface structure similar to the optimized memblet, whilst other areas showed the 
aggregation of this polymeric material. It is postulated that in areas with this build up, 
dumping of PEG 4000 rather than a consistent crosslinking had occurred. The dumping 
prevented an optimal saturated crosslinking to occur leaving a weaker inter-polymeric 
structure. This was further investigated through textural and thermal analysis.      
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Figure 5.7 Scanning electron micrographs of a) control formulation and b) optimized 
memblet illustrating the increase in polymeric and formulation debris in the control memblet  
 
a) 
b) 
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5.3.4 Mechanical evaluation and validation of structural integrity of the memblet 
system 
Mechanical evaluation of memblet systems was conducted in triplicate (N= 3). For both 
formulations (optimized and control), a typical force/distance profile was generated to 
evaluate both deformation energy and rigidity (Figure 5.8a and Figure 5.8b). In the textural 
analysis profile, the gradient represents the memblet flexibility while the area under the curve 
depicts the deformation energy for each sample. The results displayed in Table 5.3 highly 
convince that the optimized formulation has superior mechanical properties. Almost identical 
values were obtained for both memblet resilience and deformation energy (Table 5.3). 
Notably both memblets allowed for high memblet resilience. As described earlier, this is 
attributed to the high crosslinking concentration in both systems allowing for saturated ionic 
bonds to be formed. The memblet flexibility results were however quite different. Formulation 
A, with lower crosslinker concentration, displayed a greater membrane flexibility of 
7.173N.mm against 6.293N.mm for formulation B (Table 5.3). This highlights the optimized 
formulation’s superior flexibility whilst the control sample retains a rigid and hard nature. 
Furthermore, this analysis indicates that there is a maximal crosslinker concentration around 
the 30%w/v region. Extremely high concentrations (e.g. 60%w/v) have no drastic positive 
influences to improve memblet flexibility.    
 
Table 5.3 Textural analysis results for the memblet system 
Formulation Resilience (%) Flexibility (N.mm) Deformation 
Energy (J) 
Control 17.6 6.293 0.062 
Optimized 17.6 7.173 0.060 
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Figure 5.8 Force/Distance profiles depicting matrix resilience, memblet flexibility and 
membrane deformation energy: a) control formulation; and b) optimized memblet 
 
5.3.5 Thermal analysis of an optimized crosslinked polymethacrylate based memblet  
Thermal characterization was conducted in duplicate (N= 2) to identify any abnormalities or 
detrimental changes to the sample after the crosslinking process and to identify the thermal 
stability of the potential drug delivery system. The crosslinking of both the optimized memblet 
A and control memblet B with PEG 4000 and the incorporation of TEC allowed for a 
synergistic plasticizing effect. This is of significant importance as plasticizers, whilst causing 
a reduction in polymer-polymer chain secondary bonding by forming secondary bonds with 
the polymer chains, decrease the glass transition temperatures (Tg), increase flexibility and 
elongation at break and decrease Young’s modulus (Feldstein et al., 2001; Lee and Anema, 
2009). Plasticizers increase the free volume between polymer chains and in this case, 
Eudragit® E 100’s polymer chains. The absence of plasticizers would lead to a highly solid 
but brittle product unsuitable for any avenue of oral drug delivery.  
 
PEG compounds consist of polar hydroxyl functional groups and it is the hydrogen bonds 
formed from these hydroxyl groups which replace the polymer-polymer bonds within the 
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Eudragit® E 100 chains and thus provide the plasticizing effect (Gal and Nussinovitch, 2009). 
Additionally, PEG serves as a crosslinking agent for the Eudragit® E 100 molecule allowing 
for the increase in resistance to acidic gastric degradation (through hydrolytic cleavage) of 
the Eudragit® E 100 molecule. Due to the considerable length of PEG crosslinks creating a 
space between the Eudragit® E 100 chains, the network formed has enhanced free volume 
leading to the plasticizer effect. TEC serves as a better plasticizer than PEG due to its low 
volatility and its high miscibility with Eudragit® E 100.  
 
The optimized and control memblet were tested under the same formulation parameters for 
both DSC and ADSC. DSC results were very similar for both formulations and a drastic 
improvement in the glass transition can be seen in both formulations as compared to 
Eudragit® E 100’s thermograms (Tg= 40°C) from Table 3.7 of Chapter 3.5.5.2. DSC was run 
twice utilizing the same temperature programmes. The second run was selected for 
analytical purposes (as thermal information was deemed more accurate in a second run to 
remove any thermal history). The optimized memblet displays a larger relaxation peak when 
compared to the control memblet as seen in Figure 5.9. This is defined by the lower integral 
value of -14.01mJ of the control compared to the higher -137.95mJ of the optimal memblet 
indicating that more energy was required from the heating system (for the optimized) to allow 
for a first order energy transition (melting) to occur.  
 
The thermograms revealed curves that were not the definite peaks, melting points or the 
gradual curve of a glass transition but rather a hybridization as can be seen in Figure 5.9.  
 
As PEG 4000 and Eudragit® E 100 have very similar melting and glass transition points (both 
within the range of between 40-60°C) and have their glass transition and melting point fairly 
close, ADSC was used to separate the curves overlapping thermal events. A more intricate 
look into the memblets thermal characteristics was obtained through the Cp-Complex, 
reversible and total heat flow curves. The heat capacity in a DSC curve can be calculated by 
dividing the heat supplied by the resulting temperature increase or change in temperature 
and gives us an indication of the amount of energy or heat required to increase the samples 
temperature by a certain amount. Heat capacity can best be described in saying that it is the 
heat flow (HF) divided by the heating rate (HR) as shown in Equation 5.11. Complex heat 
capacity of the ADSC curve can be defined as the amplitude of the heat flow (AHF) 
modulation divided by the amplitude of the heating rate modulation (AHR) as seen in 
Equation 5.12. 
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HR
HFCp =                                                    (Equation 5.11) 
 
AHR
AHF
complexCp =                                 (Equation 5.12) 
 
Where, HF is the heat flow, HR is the heating rate, AHF is the amplitude of the heat flow and 
AHR amplitude of the heating rate modulation. 
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a)
Integral -14.01 mJ
Onset 50.11°C
 
 
b)
Integral -137.95 mJ
Onset 52.29°C
 
Figure 5.9 Differential Scanning Calorimetric thermograms of a) control memblet and b) 
optimized memblet  
 
 
Figure 5.10 identifies the glass transition and the melting point as successfully separated 
thermal events which are plotted on the reversible heat flow and total heat flow curves 
respectively. Melting point remains the same for both formulations at 59°C as was expected 
indicating no major molecular alteration, results which are in congruence with the FTIR 
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analysis.  Slight variance can be noted in the glass transition. As previously described, PEG 
4000 and TEC have a compounded effect of lowering glass transition. The control 
formulation with a higher PEG 4000 concentration (60%w/v) when compared to the optimized 
memblet (30%w/v), displayed a marginally lowered glass transition of 55°C and 56°C 
respectively, which verifies the predicted values from the optimization studies indicated in 
Table 5.4 of Chapter 5.3.7. The Cp complex (also seen in Figure 5.10), indicated that the 
control memblet utilizes slightly less energy (endothermically) than the optimal memblet for 
the melting point to be reached, giving an indication that the optimized formulation displayed 
slightly improved mobility. The optimal crosslinking concentration of 30%w/v PEG 4000 
determined through optimization studies has been validated. Coupled with FTIR analysis and 
textural analysis, this further authenticates the utilization of 30%w/v PEG as an optimal 
formulation and gives a better indication towards the relative strength of the bond through 
slightly improved thermal characteristics and rheologically superior characteristics. 
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Figure 5.10 Alternating Differential Scanning Calorimetry thermal profiles of a) control 
memblet and b) optimized memblet 
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5.3.6 Construction of a calibration curve for rifampicin to interpolate in vitro analysis 
Calibration curves formed were the same identified in Chapter 3.5.1 for preliminary analysis. 
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Figure 5.11 Calibration curve for rifampicin with corresponding regression co-efficients and y 
values 
 
5.3.7 In vitro drug release results of polyethylene glycol crosslinked polymethacrylate 
based optimized memblet system 
Release characteristics for the memblet component of the ODMUS system had to be highly 
specific for the gastric environment. In vitro testing aimed to achieve as close to zero-order 
drug release as possible within a 2 hour threshold. Complete release of rifampicin needed to 
be accomplished such that the majority of rifampicin would achieve gastric absorption and a 
fractional quantity would be concurrently released with isoniazid in the small intestine. A 79% 
MDT response desirability conveyed in Table 5.4, demonstrated the accuracy of the release 
profile generated in Figure 5.12 for the optimized formulation. At 0.5 hours, both formulations 
display a general burst effect. The optimized memblet has restricted the release to 40% of 
total drug in comparison to 70% in the control sample. It is postulated that the limited 
rheological properties of the viscoelastic optimized memblet, provided the slight burst effect 
as the SGF and mechanical rotation of the spindle (to mimic gastric churning) accelerated 
the conversion of the memblet to a more viscous state compounding erosion. Despite this, 
burst release of drug is still limited in comparison to the control memblet.  
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From 0.5 to 2 hours, a far more controlled means of release is in evidence. Retardation of 
drug release is attributed to the improved thermal, mechanical and intermolecular 
characteristics of the memblet. The improved molecular bonding through a lowered 
crosslinker concentration (30%w/v PEG) enforces a more rigid intermolecular bond than the 
overcompensated control memblet crosslinker content (60%w/v PEG). Enhanced structural 
integrity, thermal rigidity and intermolecular attraction has been achieved and detailed in 
mechanical, thermal and FTIR analysis within this Chapter. The thermal strength allows the 
memblet system to erode at a slower rate as per the elevated glass transition temperature 
(50°C), which requires greater energy to undergo a phase transition and begin erosion thus 
controlling drug release. This regulated release pattern is compounded by the improved 
intermolecular bonding indicated through FTIR and textural analysis. Furthermore, the 
maximal crosslinking concentration of 30%w/v PEG does not induce a dumping of sodium 
lauryl sulphate as debris, in comparison to the control sample as seen in Figure 5.7 of 
Chapter 5.3.3 with SEM imaging. The SLS plays a role as a surfactant within the formulation 
matrix rather than act as debris and interfere with release patterns or complex with the 
excess PEG 4000 as in the control sample. The compounded effect is in producing a robust 
delivery system that can withstand the simulated gastric environment and display a more 
controlled release pattern. Release can be described as deliberately controlled from 0.5-
2hours through the erosion of the memblet.       
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Figure 5.12 Concurrent release profiles of the optimized memblet and the control sample 
generated in simulated gastric fluid illustrating enhanced controlled release of the optimized 
memblet; where N= 3 and SD< 0.222 in all cases 
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Table 5.4 The relationship between optimization predicted and experimental values for 
responses mean dissolution time and glass transition
 
Responses Predicted values Experimental run 
values 
Desirability 
Tg 54.9090°C 56°C 100% 
MDT 200.9134 253.9557 79% 
Tg= glass transition and MDT= mean dissolution time 
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5.4 Concluding Remarks 
 
The memblet component of the ODMUS indicated desired properties for pH mediated 
release within the stomach. Experimental and predicted values (generated in optimization 
studies) are near super imposable achieving the accuracy and efficacy required for the 
optimization process. Thermal stability was displayed through calorimetric analysis which 
emphasized the optimized and slightly improved glass transition of an optimized memblet. 
Rheologically speaking, the optimized hydrogel proved to have superior qualities to the 
control sample with regards to flexibility and mobility. The internal integrity and functional 
intermolecular bonding of the fully desiccated memblet are vastly superior to the control 
sample. Surface morphology also implemented the debris concept and highlighted the 
significance of using a lowered 30%w/v PEG to ensure a relatively clear surface area to 
enhance controlled release. These factors synergistically improved drug release of rifampicin 
and the obligatory complete release of drug within 2 hours at the site-specific location of the 
stomach. Furthermore, this was accomplished in a rate controlled manner.        
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CHAPTER 6                                                                       
FORMULATION AND INVESTIGATION OF AN OPTIMIZED 
ISONIAZID-LOADED MULTIPARTICULATE SYSTEM FOR 
TARGETED DRUG DELIVERY TO THE SMALL INTESTINE 
 
 
6.1 Introduction 
 
Multiparticulate drug delivery systems have been used increasingly in recent times (Ensslin 
et al., 2009; McConnell et al., 2009; Muschert et al., 2009; Glaessl et al., 2010; Pund et al., 
2010). The advantages of multiple unit delivery systems have been well established in the 
past (Bodmeier and Paeratakul, 1994) and these include more precise bioavailability, 
decreased intra- and inter-individual variability, accurate uniformity of dispersion and reliable 
formulation processes (Zhang et al., 2002). In the case of single unit systems, the loaded 
drug can potentially lose its efficacy through premature release or dose dumping (Streubel et 
al., 2002). Conversely, the loss of a single multiparticulate does not mean complete failure 
for the rest of the system. The reproducibility of uniform distribution of the multiparticulates 
within their environment potentiates controlled release and decreases variability. The small 
size aides in passage and transfer time through the gastrointestinal tract limiting erroneous 
site-specific drug delivery. The nutritional state of the stomach can influence drug release 
and absorbance and therefore impart complex dosing intervals while multiparticulate dosing 
is independent upon such food states (Schmidt and Bodmeier, 2001).         
    
This study focused on producing multiparticulates that are pH dependent, elucidate site-
specific release and maintain controlled release. Multiparticulates have been implemented 
for site-specific delivery through regions of the gastrointestinal tract (Lamprecht et al., 2000; 
Markus et al., 2001). Optimized multiparticulates were formed through the single process 
step of crosslinking Eudragit® L 100-55 with trivalent (Al3+) and bivalent (Ba2+) cations. The 
use of Eudragit® L 100-55 imparted gastric resistance and enabled the system to deliver INH 
in a rate controlled manner due to the higher pH of the small intestine. This Chapter 
describes the release and entrapment studies of the optimized formulation with concurrent 
analyses of the porosity of the system and intermolecular network of the multiparticulates.    
 
6.2 Materials and Methods 
 
6.2.1 Materials 
Eudragit® L 100-55 was donated by Degussa AG, Pharma polymers, RÖhm GmbH (Midrand 
Gauteng, South Africa). Triethyl Citrate (TEC), isoniazid (INH) and ethylcellulose (EC) were 
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of analytical grade and purchased from Sigma Aldrich.Inc (St. Louis, Missouri USA). All 
electrolytes used for crosslinking were of analytical grade and purchased from Merck 
Chemicals (Halfway House, Gauteng, South Africa). Sodium hydroxide pellets and 
potassium dihydrogen (phosphate reagent) were purchased from Rochelle Chemicals 
(Johannesburg, Gauteng, South Africa). Silicone was obtained from Merck Chemicals 
(Halfway House, Gauteng, South Africa). All chemicals and raw materials were used as 
received without further processing. Water was purified by a MilliQ Millipore water purification 
system (Milli-Q, Millipore, Billerica, MA, USA). 
 
6.2.2 Preparation of the polymethacrylate based latex prior to double crosslinking 
An aqueous solution of 30%w/v Eudragit® L 100-55 was prepared with deionized water. The 
PMMA polymer was added gradually to the aqueous phase under agitation using a magnetic 
stirrer, over a period of 5 minutes to avoid agglomeration and sedimentation. Silicone 
(0.4mL) (antifoament) was added to the latex and the solution was left to stir for 45 minutes. 
During the 45 minute stirring process 2 solutions were dissolved. The first solution was a 
4%w/v NaOH solution, which was left to stir until complete dissolution of pellets was achieved. 
The second solution was a 20%w/v ethylcellulose (EC) solution. EC was added gradually to 
50mL of ethanol, and left to stir. Upon completion of the 45 minutes stirring period, 5mL of 
the NaOH solution was drawn up with a 20mL syringe and added to the latex within 5 
minutes in a drop wise manner for neutralization of the carboxyl functional groups of the 
PMMA. The latex was left to stir for a further 45 minutes to ensure proper dispersion and 
neutralization of the latex.  
 
After the second 45 minute stirring period, 3g of INH was then added to the latex and left for 
30 minutes to stir. The TEC was added to the latex and left to stir for 15 minutes. EC solution 
(3.75mL) was drawn up using a 20mL syringe and gradually added to the latex prior to 
homogenization (Polytron, Kinematica, Lucerne Switzerland) for 15 minutes. As 
homogenization generates a lot of heat, the latex was then left on the stirrer to cool for 10 
minutes prior to crosslinking. Thereafter, 2 batches of spheres were then formulated with 
varying crosslinking agents to produce an optimized batch of multiparticulates and a control 
sample. 
 
6.2.3 Polymethyl methacrylate polysphere formation through a double crosslinking 
process 
Initially, 2 batches of polyspheres were formulated and crosslinked in a 25%w/v electrolyte 
solution of AlCl3. A control formulation of spheres was left to cure in a second solution of 
MgCl2 and the optimized multiparticulate system was similarly was left to cure in a solution of 
BaCl2 in which both electrolyte solutions were of 20%w/v concentration. The crosslinking 
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solution was kept on a magnetic stirrer for the duration of crosslinking to prevent unwanted 
agglomeration. The first electrolyte solution (25%w/v AlCl3 saturated with 3g INH) was 
prepared and left on a magnetic stirrer. A measured 10mL of the 50mL PMMA latex was 
drawn up with a syringe and the latex was expelled in a drop wise manner into the first 
electrolyte solution for crosslinking. Once all the latex had been expelled, the polyspheres 
were left to cure for 20 minutes in a dark cupboard. The control polyspheres were washed 
twice in 500mL double deionized water and placed in the second crosslinking solution of 
MgCl2 and left to cure in a dark cupboard for 20mins. Optimized multiparticulates were left to 
cure in the BaCl2 solution following the same procedures. All secondary crosslinkers were 
saturated with 3g of INH to enhance drug entrapment efficiency. Both batches were then 
washed twice with double deionized water and then left to air dry under an extractor for 12 
hours at room temperature. 
 
6.2.4 Assessment of the surface morphology and inter- and intra-polymeric 
interactions of the optimized multiparticulate system  
Surface morphology was characterized by Scanning Electron Microscopy (SEM), (JEOL, 
JEM 840, Tokyo, Japan) at an accelerating voltage of 19kV. Multiparticulates were mounted 
on an aluminium stub. Samples were sputter-coated with carbon or gold and 
photomicrographs were then taken at various magnifications. 
  
FTIR spectroscopy was performed on the individual polymers, INH, constituents and dried 
polyspheres. Samples were analyzed with a Spectrum 2000 FTIR spectrometer with a 
MIRTGS detector (PerkinElmer Spectrum 100, Llantrisant, Wales, UK). The spectrum was a 
ratio spectrum of 16 samples against 16 background scans with a resolution of 4cm-1. 
Samples were analyzed at wavenumbers ranging from 4000-400cm-1.  
 
6.2.5 Validation of the enhancement of drug entrapment efficiency for optimized 
multiparticulates  
Solutions of 200mL phosphate buffer saline (PBS), (pH 6.8, 37oC) were prepared and used 
for drug entrapment efficiencies. A fixed amount of 100mg of polyspheres from batch A and 
B were weighed out and placed within 200mL of PBS and left to completely dissolve 
overnight with aided agitation from a stirrer at room temperature. UV analysis through a 
spectrophotometer (Cecil CE 3021, Cambridge, CB24 6AZ, England) was conducted and 
drug entrapment was calculated through Equation 6.1: 
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Where, DEE %= drug entrapment efficiency of polyspheres, Da= the actual amount of drug 
contained within multiparticulates and Dt= the theoretical amount of drug required. 
 
6.2.6 Examination of surface area and investigation into porosity analysis for 
multiparticulates 
Surface area and porosity studies were conducted using a micromeritics ASAP analyzer 
(Micromeritics ASAP 2020, GA, USA). Samples were first degassed prior to analysis and 
0.3g of polyspheres were weighed out and placed in a glass holding tube. This glass tube 
was inserted into the degassing vacuum system for complete degassing of the sample prior 
to analysis. Degassing conditions include both evacuation phase and heating phase 
parameters and adsorptive properties for analysis conditions as depicted in Table 6.1. 
 
Table 6.1 Variant properties of the degassing and analysis procedures for surface area and 
porosity analysis  
Evacuation phase parameters during the degassing process 
Evacuation phase parameters 
Temperature Ramp Rate 10°C/min 
Target Temperature 90°C 
Evacuation Rate 50.0 mmHg/s 
Unrestricted evacuation 30.0 mmHg 
Vacuum Set Point 500 µmHg 
Evacuation Time 60 min 
 
Heating phase parameters during the degassing process 
Temperature Ramp Rate 10°C/min 
Hold Temperature 120°C 
Hold Time 900 min 
 
Adsorptive properties during the analysis process 
Adsorptive gas Nitrogen 
Maximum manifold pressure 925.00 mmHg 
Non-ideality factor 0.0000620 
Density conversion factor 0.0015468 
Hard sphere diameter 3.860Å 
Molecular cross-sectional area 0.162nm2 
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6.2.7 Chemometric and molecular modelling to deduce the mechanism of crosslinking 
for the formation polyspheres and the drug release pattern thereof   
Chemometric and molecular modelling were performed to deduce the transient mechanisms, 
interaction of ions and entities and sol-gel inter-conversion of the polymethacrylate based 
latex when crosslinked with AlCl3, BaCl2 and MgCl2 to form polyspheres.  
 
This approach allowed for a provision to make predictive findings solely based on the 
chemical concepts underlying the crosslinking of the polymethacrylate based latex into 
polyspheres through double crosslinking process. Models and graphics based on the step-
wise molecular mechanism of gel formation, sol gel inter-conversion, permanent gelation and 
erosion with respect to the conceived energy profile as envisioned by the chemical behavior 
and stability were generated on ACD/I-Lab, Version 5.11 (Add-on) software (Advanced 
Chemistry Development Inc., Toronto, Ontario, Canada, 2000).  
 
All models were based on the evident molecular changes rather than on any calculation or 
predictions from the software. The critical minimum concentration of the polymethacrylate 
based latex was assessed for maximizing the sol-gel transition as a function of the 
concentration of the polymethacrylate based latex and crosslinkers employed (i.e. AlCl3, 
BaCl2 and MgCl2). The energy distribution curves generated assumed an initial population of 
mono-dispersed polymethacrylate based latex monomers, a spatially uniform distribution of 
crosslinkers in the system, and an irreversible double crosslinking process.  
 
6.2.8 Molecular modelling of a novel multi-crosslinked Eudragit® L 100-55 based 
multiparticulate system 
Molecular Mechanics (MM) Computations in solvated system with water as solvent were 
performed using the HyperChemTM 8.0.8 Molecular Modeling System (Hypercube Inc., 
Gainesville, Florida, USA) and ChemBio3D Ultra 11.0 (CambridgeSoft Corporation, 
Cambridge, UK) on an HP Pavilion dv5 Pentium Dual CPU T3200 workstation. The nonamer 
of polymethyl-methacrylate copolymer (Eudragit® L 100-55) was generated from standard 
bond lengths and angles employing polymer builder tools using ChemBio3D Ultra in their 
syndiotactic stereochemistry as 3D model. The Eudragit® L 100-55 model was initially 
energy-minimized using MM+ force field and the resulting structure was again energy-
minimized using the Amber 3 (Assisted Model Building and Energy Refinements) force field. 
The conformer having the lowest energy was used to create the polymer-cation complexes. 
All MM simulations were performed for cubic periodic boxes with a side length of 16.52Ås 
containing one centered Eudragit® L 100-55 fragment, 9 surrounding cations molecules at the 
edges and the centre of the cubic box and the remaining free space filled with water 
molecules and the same procedure of energy-minimization was repeated to generate the 
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final models: EUD-Al3+, EUD-Ba2+, EUD-Mg2+, EUD-Al3+-Ba2+ and EUD-Al3+-Mg2+. Full 
geometry optimizations were carried out in solvated system employing the Polak–Ribiere 
conjugate gradient method until an RMS gradient of 0.001kcal/mol was reached. Force field 
options in the AMBER (with explicit solvent) were extended to incorporate cutoffs to Inner 
and Outer options with the nearest-image periodic boundary conditions. The outer cutoff was 
set to 8.26Å and the inner cutoff was set to 4.26Å to ensure that there were no discontinuities 
in the potential surface. 
 
6.2.9 In vitro drug release studies on the polyspheres 
Drug release studies were conducted following the USP 33 Apparatus II (ERWEKA DT 700 
GmbH Germany), in which 100mg of spheres were weighed out in duplicate from each 
sample and placed within the vessel under stainless steel ring meshes assembly to prevent 
the paddle inflicting physical/mechanical damage to the spheres and alter release profiles as 
well as to prevent erratic fluctuation due to unstable hydrodynamics (Pillay and Fassihi, 
2000). Each vessel was filled with 900mL PBS and heated to a temperature of 37°C prior to 
the addition of the multiparticulates and the stainless steel ring mesh assembly. The rotating 
paddle method was selected at a rotational speed of 50rpm and the machine was calibrated 
for a 12 hour run with samples taken at hourly intervals. Sampling involved the drawing of 
5mL of PBS from the dissolution vessel with subsequent refilling of removed buffer to 
maintain sink conditions. Samples were then subject to UV spectroscopy in the same 
manner as entrapment studies to generate release profiles.   
 
6.3 Results and Discussion 
 
6.3.1 Assessment of the surface morphology and inter- and intra-polymeric 
interactions of the polyspheres 
Optimized multiparticulates formed were spherical in shape, glossy in appearance, robust 
and devoid of any brittleness as observed in Figure 6.1. SEM studies revealed a solid and 
non porous surface morphology for the optimized batch (Figure 6.2). This is accentuated by 
the fact that porosity studies revealed a low pore volume. Larger crystal-like structures were 
identified on the surface of the polyspheres and postulated to be ethyl-cellulose crystals. The 
crystals were largely distributed on the peripheral surface of the multiparticulates. An 
inconsistent PMMA latex preparation could be the reason for the high quantity of irregularly 
placed surface crystals as well as the effects of the non homogenous latex solution when EC 
was added to the latex. These surface crystals would have been expected to have an impact 
on drug delivery by facilitating controlled delivery but due to the random accumulation of the 
EC, an inconsistent type of drug release was expected.  
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However, the drug release (indicated in Figure 6.8 of Chapter 6.3.6), was relatively controlled 
highlighting an acceptable incorporation of crystals into the matrix of the spheres. In both 
control and optimized formulations, both superficial layering and internal constitution of the 
matrix core in the EC content were not factors that portrayed comparative data as to the 
significant secondary crosslinker.  
 
However, EC did impart improvement on drug release for both formulations. The images also 
portrayed few localized pores within the system identified via of cracks and fissures (Figure 
6.2a). The presence of these pores could be associated with the varying environmental or 
manufacturing factors. The most likely combination of factors that determine the size and 
volume of pores include the non-homogenicity in the latex prior to crosslinking as well as 
prolonged exposure during the drying phase. Since these factors could carefully be 
monitored, pore size and volume were minimized so as not to drastically affect drug release. 
However, this could only be found in a few localized areas of the spheres substantiating the 
results obtained in the porosity studies in which there was a low volume of pores.  
 
An FTIR spectroscopy of the optimized formulation is plotted in Figure 6.3. Al3+ can be 
described as a hard electrophile according to Pearson’s HSAB scale. The ionic bond formed 
with carboxyl groups is an electrostatic, columbic type bond (Fleming, 1996).  Al3+ therefore 
induced a strong negative charge at the carboxyl functional groups and therefore not altering 
the carbonyl/carboxyl stretching bands at 1600cm-1. Due to the double crosslinking with Ba2+ 
or Mg2+ for polyspheres from the optimized and control multiparticulates respectively, their 
characteristic bands were shifted to 1726.42cm-1 as demonstrated in Figure 6.3.  
 
When compared to Al3+, Ca2+ and Ba2+ are referred to as “soft” electrophiles which accept 
electrons from the carboxyl functional groups. Covalent co-ordinate bonds are formed with 
the subsequent loss of the negative charge of the carboxyl functional groups which ultimately 
causes the stretching of the carbonyl band (Williams and Fleming, 1997). Both formulations 
displayed no other changes in structure and no other interactions were seen amongst the 
constituents.  
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Figure 6.1 Optimized crosslinked polymethyl-methacrylate based polyspheres 
  
 
a) b)
            
Figure 6.2 Scanning electron microscopy taken at a) 650X magnification and b) 100X 
magnification for the optimized double crosslinked multiparticulates to examine the surface 
morphology of optimized multiparticulates  
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Figure 6.3 Fourier Transmission Infrared Spectroscopy spectrum of crosslinked Eudragit® L 
100-55 based multiparticulates   
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6.3.2 Evaluation of the augmentation of drug entrapment efficiencies of novel isoniazid 
loaded Eudragit® L 100-55 based multiparticulates 
Drug entrapment is always of primary importance during development of a drug delivery 
system. The manufacturing procedure that involved a 20 minute double crosslinking process 
and the high quantity of polymeric material employed, both contributed to the observed low 
entrapment efficiency.  Polyspheres from the control sample reflect a lower drug entrapment 
of 50% relative to the 71% of optimized spheres portrayed in Table 6.2. This attributed Mg2+ 
as a crosslinker. It is evident from Table 6.4 and Figure 6.6 of Chapter 6.3.5 that the 
hydrophobic van der Waals energies are directly correlated to the size of the cation where 
Ba2+, having the largest atomic radius, represented highest van der Waals energy followed 
by Mg2+ and Al3+. This predisposes the polymeric backbone to reduced entrapment efficiency 
due to destabilization of the backbone in comparison to the optimized Ba2+ cations which 
promote enhanced stability and intermolecular forces and ultimately an enhanced DEE.   
 
The greater the bombardment of ionic molecules to free carboxyl groups, which results in a 
higher saturation of ionic bonding than drug incorporation, the less the drug to be included 
into the matrix of the sphere. This is furthered by the initial crosslinking of AlCl3 for double 
crosslinking, compounding the filling of molecular space. The crosslinking time influenced 
drug entrapment and release in an indirectly proportional manner. Extended crosslinking time 
would improve drug release but significantly decrease drug entrapment as drug would be 
given more time to leech out of the matrix and into the solution. Duration of 20 minutes 
crosslinking time was selected to achieve a balance between entrapment and saturated 
crosslinking for controlled release. The crosslinking solutions (both primary and secondary 
crosslinkers) were saturated with INH to negate the diffusion of drug into the electrolyte 
solution during the 20 minute period. The inclusion of EC has affected the amount of drug 
that can be loaded, because the greater the number of polymeric constituents results in 
lower drug entrapment within the control sample. However, EC is not a detrimental factor in 
the optimized formulation. Therefore, EC is an independent factor in drug entrapment 
efficiency which is based primarily on type of cationic molecule. The correlation between 
predicted and experimental DEE achieved 100% desirability as depicted in Chapter 6.3.6 
Table 6.5. 
 
Table 6.2 Drug entrapment efficiencies for 100mg of polyspheres from optimized and control 
batches of multiparticulates 
Batch Yield (mg) Drug content in 
Yield (mg) 
Entrapment 
Efficiency (%) 
Optimized 4400 428.76 71.5 
Control 4222 300.42 50.0 
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6.3.3 Inspection of surface area and corollary porosity data for optimized 
multiparticulates 
The conducted studies were used to analyze the total surface area exposed by optimal 
multiparticulates as well as the volume of distribution of pores and pore size. The 
multiparticulates were subject to analysis following the Barret, Joyner and Halenda method 
(BJH) and the t-plot of Lippins, Linsen and de Boer. Table 6.3 shows the surface area for 
both adsorption and desorption isotherms, in which polyspheres both the optimal and control 
formulations, depicted similar low exposed surface areas after adsorption and desorption of 
nitrogen. Successful degassing was achieved for both formulations and illustrated in Figure 
6.4a and Figure 6.4b for both formulation batches. Both figures depict an isothermal linear 
plot which depicts the layering of liquid nitrogen in the adsorptive phase (the adsorption 
isotherm) and the removal of the liquid nitrogen in the desorptive phase (desorption 
isotherm). The isotherms depicted a closure of adsorption and desorption curves at the start 
and end points, proving that successful degassing had occurred with the removal of all liquid, 
gas and solid impurities. The low surface area can be attributed to the shape and size of the 
multiparticulates because all spheres had a uniform spherical shape. The surface area 
determined from each formulation however was sufficient for further evaluation of pore size 
and pore volume.   
 
Table 6.3 Surface area of control and optimized polyspheres  
Batch BJH AdsorptionA BJH DesorptionA 
Control 3.5910 3.8777 
Optimized 3.4890 3.8777 
A: cumulative surface area of pores between 17.000Å and 3000.000Å diameter (m2/g) 
Pore Volume and Size of polyspheres 
Formulation t-Plot 
(cm3/g) 
BJH 
Adsorption 
for Pore 
Volume1 
BJH 
Desorption 
for Pore 
Volume1 
Pore Size: 
BJH 
Adsorption 
(Å) 
Pore Size 
BJH 
Desorption 
(Å) 
Control -0.000892 0.028310 0.020460 315.314 292.000 
Optimized -0.001076 0.020460 0.020411 234.603 210.545 
1: cumulative surface area of pores between 17.000Å and 3000.000Å diameter (m2/g) 
 
T-plot isotherms were generated to determine the presence of micropores (pores with a 
diameter of 2nm or 20Å) within the formulation. For t-plot isotherms, the quantity of nitrogen 
adsorbed (Va) is plotted against the thickness (t) of the adsorbed layer. Extrapolation of the 
linear isotherm to the adsorption y axis will give the micropore volume if the intercept value is 
a positive one. As seen in Table 6.3, T-plot volumes were -0.000892cm3/g and -
0.001076cm3/g for polyspheres from control and optimized batches respectively and a linear 
representation can be seen in illustrating a negative intercept on the adsorption y axis 
indicating the lack of micropores in the system. This is illustrated in Figure 6.4a and Figure 
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6.4b), in which extrapolation of the linear curves resulted into a negative intercept that was 
observed in both formulations.  
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Figure 6.4 Surface area and porosity analysis of polyspheres with regards to: a) isothermal 
linear plots for optimized batch; b) Isothermal linear plot for control batch; c) T-plot micropore 
isotherm for batch A; d) T-plot micropore isotherm for batch B; e) BJH adsorption cumulative 
pore volume for batch A; and f) BJH adsorption cumulative pore volume for batch B 
 
Pore volume in both formulations showed relatively small values when compared to the 
surface areas. Figure 6.4a and Figure 6.4b depict the BJH adsorption cumulative pore 
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volume for control and optimized formulations respectively. The Halsey: Faas correction 
equation was used for both Figure 6.4a and Figure 6.4b as this equation assumes an 
adsorbed liquid monolayer with the same density and packing as the normal liquid (Webb 
and Orr, 1997). In both cases, a significant decrease in pore volume is noted with 
subsequent increases in pore diameter. Control polyspheres showed a larger cumulative 
volume of pores in the 200-300Å region when compared to the optimized batch and had 
significantly larger pores in comparison. A detailed an average pore size of 315.314Å and 
292.000Å for adsorption and desorption isotherms respectively were documented for control 
samples, which were inferior to optimized polyspheres with a BJH adsorption of 234.603Å 
and a BJH desorption of 210.545Å. Pore size can influence drug release within the context of 
improper crosslinking. Figure 6.8 of Chapter 6.3.6 corroborates cumulative effects of poor 
crosslinker and large pores illustrated by the burst release in the dissolution profile for the 
control sample. Whilst the volume of pores is low for both formulations, the larger pores in 
evidence for the control sample, provide an expeditious means of polysphere erosion when 
exposed to a pH of 6.8 concurrently with the weaker crosslinking noted in molecular 
modeling of Chapter 6.3.5. For the purposes of the multiparticulates in this study, pore sizes 
greater that 300Å, were identified as potentiating factors for burst release identified in Figure 
6.8 of Chapter 6.3.6. By limiting the pore size to under 240Å, the burst effect was significantly 
diminished for the optimized formulation (Figure 6.8 of Chapter 6.3.6). This study confirmed 
that formulations are obligated to have a limited pore size below 240Å such that pore size is 
a negligible factor in modulating drug release profiles as the influence of pore size on 
controlled release can be seen as prominent. 
 
Since EC did not interact or bond with the PMMA latex (shown in Chapter 6.3.1
 
FTIR 
analysis), the few pores identified, can be attributed to uneven allocation of this cellulose 
derivative. This is an ideal situation as the system relies on a rate modulated drug release, 
with an ideal formulation having a low volume of pores relative to the surface area as 
evaluated and described in this study. This particular low distribution of pores is due to the 
crosslinking process and good formulation technique.  
 
Control batches, with a surface area of 3.5910m2/g and 3.8777m2/g for adsorption and 
desorption isotherms respectively, revealed an adsorption isotherm of 0.028310m2/g and 
desorption isotherm of 0.020460m2/g. Similarly optimized multiparticulates indicated an 
adsorption isotherm of 0.020460m2/g and a desorption isotherm of 0.020411m2/g for a 
surface area with an adsorption isotherm indicating 3.4890m2/g and desorption isotherm of 
3.8777m2/g. Relative to the surface area determined, both batches showed a low volume of 
pores for adsorption and desorption isotherms despite the formulation variance.  
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6.3.4 Chemometric and molecular modelling deducing the mechanism of crosslinking 
for the formation polyspheres and the drug release pattern thereof   
Ionic bonding and weak intra and inter-ionic physical force interactions located on sites within 
and around the PMMA latex pockets determined the matrix resilience of the resultant 
polyspheres (Figure 6.5a and Figure 6.5b). Ionic interactions of crosslinked PMMA latex 
strands depended most on the ionization energies of the crosslinkers (i.e. AlCl3, BaCl2 and 
MgCl2), hydration enthalpies over time and the thermodynamic stability of molecules 
accumulated at PMMA latex subunits.  
 
The PMMA latex subunits exhibited a desirable selectivity for crosslinking ions due to its 
structural orientation and the ability to provide a pocket for crosslinkers to assemble in a 
thermodynamically stable form resulting in a latex-like intermediate phase. The adjacent 
carboxylate groups provided a thermodynamic barrier for the release of INH molecules. Ba2+ 
ions have larger atomic radii (1.35Å) as compared to Mg2+ (0.65Å) and Al3+ (0.5Å) ions and 
therefore restricted hydration in the PMMA latex pockets. Al3+ having the smallest atomic 
radii would have been expected to result into polyspheres with the best drug release (small 
ionic radius would have allowed the Al3+ ions to diffuse throughout the polysphere matrix and 
crosslink strongly on the PMMA latex surface) but on the contrary, its high degree of 
hydration resulted into a reduced effect, specifically a potential burst effect. Placement of a 
crosslinker between the PMMA latex subunits through double crosslinking process reduced 
the chain flexibility. The voids generated by the interaction of PMMA latex strands were firmly 
bound by the Ba2+ and Mg2+ crosslinkers. The physical interactions of inter- and intra-
structural ions (Ba2+ and Mg2+) with structural moieties present in clusters, resulted into 
reduced hydration of the latex-like PMMA matrix and therefore the best drug release patterns 
obtained particularly for Ba2+ crosslinked polyspheres due to the larger atomic radii and the 
more stable larger electrostatic energy output detailed in Chapter 6.3.5.  
 
Furthermore, the irregular and heterogeneously scattered structure of PMMA latex subunits 
and their interaction with crosslinking ions were attributed to the physic-mechanical, 
hydrational and erosion differences of the resultant polyspheres. 
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Figure 6.5 Polysphere formation process depicting: a) polymethacrylate latex with non-
chemically crosslinked polymeric outer wall with load (isoniazid) in the polymethacrylate 
cavity; b) polymethacrylate latex with chemically crosslinked polymeric outer wall with load 
(isoniazid) in the polymethacrylate cavity 
 
6.3.5 Molecular modelling of a novel multi-crosslinked Eudragit® L 100-55 based 
multiparticulate system 
The environment surrounding the molecules of interest in molecular mechanics was defined 
in terms of a solvated system to prevent artefacts that arise from vacuum simulations and to 
reproduce bulk solvent properties well. Although the system could also be simulated in 
vacuum, but it may introduce artefacts in the molecular geometry caused due to surface 
charges of the charged molecules interacting with each other (as against interacting with the 
solvent in a solvated system), producing molecular conformations that are unlikely to be 
present in any other environment. The system was solvated by placing explicit water 
molecules, as 3 separate particles with fixed bond angles, in the simulation box with 
Eudragit® L 100-55 and the cations and the water molecules were treated as interacting 
particles like the molecules.  
 
The association of the cations to the polymer was found to be dependent on the charge 
density and the size of the respective cation. In the calculated values for the various energies 
for the Eudragit® L 100-55 fragments caused by the interaction with cations are illustrated 
separately as van der Waals, electrostatic and H-bond energies in Table 6.4. It is evident 
from Table 6.4 and Figure 6.6 that the hydrophobic van der Waals energies are directly 
correlated to the size of the cation where Ba2+, having the largest atomic radius, represented 
highest van der Waals energy followed by Mg2+ and Al3+. The interaction energies of the 
Eudragit®-monocations appeared to be more influenced by the electrostatic energies of 
interaction. The Eudragit® L 100-55  molecule behaves like a cation in the presence of 
aqueous environment due to the prevalence of –COO- groups in its structure and tends to 
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interact with the cations in water solvated systems as depicted in Figure 6.6. The 
electrostatic interactions were calculated as Eudragit®-Mg2+ > Eudragit®-Ba2+ > Eudragit®-
Al3+. Thus Eudragit®-Al3+ (∆E= -2041.68kcal/mol) and Eudragit®-Ba2+ (∆E= -1806.77kcal/mol) 
are highly stabilized in comparison to Eudragit®-Mg2+ (∆E= -624.64 kcal/mol) because of high 
charge densities and low intermolecular forces. These results corroborated with the 
assumption made in the in vitro drug release studies of Chapter 6.3.6 where it is postulated 
the Al3+ imparted a strong electrostatic ionic bond (high charge density) and a hydrophilic 
property (low van der Waals forces) on the multiparticulates. Spatially too, the Al3+ and Ba2+ 
ions are more closely packed in the conformational space of the periodic box (Figure 6.6). 
The hydrogen bonding interactions emerged to be insignificant with very small interaction 
values. 
 
Although, Al3+ might provide superior crosslinking, the high hydration energy of the Al3+ 
cation (-4665kJ/mol) weakens the stability of the ionic bond to hydrolytic cleavage. 
Therefore, the polyspheres were doubly crosslinked with divalent cations, Mg2+ and Ba2+, 
having low hydration energies of -1921kJ/mol and -1305kJ/mol, respectively. The cations 
were thus disposed alternatively, as shown in Figure 6.6, with the concentration of divalent 
ions being kept higher (5) as against trivalent ions (4) complementing the concentration used 
in crosslinking. After molecular mechanics simulations, Eudragit®-Al3+-Ba2+ was observed to 
be stabilized by 102.252kcal/mol and Eudragit®-Al3+-Mg2+ was destabilized by 213.13kcal/mol 
(Table 6.4). The high burst release in case of the control multiparticulates (AlCl3-MgCl2 
crosslinked) may be due to the tendency of Eudragit®-Al3+-Mg2+ system to attain energy 
minimized geometrical preferences thereby forming stabilized molecular conformers. 
Confirmation of Ba2+ as a valid and enhanced crosslinker was proven through this study. 
 
Experimental and theoretical investigations on the crosslinking and cation interaction of 
different divalent and/or trivalent cations to Eudragit® L 100-55 polyspheres were in excellent 
agreement. The experimentally observable polymer-ion interaction behaviour could be 
predicted by the computational method. Furthermore, the calculations allowed for a 
prediction of the interaction mechanisms. This particular study allowed for a successful and 
in depth introspection of the interactions between the Eudragit® L 100-55 polymer and the 
relevant crosslinking primary and secondary crosslinkers, which constitute the novel pH 
responsive multiparticulate intended for the release of active within the small intestine of the 
GIT. 
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Table 6.4 Calculated energy parameters (kcal/mol) of the complexes between Eudragit® L 
100-55  and divalent and/or trivalent cation 
Energy (kcal/mol) Structure 
Total ∆E interaction VDW H bond Elec 
Eudragit -1470.834  13.1403 -4.47725 -1568.98 
Eudragit - Al3+ -3512.516 -2041.68 181.064 -5.09441 -3876.58 
Eudragit - Ba2+ -3277.600 -1806.77 145.114 -5.89739 -3758.47 
Eudragit - Mg2+ -2095.474 -624.64 348.451 -5.55139 -2356.45 
Eudragit - Al3+- Ba2+ -1573.086 -102.252 72.2477 -3.15595 -1733.57 
Eudragit - Al3+- Mg2+ -1239.704 231.13 -11.3466 -4.04261 -1314.09 
∆Einteraction= E(Host:Guest) - E(Host) - E(Guest), Vdw: van der Waals energy and Elec: 
Electrostatic energy 
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Figure 6.6 Visualization of geometrical preferences of Eudragit® E L100-55 molecule in 
complexation with divalent and trivalent cations after molecular simulation in a solvated 
system. Color codes: C (cyan), O (red), H (white), Al (yellow), Ba2+ (violet) and Mg2+ (brown) 
 
6.3.6 In vitro drug release profiles for a novel Eudragit® E L100-55 based double 
crosslinked multiparticulate system for site-specific delivery of isoniazid to the small 
intestine  
The results from drug release studies varied drastically due to type of crosslinker as can be 
seen in Figure 6.8. Both formulations utilized AlCl3 for the initial crosslinking. As seen in 
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Chapter 6.3.1
 
Figure 6.3 for
 
FTIR analysis, crosslinking using AlCl3 does not disrupt the 
carboxylate band and is within the conventional band region. The Al3+ bonded carboxylate 
group is protected from immediate hydrolysis and hydration due to the ionic bond formed 
validated thorough high electrostatic energy (∆E= -2041.68kcal/mol) derived in Chapter 
6.3.5.  
 
Pearson’s HSAB scale describes Al3+ as a hard acid and thus the Al3+ imparted a strong 
electrostatic ionic bond and a hydrophilic property on the multiparticulate. The Hofmeister 
series similarly describes Al3+ as being the most susceptible ion for interacting with H2O 
molecules and consequently weakening the stability of the ionic bond to hydrolytic cleavage 
(The Hofmeister series, 2009). Al3+ has an ionic radius of 0.5Å and is a trivalent ion. The 
trivalent ion can allow for a 3-dimensional bonding structure with the PMMA molecule, which 
when compared to the planar 2 dimensional bonding of divalent ions, allows for a more rigid 
bond formation (Winter, 2010). The small ionic radius can allow the Al3+ ions to diffuse 
throughout the polysphere matrix and not just crosslink at the surface of the formulation. 
Hydration of the Al3+ metal ion is relatively fast and a burst release of drug could be expected 
despite a saturated crosslinking process. It was for this reason that a secondary crosslinking 
electrolyte solution was incorporated for each solution. Ba2+ and Mg2+ are considered to be 
softer acids than Al3+ on Pearson’s HSAB scale and interact less with H2O when compared to 
Al3+.  
 
The control multiparticulates displayed a burst effect with 70% drug release within the first 
hour and thereafter a rapid release of the remaining 30%. Complete drug release occurred 
between 8-10 hours. The discrepancy between the control and optimized formulation is 
easily identified with the initial moderated 20% drug release. The consistent rate controlled 
release profile generated for the optimal formulation confirms the postulated MDT release for 
with an 80% correlation from Table 6.5.     
 
Porosity evaluation, Chapter 6.3.3, implemented a large pore incongruity which influenced 
the respective formulation release profiles. Burst release was attributed to a combination of 
large pores (300Å for control samples), which propagated a faster matrix erosion and poor 
ionic crosslinking.  
 
The crosslinking between the Eudragit® L 100-55 polymeric backbone and the respective 
cations have been fully documented in Chapters 6.3.5 and 6.3.4. Ionic radii of the cationic 
molecules play a highly influential role in intermolecular bonding. Barium with a larger an 
ionic radius of 1.35Å produces the highest van der Waals energy attraction in comparison to 
both magnesium (0.65Å) and aluminum (0.5Å). Electrostatic energies of interaction affected 
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the strength of bonding more so than the Van der Waals forces with barium displaying a 
predominant energy interaction over magnesium (Table 6.4, Chapter 6.3.5). Spatially too, the 
Al3+ and Ba2+ ions are more closely packed in the conformational space of the periodic box 
(Figure 6.6 of Chapter 6.3.5). Hence the crosslinking saturation was improved upon in 
comparison with the Mg2+ ions and the control sample which explains the burst release 
obtained for the control sample (Figure 6.8). A higher concentration of EC aided in achieving 
a more controlled release and prevented the burst effect for the optimal formulation.  
 
Optimized multiparticulates were subjected to release testing within simulated gastric fluid 
(pH1.2) to ascertain the affinity of the formulation to prevent maximal release of INH within 
the stomach and consequently prevent the deleterious drug-drug interaction between INH 
and RIF. Figure 6.7 illustrates the efficacy of the system to retard INH release to a maximum 
10% drug release within the gastric environment for a period of 2 hours (mimicking gastric 
transit time). 
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Figure 6.7 Limited isoniazid release from optimized multiparticulates within simulated gastric 
fluid at pH 1.2 (insert with full scale reference); where N= 3 and SD< 0.002 in all cases 
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Table 6.5 Correlation between predicted and experimental responses of mean dissolution 
and drug entrapment efficiency for the optimized multiparticulates 
Responses Predicted Values Experimental Run 
Values 
Desirability 
DEE (%) 67.2216  71.4606 100% 
MDT 74.4739 57.5162 80% 
DEE (%)= drug entrapment efficiency and MDT= mean dissolution time 
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Figure 6.8 Percent drug release indicating the superior controlled drug release for an 
optimized multiparticulate system in relation to a control sample; where N= 3 and SD< 0.02 
in all cases  
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6.4 Concluding Remarks 
 
Controlled in vitro release of isoniazid was achieved for a 12 hour period for an optimized 
multiparticulate system. Segregated delivery of rifampicin and isoniazid was achieved in a 
rate controlled manner. Site-specific release of isoniazid with minimal quantities of drug 
releasing in the acidic pH of the stomach through simulated gastric fluid was achieved thus 
corroborating this concept. Optimized multiparticulates displayed enhanced intermolecular 
bonding, thoroughly investigated through chemometric and molecular modelling. The 
improvement on molecular bonding drastically affected both drug entrapment efficiencies and 
drug release profiles positively. A 71% drug entrapment was a large improvement of 
preliminary studies which barely entrapped adequate quantities of drug. Similarly, the lack of 
a major burst release of isoniazid in optimized multiparticulate profiles, can be attributed to 
this greater affinity of the Ba2+ cationic molecule to the Eudragit® L 100-55 polymeric 
carboxylic functional groups to produce electrostatic bonds. The primary Al3+ crosslinking 
interaction provided a dualistic strengthening of the polymeric backbone to regulate 
controlled release. Ethyl cellulose rather than negatively impact entrapment efficiencies, 
played a negligible role in drug entrapment but a significant one in moderating isoniazid 
release profiles. The optimized multiparticulate system achieved the objective of retarding 
drug isoniazid release within the simulated acidic pH of the stomach, whilst elucidating site-
specific and controlled release for up to 12 hours within the simulated pH of the small 
intestine.        
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CHAPTER 7                                                                                          
THE IN VIVO INVESTIGATION INTO THE DUALISTIC DRUG 
BEHAVIOUR PATTERNS OF A COMBINATION OF RIFAMPICIN AND 
ISONIAZID LOADED ORAL SYSTEMS 
 
 
7.1 Introduction 
 
Selection of an animal model is an initial concern for in vivo studies. The animal’s storage, 
eating and ablution patterns must be relative to a human. The size of an animal impacts 
sampling frequency. Smaller animals such as rats and mice are restricted in daily sampling 
intervals as compared to larger animals such as dogs, monkeys and pigs (Garrett and Hunt, 
1977; Cryan et al., 2007; Schroeder et al., 2007). This is a crucial factor as more frequent 
sampling has a direct relationship with quantifiable controlled drug release data. The larger 
the data pool of sampling, the higher the accuracy of understanding drug release in vivo. The 
dosage quantity between species relies on the size of animals. Human dosage can be 
accurately correlated to larger animals such as pigs and dogs but the same dosage needs to 
be scaled down for a rat model (Sutton et al., 2006). From the larger animals listed, the dog 
and the monkey are considerably more expensive than the pig and pose more of an ethical 
dilemma. The pig model was selected over other models for in vivo analysis. The analogous 
features between the pig and the human include feeding patterns, digestive physiology, 
coronary artery distribution and the omnivorous nature (Brunet et al., 2006). The use of the 
pig as a model has been thoroughly exploited for drug delivery (Kumar et al., 1992; 
Dorkoosha et al., 2002; Dorkoosha et al., 2002) making it the ideal choice for in vivo studies. 
 
The pig model is ideal for comparative in vivo analysis due to the physiological similarities 
between a human. Validity of the model chosen is seen by the near identical metabolism of 
pharmacological actives via common enzymatic metabolic pathways (cytochrome P450). The 
similarity between pig and human physiology extends to the total activity of cytochrome P450 
which are comparable (Skaanild and Friis, 1997). Additionally, the slow gastric emptying time 
exemplifies a comparative model and the pig is considered an ideal animal for slow release 
formulations (Lennernäs H, 2007). Through continuous habituation, pigs are considered easy 
to handle, manipulate for blood sampling and to accommodate.      
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7.2 In Vivo Analytical Methodology for the Once Daily Multi-Unit System 
 
7.2.1 Development of a blood sample retrieval protocol for the accurate analysis of 
plasma samples through the marginal ear vein 
The initial phase of in vivo studies was focused on identifying an efficacious blood sampling 
protocol that was to be sustainable for the duration of the study. Due to the numerous studies 
being conducted in conjunction with this project, a carefully formulated timeline was 
implemented. To ensure reproducibility, 5 pigs were used at a time for the various projects 
undertaken and studies were conducted in a staggered fashion to allocate for wash out 
periods between the variant formulations drugs. Female white pigs were chosen for the study 
and upon arrival and averaged 30kg in mass.   
 
To ensure expeditious and accurate blood sampling, habituation of the pigs was attempted 
which involved daily visitation of the pigs. During the course of habituation, pigs were fed an 
assortment of food such as raisins and sweet potatoes to build a relationship with the animal 
for easier handling, a strategy which proved effective. Pigs were anaesthetized with Anaket®, 
Dormicum® and Isofor® gas and were then monitored whilst under a constant sleep with 
oxygen.   In an observational evaluation of the pig, the only visible veins were at the external 
surface of the ear. Consequently, catheterization at the marginal ear vein was attempted. 
The formulation samples for testing were administered via gastric intubation utilizing gastric 
tubing.  
 
Prior to sampling, pigs began a 24 hour fast such that digested food would not impede 
results. Drawing blood samples proved to be an arduous task of luring the pig into a handling 
cage and keeping it occupied whilst drawing up blood from the marginal ear vein (Figure 
7.1). Roughly 2mL of blood was drawn up from the conscious pig every 2 hours for a 0-12 
hour interval and every 4 hours for the 16-24 hour time interval. Blood samples were stored 
in a heparinized tube and then centrifuged at 5000rpm for 10 minutes. The separated plasma 
was removed and stored in a -70°C freezer until further analysis. 
 
This particular protocol proved to be unsuccessful for many reasons. Blood sampling was not 
always successful as the marginal ear vein was sporadically blocked throughout the 24 hours 
testing period resulting in lost data at various time intervals. The marginal ear vein also ran 
the risk of rupturing, collapsing, bursting and hardening, all of which occurred frequently 
throughout the study. Trauma to the pig itself was undesirable through the work in the 
handling cage and the pain experienced through the physical act of blood sampling was 
extensive. The protocol was abandoned as unsatisfactory for accurate sampling.  
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Figure 7.1 Placement of the female white pig in a handling cage and blood sampling via the 
catheterized marginal ear vein 
 
7.2.2 Development of a blood sample retrieval protocol for the accurate analysis of 
plasma samples through the insertion of a chronic catheter 
A secondary strategy was to insert a permanent catheter through a surgery. A female white 
pig weighing 40-42kg was anaesthetised with Ketamine® (11mg/kg I.M.) and Midazolam®, 
(0.3mg/kg I.M.). Buprenorphine® (0.05mg/kg I.M.) and Carpofen® (4mg/kg I.M.) were 
administered for analgesia and inflammation. The pig was then intubated and anaesthesia 
was maintained with 2% Isoflurane® in 100% oxygen. Under aseptic conditions, a 7 french 
gauge double lumen 35cm catheter (CS-28702) (Arrow Deutschland GmdH, Erding, 
Germany) was surgically inserted into the left jugular vein. The jugular vein was exposed by 
an incision made dorsal to the jugular groove on the left lateral aspect of the neck.  
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Via blunt dissection, the vein was isolated and the catheter was inserted 10cm into the lumen 
of the vein. The lumen of the catheter was fastened to the wall of the vein using a purse 
suture technique. The remaining length of the catheter (25cm) was tunnelled 
subcutaneously, with the use of trocar, to an exit point cranial to the dorsal aspect of the 
scapula. The externalised injection ports of the catheter were sutured to the skin of the pig so 
as to limit excessive movement and bending. Blood was removed via the catheter and the 
catheter was flushed with heparin saline (1000i.u. of heparin in 1L of 0.9% saline). Thereafter 
the animal was allowed 10 days to recover from the surgical procedure. During this time, pigs 
were habituated to the process of blood sampling. Throughout the study, the catheter was 
flushed with heparinised saline 3 times a day. 
  
A mixture of Dormicum® and Anaket® was injected directly into the jugular vein catheter. 
Once sedated, the pig was anaesthetised with 2% isoflurane in 100% oxygen. An intragastric 
tube was inserted into the stomach of the pig through which the testing samples were placed. 
To prevent accidental pulmonary insertion, wedging of samples on the oesophageal wall and 
regurgitation of the samples, all the formulations were washed down the tube with 10mL 
water. While under sedation, all wounds were checked and sutures were repaired. The pig 
was returned to its pen to recover under observation. 
  
Blood samples were taken over a 24 hour period. A constant 2 hour interval was utilised for 
the first 12 hours, while samples were taken every 4 hours for the remaining 12 hours. The 
catheter was disinfected and an aseptic technique was utilised to prevent the introduction of 
foreign organisms. Before blood was sampled, the catheter was flushed with heparinised 
saline in order to clear any clots or remove old blood. Thereafter, blood was drawn and 
placed in a lithium heparin vial. To prevent accumulation of blood post sampling, the 
catheters were once again flushed with heparinised saline. Blood samples were centrifuged 
at 5000rpm for 10 minutes. The plasma supernatant layer was removed and frozen at -72°C 
until analysis. Figure 7.2 illustrates an overview of the optimized sampling protocol for both 
the optimized ODMUS and the conventional dosage form (Rifinah®). 
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Figure 7.2 Dosing protocol employed to anaesthetize, monitor vitals, intubate and insert 
formulations 
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Figure 7.3 Schematic outline of the optimized blood sampling protocol for conventional and 
Once Daily Multi-Unit Systems 
 
7.3 Materials and Methods 
 
7.3.1 Materials 
Solvents used for UPLC–MS/MS measurements were of UPLC grade, and all other reagents 
were of analytical grade. Oases HLB cartridges, for solid phase extraction, were provided by 
Waters (Milford, MA, USA). Double deionized UPLC grade water was obtained from a Milli-Q 
In vivo 
CONVENTIONAL DRUG DELIVERY 
SYSTEMS UTILIZING 5 PIGS 
• Rifina® 75mg Isoniazid/150mg 
Rifampicin 
OPTIMIZED ODMUS UTILIZING 5 
PIGS 
• Multiparticulates 75mg 
Isoniazid   
• Memblet 150mg Rifampicin 
SURGICAL PROTOCOL 
• Anesthesia and Surgical catheterization at 
the internal jugular vein 
• Recovery period of 10 days 
• Routine flushing with heparinized saline 
SAMPLE PROCEDURE 
• Drawing3-5mL of blood using 
aseptic techniques 
• Blood sampling conducted over a 
24 hour period with sampling 
occurring every 2 hours for the 
first 12 hours and subsequently 
every 4 hours for the remaining 12 
hours 
• Samples subjected to 
centrifugation at 3000rpm for 15 
minutes 
• Supernatant collected and frozen 
at -70°C till analysis 
SURGICAL PROTOCOL 
• Anesthesia and Surgical catheterization at 
the internal jugular vein 
• Recovery period of 10 days 
• Routine flushing with heparinized saline 
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system, (Milli-Q, Millipore, Johannesburg). Isoniazid (INH) (Sigma Aldrich.Inc St. Louis, 
Missouri USA), rifampicin (RIF) and the internal standards methylparaben (MP) for in vitro 
testing (Sigma Aldrich.Inc, St. Louis, Missouri USA) and furosemide (FUR) (Sigma 
Aldrich.Inc, St. Louis, Missouri USA) for in vivo testing were of analytical grade. A total of 5 
female white pigs were used for study, each healthy and with an average weight of 35kg. 
Fresh blank plasma was routinely drawn and supplied from the catheterized pigs. Rifinah 
(Sanofi-aventis, pty.ltd, Midrand, South Africa).  
 
7.3.2 Surgery and implantation of a permanent jugular catheter 
Female white pigs, weighing on average 35kg, were anaesthetised with Ketamine® (11mg/kg 
I.M.) and Midazolam®, (0.3mg/kg I.M.). Buprenorphine® (0.05mg/kg I.M.) and Carpofen® 
(4mg/kg I.M.) were administered for analgesia and inflammation. Pigs were then intubated 
and anaesthesia was maintained with 2% Isoflurane® in 100% oxygen. Under aseptic 
conditions, a 7 french gauge double lumen 35cm catheter (CS-28702) (Arrow Deutschland 
GmdH, Erding, Germany) was surgically inserted into the left jugular vein. The jugular vein 
was exposed by an incision made dorsal to the jugular groove on the left lateral aspect of the 
neck.  
 
Via blunt dissection, the vein was isolated and the catheter was inserted 10cm into the lumen 
of the vein. The lumen of the catheter was fastened to the wall of the vein using a purse 
suture technique. The remaining length of the catheter (25cm) was tunnelled 
subcutaneously, with the use of trocar to an exit point cranial to the dorsal aspect of the 
scapula. The externalised injection ports of the catheter were sutured to the skin of the pig so 
as to limit excessive movement and bending. Blood was removed via the catheter and the 
catheter was flushed with heparin saline (1000i.u. of heparin in 1L of 0.9% saline). Thereafter 
the animal was allowed 10 days to recover from the surgical procedure. During this time, pigs 
were habituated to the process of blood sampling. Routine flushing consisted of flushing the 
catheter with heparinised saline 3 times a day to prevent clotting of blood. 
 
7.3.3 Administration of the once daily multi-unit system  
A mixture of Dormicum® and Anaket® was injected directly into the jugular vein catheter. 
Once sedated, the pig was anaesthetised with 2% isoflurane in 100% oxygen. Both 
components of the ODMUS (spheres and memblet) were dosed via intubation utilizing a 
standard intra gastric tube. To prevent accidental pulmonary aspiration, wedging of samples 
on the oesophageal wall and regurgitation of the samples, all the formulations were washed 
down the tube with 10mL water. While under sedation, all wounds were checked and sutures 
were repaired. The pig was returned to its pen to recover under observation. 
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7.3.4 Blood sampling protocol for the once daily multi-unit system 
Blood samples were taken over a 24 hour period at 2 hour intervals were for the first 12 
hours, while samples were taken every 4 hours for the remaining 12 hours. The catheter was 
disinfected and an aseptic technique was used to prevent the introduction of foreign 
organisms. Before blood was sampled, the catheter was flushed with heparinised saline in 
order to clear any clots or remove old blood. Thereafter, blood was drawn and placed in a 
lithium heparin vial. The catheters were once again flushed with heparinised saline. Blood 
samples were centrifuged at 5000rpm for 10 minutes. The plasma supernatant layer was 
removed and frozen at -72°C until analysis.  
 
7.3.5 Ultra performance lipid chromatography for the in vivo determination of drug 
content  
Ultra performance lipid chromatography is a widely used technique to utilizing a liquid mobile 
phase to separate compounds via peak identification. Through increases in pressure, 
samples are forced through a column. Furthermore, the UPLC is coupled with an 
Evaporative Light Scattering Detector which provides the qualitative and quantitative analysis 
of drug samples. According to the Van Deemter equation (Equation 7.1), the underlying 
principles of UPLC analysis is explained as an empirical formula which explains the 
relationship between linear flow rate and plate height or column efficiency. By utilizing 
particle sizes of below 2.5µm, efficiency is improved regardless of the flow rate. Since ultra 
performance liquid chromatography uses smaller particles, speed and peak capacity, a 
higher resolution peak can be determined in chromatographic analysis and determination of 
individual drug components (Swartz, 2005; Waters Chromatography Columns and Supplies 
Catalog, 2009). 
 
uC
u
B
AH ×++=                                      (Equation 7.1) 
 
Where, A= Eddy-diffusion, B= longitudinal diffusion, C= mass transfer kinetics of the analyte 
between mobile and stationary phase and = linear velocity.  
 
As prerequisite data, a UPLC method is required to be produced for an in vitro assessment 
to function as the framework for plasma method determination. Dissolution testing of a 
conventional Rifinah® Tablet (75mg INH and 150mg RIF) was to be conducted and tested 
with an in vitro UPLC method and assessed against optimized release profiles generated in 
Chapters 5 and 6.  
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7.3.5.1 Preparation of calibration curves for the in vitro analysis of isoniazid and 
rifampicin from a conventional dosage form 
Stock solutions of INH (0.083mg/mL) MP (1.0mg/mL) were dissolved in simulated gastric 
fluid of pH 1.2. Serial dilutions (5 dilutions) of INH were prepared for analytical evaluation of 
the calibration curve. 1.5mL of each dilution solution was mixed with 0.5mL of internal 
standard and passed through a 0.22µm Cameo Acetate membrane filter (Millipore Co., 
Bedford, MA, USA) within respective 2mL ANSI48 vials and subjected to analysis.                
  
Similarly, stock solutions of RIF (0.1668mg/mL) MP (1.0mg/mL) were dissolved in simulated 
gastric fluid of pH 1.2. Serial dilutions (5 dilutions) of RIF were prepared for analytical 
evaluation of the calibration curve. 1.5mL of each dilution solution was mixed with 0.5mL of 
internal standard passed and through a 0.22µm Cameo Acetate membrane filter (Millipore 
Co., Bedford, MA, USA) within respective 2mL ANSI48 vials and subjected to analysis. 
  
7.3.5.2 Development of a method for the concomitant in vitro analysis of isoniazid and 
rifampicin with subsequent analysis thereof 
Drug release studies were conducted following the USP 33 Apparatus II (ERWEKA DT 700 
GmbH Germany), in which Rifinah® Tablets were tested in duplicate and placed within the 
vessel under stainless steel ring meshes assembly to prevent the paddle inflicting 
physical/mechanical damage to the tablet and alter release profiles as well as to prevent 
erratic fluctuation due to unstable hydrodynamics (Pillay and Fassihi, 2000). Each vessel 
was filled with 900mL simulated gastric fluid (SGF) and heated to a temperature of 37°C prior 
to the addition of the multiparticulates and the stainless steel ring mesh assembly. The 
rotating paddle method was selected at a rotational speed of 50rpm and the machine was 
calibrated for a 90 minute run with samples taken at regular intervals. Sampling involved the 
drawing of 5mL of SGF from the dissolution vessel with subsequent refilling of removed 
buffer to maintain sink conditions. Samples were then subject to UPLC analysis. 
 
Successful in vivo data is derived from a fundamental understanding of in vitro UPLC 
analysis. Prior to the construction of an in vivo method, an in vitro method was developed 
and used as the template of the plasma method derived.  
 
Priming of the UPLC included a washing protocol of 2 cycles of 10 minutes each. A strong 
(90%v/v acetonitrile and 10%v/v water) and weak (90%v/v water and 10% v/v acetonitrile) wash 
were of analytical grade were used with the column temperature set at a constant 25°C.   
 
Optimization of the in vitro UPLC method required a selection of either a gradient or isocratic 
method with varying quantities of mobile phases were selected to elute a detectable peak of 
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either drug component based on the affinity of the drug to that mobile phase. The 2 mobile 
phases selected were 100% acetonitrile and a 0.1% formic water mixture. The selection of a 
gradient method at a constant flow rate of 0.4mL/min is tabulated in Table 7.1. 
   
Table 7.1 Method parameters for the simultaneous determination of isoniazid and rifampicin 
concentrations 
Time (min) Flow Rate (mL/min) %A %B 
0 0.4 100 0 
0.63 0.4 95 5 
1.5 0.4 20 80 
1.6 0.4 0 100 
1.94 0.4 60 40 
2.8 0.4 100 0 
%A= 0.1% formic water and %B= pure acetonitrile 
 
7.3.5.3 Plasma calibration curve development for the simultaneous evaluation of 
isoniazid and rifampicin concentrations 
Stock solutions of INH (0.0002mg/µL), RIF (0.0002mg/µL) and internal standard FUR 
(0.0003mg/µL) were prepared. Blank plasma samples were removed from storage conditions 
(-70°C) and left to thaw at room temperature. For qualitative studies, the sample preparation 
method involved a combination of protein precipitation, freeze-liquid and solid-phase 
extraction (SPE) approaches. 0.5mL plasma and 125µL of serial diluted stock solutions (5 
dilutions) of INH were placed in 10mL plastic centrifuge tubes. Samples were vortexed 
(Vortex genie 2, Bohemia, NY, USA) for 15 seconds to induce protein binding of the INH, 
similar to in vivo conditions. De-protenation was achieved using 3mL of acetonitrile and the 
sample was vigorously vortexed for 60 seconds. All serial dilutions were then centrifuged at 
3000rpm for 15 minutes (Optima® LE-80K, Beckman, USA).   
 
This liquid -liquid extraction method resulted in 3 immiscible layers (Figure 7.4) including an 
upper aqueous layer, a middle inorganic phase (acetonitrile) and a lower protein precipitate. 
Liquid supernatants (both aqueous and inorganic phases) were removed and placed into 
new sample tubes and were then frozen for 10 minutes in a -70°C freezer. Thereafter 
samples were removed from the freezer and left to thaw. Due to density differences, the 
upper aqueous layer (containing water soluble INH) thawed out first and could be removed 
for solid phase extraction leaving behind the lower inorganic phase (containing RIF). 
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Figure 7.4 Formation of 3 immiscible layers via centrifugation of spiked plasma samples 
 
The Generic Oasis® HLB Solid Phase Extraction (SPE) method was employed to determine 
the concentrations of methanol that would increase the elution purity of the analyte INH and 
thereby allow the determination of drug concentration within the samples. Oasis® HLB 
cartridges enabled with the Visiprep Vacuum Manifold and Standard Lid (Waters,) were 
conditioned with 1mL methanol and 1mL deionized water. The prepared INH loaded plasma 
standards were loaded onto the cartridges post-conditioning. Varying concentrations of 
methanol (10-100%) were used to elute INH loaded plasma samples which were then 
subjected to UPLC analysis to determine the most efficient methanol concentration for 
elution of INH spiked calibration standards. SPE confirmed that 30%v/v methanol was 
evaluated as the most efficacious in producing the most distinctive peaks and determined as 
the viable elution standard for plasma analysis thereof.  
 
Consequently, plasma calibration standards were loaded onto the HLB cartridges and eluted 
with 2mL of 30%v/v methanol. These eluted aqueous samples and the organic phase remnant 
were combined in a sample tube and spiked with 125µL FUR (0.0003mg/µL).  These mixed 
calibration sample tubes (INH, RIF and FURO) were passed through a 0.22µm Cameo 
Acetate membrane filter (Millipore Co., Bedford, MA, USA) and then expelled into 2mL ANSI 
48 vials and subjected to analysis to construct suitable calibration curves for both INH and 
RIF.  
 
Method parameters were altered in comparison to the in vitro testing as the plasma 
constituents (enzymes, proteins etc) affected the individual drug peaks. A new internal 
standard furosemide (FUR) was selected, as the MP peak was superimposed onto the RIF 
peak due to biological plasma interactions. Consequently, a noise degradation peak was in 
evidence at the elution times of both RIF and FUR, obscuring peak definition and sharpness 
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and affecting accuracy of data through an elevated baseline. Manipulation of method 
parameters (Table 7.2) produced a change to the chromatogram at 1.60 minutes and 2.25 
minutes by inducing a flow of 100% formic water and 100% acetonitrile respectively. This 
manipulation successfully shifted the degradation peak to between 2.20 and 2.60 minutes as 
seen in Figure 7.9 of Chapter 7.4.3. 
  
Table 7.2 Plasma method parameters for dual analysis of rifampicin and isoniazid 
Time (min) Flow Rate 
(mL/min) 
%A %B 
0 0.4 100 0 
0.63 0.4 100 0 
1.5 0.4 20 80 
1.6 0.4 0 100 
2.25 0.4 100 0 
%A= 0.1% formic water and %B= acetonitrile 
  
7.3.5.4 Plasma sample analysis for the simultaneous evaluation of the once daily 
multi-unit system in a female white pig 
Plasma samples of both the conventional Rifinah® and the ODMUS system were removed 
from storage conditions (-70°C) and left to thaw at room temperature. For qualitative studies, 
the sample preparation method involved protein precipitation, freeze-liquid and solid-phase 
extraction  (SPE) approaches. 0.5mL plasma was added to 10mL plastic centrifuge tubes. 
An amount of 3mL acetonitrile was added to achieve full de-protenation and the sample was 
vigorously vortexed (Vortex genie 2, Bohemia, NY, USA) for 60 seconds. All plasma samples 
were then centrifuged at 3000rpm for 15 minutes (Optima® LE-80K, Beckman, USA).  
 
The liquid-liquid extraction method described in Chapter 7.3.2.9 was adopted and resulted in 
3 immiscible layers including the upper aqueous layer, a middle inorganic phase (acetonitrile) 
and a lower protein precipitate. Liquid supernatants (both aqueous and inorganic phases) 
were removed and placed into new sample tubes and were then frozen for 10 minutes in a -
70°C freezer. Thereafter samples were removed from the freezer and left to thaw. Due to 
density differences, the upper aqueous layer (containing water soluble INH) thawed out first 
and could be removed for solid phase extraction leaving behind the lower inorganic phase 
(containing RIF). 
 
The aqueous extracted supernatant layers from both Rifinah® and ODMUS samples were 
loaded onto the HLB cartridges and eluted with 2mL of 30%v/v methanol. These eluted 
aqueous samples and the organic phase remnant were combined in a sample tube and 
spiked with 125µL FUR (0.0003mg/µL).  These mixed calibration sample tubes (INH, RIF and 
FURO) were passed through a 0.22µm Cameo Acetate membrane filter (Millipore Co., 
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Bedford, MA, USA) and then expelled into 2mL ANSI 48 vials and subjected to analysis to 
generate drug release profiles for both Rifinah® and ODMUS samples.   
 
7.4 Results and Discussion 
 
7.4.1 Validation of a method for the concomitant in vitro analysis of isoniazid and 
rifampicin with subsequent analysis thereof 
Dissolution samples were tested at 5, 30, 60 and 90 minutes. 5mL samples were drawn of 
which 1.5mL was expelled into a 2mL ANSI 48 vial. Additionally, 0.5mL of internal standard 
was included in each vial. Relative to in vitro release profiles illustrated in Chapters 6.3.6 and 
5.3.7, INH and RIF exhibit no control release patterns from the conventional Rifinah® tablet. 
Calibration curves developed for both INH and RIF (Figure 7.5a and Figure 7.5b) were used 
to generate the release profiles, displayed in Figure 7.6, within simulated gastric fluid. Within 
this simulated environment, dose dumping is evidently seen within the first 5 minutes. After 
half an hour of dissolution testing, the bulk of both INH and RIF are released. Within 90 
minutes of conducting the dissolution test, complete dissolution of the Rifinah® tablet 
occurred. The optimized ODMUS system achieved vastly improved release profiles 
(Chapters 6.3.6 and 5.3.7). Furthermore, site-specific drug delivery was corroborated through 
segregated delivery of INH and RIF throughout specific gastrointestinal locations negating 
the deleterious drug-drug interactions that can occur. The conventional Rifinah® tablet fails to 
achieve the extended control release patterns of the ODMUS and does not ensure 
segregated delivery of INH and RIF. The lack of a delivery system as in the ODMUS clearly 
identifies Rifinah® to be inferior. A gradient method was selected such that an initial elution of 
the water soluble INH would occur at 0.621 minutes due to a higher formic water constitution 
(100%). Elution times of 1.907 and 2.065 minutes, successfully displayed 2 separate and 
distinct peaks of RIF and MP respectively. Figure 7.7 indicates the successful in vitro profile 
displaying INH, RIF and MP utilizing a single method. RIF metabolites are noted to elute prior 
to the RIF peak. 
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Figure 7.5 In vitro calibration curves for a) isoniazid and b) rifampicin to elucidate the 
conventional dosage form’s (Rifinah®) drug release profiles 
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Figure 7.6 Determination of release patterns of isoniazid and rifampicin from the 
conventional Rifinah® tablet within simulated gastric fluid (pH 1.2); where N= 3 and SD< 0.04 
in all cases 
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Figure 7.7 Ultra performance lipid chromatography chromatogram identifying isoniazid, 
rifampicin, methylparaben and the corresponding metabolites of rifampicin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.4.2 Plasma calibration curves for the simultaneous evaluation of isoniazid and 
rifampicin concentrations 
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Figure 7.8 In vivo calibration curves for a) isoniazid and b) rifampicin 
 
7.4.3 Plasma sample analysis for the evaluation of the once daily multi-unit system 
drug release in a female white pig 
The purpose of in vivo drug content determination was to evaluate the variance of drug 
release between the ODMUS and conventional dosage form Rifinah®. In vitro release studies 
described in Chapters 6.3.6, 5.3.7 and 7.4.1 fully identify the large discrepancy that exists 
between the novel ODMUS and the Rifinah® tablet in a simulated environment. The 
combination of the memblet and the multiparticulate system successfully produced superior 
drug release profiles, site-specific drug distribution and segregation of actives within the 
gastrointestinal tract. However, whilst dissolution testing is a USP recognized methodology, it 
cannot emulate the dynamic and unique environment of the body. Through in vivo testing 
within the pig model, an accurate portrayal of how the body’s physiological and anatomical 
design affects drug release of both the ODMUS and Rifinah® could be established. 
  
Plasma UPLC method development was a critical first step in the determination of drug blood 
content. The template method derived from in vitro studies of Chapter 7.3.2.6 was moderated 
to accommodate the presence of blood constituents (enzymes, proteins etc) which 
biologically altered drug content. Method altercation proved essential due to the presence of 
a biological degradation product, absent with in vitro chromatograms. The undesirable 
phenomenon of superimposition of the degradation peak onto the FUR and RIF peaks was 
negated and is illustrated as being shifted to between 2.20 and 2.60 minutes in Figure 7.9. 3-
Dimensional scrutiny was a valuable tool in isolating the range of absorption for each specific 
drug molecule and aided in separation of the drug degradation product (Figure 7.10).  
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Figure 7.9 Ultra performance lipid chromatography method development for the concomitant 
plasma drug content evaluation of isoniazid and rifampicin with separation of the undesirable 
degradation product using blank plasma  
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Figure 7.10 3-D modelling of a typical plasma chromatogram for isoniazid, rifampicin and 
furosemide indicating the respective range of absorption  
 
Plasma levels of drug concentration for both conventional and the ODMUS are plotted in 
Figure 7.11 and Figure 7.12. Rifinah® tablets can be simply described as compressed INH 
and RIF powders. Release of both drugs is based on the dissolution and erosion upon 
immediate contact with gastric fluid. Within 2 hours of exposure to the gastric environment, a 
complete release of INH and RIF has occurred. In correspondence with the deleterious drug-
drug interaction described in Chapter 2.3.3, the simultaneous delivery of INH and RIF within 
acidic stomach conditions provides the environment for formation of an insoluble complex. 
Blood drug content of both pharmacological actives showed considerable decreases in 
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relation to the optimized ODMUS formulation (CmaxINH= 0.0138ng/mL and CmaxRIF= 
0.052ng/mL).   
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Figure 7.11 24 hour investigation into the divergence of drug blood content between 
isoniazid and rifampicin from a conventional dosage form; where N= 5 and SD < 0.1 in all 
cases 
 
Significant improvement on release patterns and blood drug concentration is immediately 
noted in Figure 7.12. During the gastric retention period (0-4 hours), a complete release of 
RIF was achieved. Minimal INH levels were ascertained during these 4 hours, authenticating 
the acid resistant characteristic of the multiparticulates. Segregated, site-specific drug 
release, as per the objectives of this dissertation, was accomplished and reinforced with the 
notable increase in maximal blood drug content (CmaxINH= 0.0368ng/mL and CmaxRIF= 
0.1052ng/mL) through avoidance of the deleterious interaction. Furthermore, an extended 
duration of release of INH is noted. A prolonged 10 hours of controlled release is illustrated 
which is a significant improvement on the conventional Rifinah® formulation (2 hours). No 
untoward, idiosyncratic toxic side effects were noted and the pigs remained healthy for the 
duration of the study validating the biocompatibility of the formulation. 
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Figure 7.12 24 hour investigation into the divergence of drug blood content between 
isoniazid and rifampicin from the novel Once Daily Multi-Unit System; where N= 5 and SD< 
0.33 in all cases 
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7.5 Concluding Remarks 
 
This Chapter sought to address the behaviour of the ODMUS under in vivo conditions 
employing ultra performance lipid chromatography as an analysis tool. 
 
Development of a suitable and efficacious in vivo model was theorized and implementation of 
the protocol was successfully achieved through the Pig model. Biocompatibility was 
determined as successful for this novel ODMUS.  
   
The ODMUS system, through stringent UPLC method development and in vivo analysis, was 
determined to corroborate with data presented with in vitro testing. In addition, superiority of 
the system over the conventional Rifinah® formulation was made apparent. Segregated site-
specific release of INH within the small intestine and RIF in the stomach was successfully 
executed. Noteworthy increases in blood drug concentration for both INH and RIF relative to 
the conventional system were indicative of counteraction of the deleterious interaction that 
occurs with simultaneous delivery of INH and RIF within an acidic environment.  
 
In conclusion, the OMDUS was determined to be biocompatible and to display superior 
release patterns, to negate drug-drug interactions and to achieve segregated delivery of 
pharmacological actives in comparison to the conventional dosage form. 
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CHAPTER 8                                                                           
CONCLUSIONS AND RECOMENDATIONS 
 
 
8.1 Conclusions 
 
Drug regimen therapy has been described as considerable problem over the years for both 
patient and practitioner (Lenert et al., 1989, Ormerod and Prescott, 1991; Jindani and Griffin, 
2010). The compounding of factors side effects, high pill burden and the effort to take 
medication in a segregated fashion more than once a day, result in poor patient compliance 
ad drug therapeutic failure. Debilitating conditions such as tuberculosis and HIV are 
specifically notorious having close to unmanageable drug regimens especially within 
resource poor countries (De Cock and Wilkinson, 1995; Mehdi et al., 2005; Vermund and 
Yamamoto, 2007). 
 
Much emphasis has been placed on research and development to manage drug regimen 
therapies (Hernández et al., 2010; Renteria et al., 2010; Wong et al., 2010), but the allocated 
funding and skilled individuals to conduct such research is limited in South Africa. 
Pharmaceutical development is a benchmark to safer, more cost effective and efficacious 
drug regimen therapy. 
 
Within a South African context, HIV and tuberculosis are seen as highly debilitating 
conditions, but it is the medication management that is seen as an equal challenge. The cost 
of treatment alone is a burden many South Africans cannot manage. It is fairly common 
through many drug regimen based conditions to see opportunistic infections occur and 
convolute and increase pharmacological actives complicating dosing and affecting cost. As a 
result, much treatment is left unattended.  
 
This dissertation sought to highlight the research conducted on a similar complication within 
tuberculosis treatment with regards to the deleterious interaction occurring between isoniazid 
and rifampicin, 2 components essential for efficacious tuberculosis management.  
 
The once daily multiple unit drug delivery system (ODMUS) provided a unique concept of 
manipulating Eudragit® molecules L 100-55 an E 100 to produce multiparticulate and 
memblet  drug delivery systems respectively. The novelty of the system lies in the unique 
single process step for both formulations. The concomitant intake of the formulations would 
also ensure a controlled, segregated site-specific release of isoniazid and rifampicin to 
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negate the deleterious interaction that can occur between them and increase bioavailability 
of each active.  
 
Extensive in vitro preliminary testing of each formulation was accomplished to produce an 
optimized design. Preliminary evaluation of dissolution and drug entrapment testing of the 
multiparticulate component established upper and lower limits for variant formulation 
parameters of crosslinker type, crosslinker and ethyl cellulose concentration. Similarly, the 
memblet variables were deduced through dissolution and differential scanning calorimetry to 
be crosslinker concentration, plasticizer content and surfactant contributions.    
 
A total of 15 formulations for both the memblet and multiparticulate component of the 
ODMUS were proposed using a Box-Behnken factorial design and were accordingly 
synthesized. Responses testing for multiparticulates were MDT through dissolution testing 
and DEE through drug entrapment studies. Tg and MDT were responses tested through DSC 
and dissolution studies respectively for memblet optimization. Through these rigorous testing 
protocols, and optimized formulation was calculated for each component of the ODMUS. 
 
A full testing protocol of the each optimized formulation was conducted to corroborate with 
the predicted data. Multiparticulate verification was successfully implemented through 
dissolution, FTIR, SEM, DEE, surface area and porosity analysis and chemometric 
modelling. These highly individualized tests were specifically chosen to understand the 
release mechanisms with relation to its internal structure and molecular interactions.  
 
Memblet formulations underwent stringent rheological, thermal, mechanical and molecular 
characterization to ascertain the relevant nature of the memblet and the consequent release 
patterns.  
 
This led to the development of an individualized in vivo protocol and the adoption of said 
protocol into a test procedure. The model adopted successfully indicated the segregated site-
specific delivery of each isoniazid and rifampicin in a rate controlled manner with an 
improvement on bioavailability in relation to a concurrently tested conventional dosage form.  
 
These delivery systems have been proven to be successful in managing a tuberculosis 
regimen, but the system itself is not exclusive to this conditions. Manipulation of variant 
polymers, surfactants and crosslinkers could very well alter the formulation to achieve even 
further release times and in a more controlled manner.  
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8.2 Recommendations 
    
Multiparticulate and membranous technology must be thoroughly investigated as a combined 
delivery system such that the 2 technologies can be taken as a single dosage form. The 
benefits of such a combination of technologies have tremendous applications for drug 
regimen therapies with more emphasis placed on in vivo testing.  
 
Multiparticulate formulations must have improved drug entrapment efficiency to limit the large 
quantity of multiparticulates required. Controlled release can also be extended up to 24 
hours.  
 
The memblet could potentially be manipulated into a gastro-floatable or adhesive system 
which could then be moderated to achieve an even longer release pattern for up to 8 hours. 
A modified desiccation strategy must be defined to reduce the drying time to less than a day 
without compromising optimized characteristics.  
 
In vivo diagnostics must be furthered with expanded testing such as gamma scintigraphy and 
further improve in vivo assessment for future works.  
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Abstract: 
This invention relates to a heterogeneously configured multiparticulate drug delivery system for 
gastrointestinal delivery of at least one or a combination of active pharmaceutical compositions. The 
system comprises a multiplicity of enterosoluble or gastrosoluble multiparticulates loaded with the 
active pharmaceutical composition or compositions for the site-specific delivery of said active 
pharmaceutical composition or compositions to a specific region in the gastrointestinal tract of a 
human or animal body. The system can be supplied as reconstitutable granules which are 
reconstituted immediately before oral administration. 
 
Read more: http://www.faqs.org/patents/app/20100179170#ixzz0ySGWZrug 
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Appendix D: Central Animal Services Clearance Letter 
  
 
 
 
CENTRAL ANIMAL SERVICES 
Tel: 011717-1312 
 Fax:  011 643-4318 
 
DEAR ANIMAL USERS 
 
It is with great satisfaction that we can relay to users, the positive outcome of their respective 
in vivo research. Central Animal Service acquired a batch of 30 pigs for in vivo research with 
the Department of Pharmacy and Pharmacology, for disease screening.  
  
An ongoing animal surveillance program pre and post studies continued on a daily basis to 
assess the health and well being of the animals. We are confident to say that any unforeseen 
or fatal circumstance due to researchers or the research material itself had occurred. All pigs 
maintained an acceptable health status during and post studies.  
 
Kind regards 
 
Dr Leith Meyer (Director of the Central Animal Services) and the CAS team 
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